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RÉSUMÉ 
 
L’hypertrophie cardiaque représente un mécanisme d’adaptation du myocarde en réponse à 
différents stress. Sur le long terme, l'hypertrophie cardiaque peut évoluer vers l'insuffisance 
cardiaque, l'une des principales causes de morbidité et de mortalité dans les pays 
industrialisés, pour cette raison, la communauté scientifique est très intéressée à élucider les 
voies de signalisation qui régulent ce phénomène pathologique dans le cœur.  
Notre laboratoire a montré que AKAP-Lbc, une protéine d’ancrage de la protéine kinase A 
(AKAPs), est principalement exprimée dans le cœur et peut réguler des processus 
importants tels que l’hypertrophie des cardiomyocytes. 
AKAP-Lbc fonctionne comme un facteur d’échange de nucléotides guanine (GEF) pour la 
petite Rho-GTPase RhoA. Cette fonction est activée par différents récepteurs qui activent 
son domaine Rho-GEF. Des études récentes ont démontré que AKAP-Lbc est impliquée 
dans la réponse hypertrophique des cardiomyocytes suite à l'activation des récepteurs !1-
adrénergiques. Le but général de ce travail de thèse est la caractérisation de la voie de 
signalisation hypertrophique activée par AKAP-Lbc dans les cardiomyocytes. 
Mes travaux montrent que AKAP-Lbc organise un complexe macromoléculaire, 
comprenant les protéines kinases PKN, MLTK, MKK3 et p38 et active la protéine kinase 
p38 en réponse à l'activation des récepteurs !1-adrénergiques. 
Nos résultats indiquent que cette voie de signalisation au cours de la réponse 
hypertrophique active le facteur de transcription GATA4 et la protéine Hsp27. 
GATA4 est un important facteur de transcription qui régule la transcription de plusieurs 
gènes au cours de la réponse hypertrophique, alors que Hsp27 est une protéine chaperonne 
qui interagit avec le cytosquelette des cardiomyocytes et les protége contre le stress 
hypertrophique. 
Pris ensembles, ces études contribuent à comprendre comment le complexe de signalisation 
formé par AKAP-Lbc régule l’hypertrophie dans les cardiomyocytes. Au-delà de leur 
intérêt au niveau biochimique, ces travaux pourraient aussi contribuer à la compréhension 
du phénomène de l’hypertrophie  dans le cœur. 
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ABSTRACT 
 
In response to various pathological stresses, the heart undergoes a remodelling process that 
is associated with cardiomyocyte hypertrophy. Since cardiac hypertrophy can progress to 
heart failure, one of the major cause of lethality worldwide, the intracellular signalling 
pathways that control cardiomyocyte growth have been subjected of intensive investigation. 
While we have previously shown that AKAP-Lbc, an A-kinase anchoring protein (AKAP) 
with an intrinsic Rho specific guanine nucleotide exchange factor activity, is critical for 
activating RhoA and transducing hypertrophic signals downstream of the !1-adrenergic 
receptors (ARs), the hypertrophic pathways activated by this anchoring protein are poorly 
characterized. Here we show that AKAP-Lbc can assemble a novel transduction complex 
containing the RhoA effector PKN!, MLTK", MKK3" and p38!, which integrates signals 
from !1-ARs, to promote RhoA-dependent activation of p38!.  
In particular, molecular disruption of the AKAP-Lbc/p38 complex in rat neonatal 
cardiomyocytes, reduces the ability of !1-AR to activate p38 and to induce cardiomyocyte 
hypertrophy.  
It is well established that activated p38 can promote cardiomyocyte hypertrophy through the 
activation of different transcription factors and cytosolic proteins. Importantly, we could 
show that suppression of AKAP-Lbc expression in cardiomyocytes, inhibits !1-AR 
mediated activation of the hypertophic transcription factor GATA4 as well as the heat shock 
protein Hsp27, a protein that stabilizes sarcomeres and cytoskeleton during hypertrophic 
stress. 
Altogether these results indicate that in cardiomyocytes AKAP-Lbc organizes a 
transduction complex that includes PKN!, MLTK", MKK3" and p38!, that promotes 
cardiomyocyte hypertrophy, potentially through the activation of GATA4 and Hsp27. 
These findings provide a novel mechanistic hypothesis explaining how assembly of 
macromolecular complexes, that specify MAPK signaling, mediate cardiomyocyte 
hypertrophy downstream of !1-ARs. 
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ABBREVATIONS 
 
AC        Adenylyl cyclase  
AKAP       A-kinase anchoring protein  
ANF       Atrial natriuretic factor  
Ang-II       Angiotensin-II  
AR        Adrenergic receptor  
ATP     Adenosine triphosphate 
ATR     Angiotensin II receptors 
Brx        Breast cancer nuclear receptor auxiliary factor  
!-CA     alpha-cardiac actin 
C3        Clostridium botulinum C3 toxin     
cAMP       Cyclic 3,5-adenosine monophosphate  
CC        Coiled-coil region  
cDNA       Complementary deoxyribonucleic acid  
DAG       Diacylglycerol  
Dbl        Diffuse B-cell lymphoma  
DH        Dbl Homology domain  
EPI     Epinephrine 
ERK       Extracellular signal-regulated kinase  
ET-1       Endothelin-1 
ETR     Endothelin receptors     
FSK       Forskolin  
GAP       GTPase activating protein  
GATA    GATA binding protein 4 
GDI       Guanine nucleotide dissociation inhibitor  
GDP       Guanosine diphosphate  
GEF       Ganine nucleotide exchange factor  
GFP       Green fluorescent protein  
GPCR       G protein-coupled receptor  
GST       Gluthatione S-transferase  
GTP       Guanosine triphosphate  
HEK-293      Human embryonic kidney 293 cells  
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Hsp-27    Heat shock proteins 27 
IP3        Inositol triphosphate  
JIP        C-Jun N-terminal kinase)-interacting protein  
JNK       C-Jun N-terminal kinase  
LARG       Leukemia-associated Rho guanine nucleotide exchange 
factor 
Lbc       Lymphoid blast crisis  
LC3       Microtubule –associated light chain 3  
LPA       Lysophosphatidic acid  
MAPK       Mitogen-activated protein kinase  
MEF2       Myocyte-specific enhancer factor 2 
!-MHC    alpha-Myosin heavy chain  
"-MHC     beta-Myosin heavy chain 
MLK3     Mixed-lineage protein kinase 3 
MLTK     MLK-like mitogen-activated protein triple kinase 
MKK3     Mitogen-activated protein kinase kinase 3 
mRNA       Messenger ribonucleotidic acid  
NF-AT       Nuclear factor of activated T cells  
NF-!B       Nuclear factor kappa B   
PDE       Phosphodiesterase  
PDZ       PSD-95, DLG, and ZO-1 domain  
PE        Phenylephrine  
PH        Pleckstrin homology domain  
PI3K      Phosphatidylinositol-3 kinase  
PKA      cAMP dependent protein kinase  
PKC       Protein kinase C  
PKD       Protein kinase D  
PKN       Protein kinase N  
PLC       Phospholipase C  
PP1       Protein phosphatase 1  
PP2A       Protein phosphatase 2 A  
PP2B       Protein phosphatase 2 B / calcineurin  
PRK       PKC-related kinase  
 15 
RNVMs     Rat neonatal ventricular cardiomyocytes 
RBD       Rho-binding domain  
RGS       Regulator of G protein signaling  
ROCK       Rho kinase  
SH2       Src homology 2 domain  
SH3       Src homology 3 domain  
shRNA    Short hairpin ribonucleotidic acid 
SRE       Serum response element  
SRF       Serum response factor  
!-Ska    alpha-skeletal actin 
TAC     Transverse aortic constriction 
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I. INTRODUCTION 
 
1.1. Cardiac Hypertrophy  
 
The mammalian heart is a dynamic organ that can grow and change to accommodate 
alterations in its workload. In response to various biomechanical or neurohumoral stresses, 
the heart undergoes an adverse remodeling process that leads to the development of cardiac 
hypertrophy, a process characterized by the hypertrophic non-mitotic growth of 
cardiomyocytes, apoptotic cardiomyocyte death, activation and proliferation of fibroblasts 
and excessive deposition of extracellular matrix [1-3]. Hypertrophy can be induced both by 
biomechanical stresses including hypertension, myocardial infarction, ischemia associated 
with coronary artery disease, valvular insufficiency and stenosis and inherited mutation of 
genes encoding contractile proteins; as well as neurohumoral stresses induced by excessive 
release of hormones, cytokines and peptide growth factors at the level of the myocardium.  
Remodeling events associated with cardiac hypertrophy are maladaptive and ultimately 
contribute to depressed contractile function and progression to heart failure, a major cause 
of lethality worldwide.  
Interestingly it is well described another form of hypertrophy named physiological cardiac 
hypertrophy. Physiological cardiac hypertrophy is a physiological response to exercise 
training and it differs from pathological hypertrophy in its structural and molecular profile 
and is characterized by normal organization of cardiac structure and normal or enhanced 
cardiac function [4] (Fig.1.1). 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Progression of 
pathological cardiac hypertrophy: 
Pathological cardiac hypertrophy 
can produce concentric hypertrophy 
in which the ventricular wall and 
septum thicken with a net decrease 
in ventricular chamber dimensions. 
This remodelling is associated with 
a greater increase in cardiac 
myocyte width than length. 
However, pathological cardiac 
hypertrophy can also produce a 
phenotype of eccentric and dilatory 
cardiac growth. Cardiac dilation, 
although not typically referred to as 
hypertrophy, can result from a 
growth response in which 
sarcomeres are predominantly added 
in series to individual myocytes. 
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On the other hand, at the cellular level, the pathological cardiomyocyte growth is associated 
with a profound reorganization of the myofibrilles that constitute sarcomers and the 
upregulation of specific subsets of “fetal” genes that are normally expressed during 
embryonic life including sarcomeric proteins such as myosin heavy chain ", myosin light 
chain 2v and !-skeletal actin as well as several signal transduction proteins and 
transcription factors that directly control protein synthesis, calcium homeostasis and 
cardiomyocyte metabolism [5]. It is now clear that aberrant expression during adult life of 
these fetal proteins strongly affects cardiac contractility, calcium handling and myocardial 
energetics and leads to maladaptive changes in cardiac function [6].  
At the molecular levels the most proximal initiating stimuli for cardiomyocyte hypertrophy 
can be broadly segregated into biomechanical and stretch-sensitive mechanisms, or 
neurohumoral mechanisms that are associated with the release of hormones, cytokines, 
chemokines and peptide growth factors.  
All these different stimuli are sensed by cardiac myocytes through an array of different 
receptors that initiate the cardiac growth response by activating a circuit of signaling 
pathways that alter different genes expression (Fig. 1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Most of these stimuli induce a first phase of the cardiac hypertrophy named compensatory 
hypertrophy, where it is activated the growth of each single cardiomyocyte, it is increased 
 
Figure 1.2 Signal-transduction pathways that coordinate the cardiac hypertrophic response: The 
most well characterized signaling pathway activated during the process of cardiac hypertrophy. 
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the cardiac pump function and it is decreased the ventricular wall tension. Unfortunately, all 
these stimuli in the long term induce a second phase of the cardiac hypertrophy that 
predisposes to heart failure, arrhythmia and sudden death. 
This second phase is characterized by a progressive deterioration of the left ventricular 
function that is related to a progressive loss of cardiomyocytes due to apoptosis. In addition 
to the cardiomyocyte apoptosis, progressive accumulation of cardiac fibroblasts in the heart 
occurs in the failing heart that may lead to ventricular diastolic or systolic dysfunction. 
Since heart failure remains the main cause of mortality in the Western world, the 
investigations to understand the different pathways that regulate this complex pathology are 
becoming an important priority to the scientific community and to the health systems. 
1.2. Sensing of hypertrophic signals by G protein coupled-
receptors 
 
Most stimuli, known to initiate pathological changes associated with the development of 
cardiac hypertrophy, are sensed by cardiomyocytes through an array of membrane-bound 
receptors that include mainly Receptor tyrosine kinases (RTK)s, Receptor Serine/Threonine 
Kinases (RSTK), Cytokine receptors and G protein-coupled receptors (GPCRs). 
GPCRs constitute a family of over 800 genes encoding receptor proteins that are 
characterized by a seven-transmembrane (7TM) configuration. Members of this family 
include receptors for many hormones, neurotransmitters, chemokines and calcium ions, as 
well as sensory receptors for various odorants, bitter and sweet taste, and even photons.  
Although several studies have demonstrated that this family of receptors can mediate their 
biological function through different signaling pathways the best characterized mechanism 
is the ability of these receptors to activate the heterotrimeric G proteins. 
Heterotrimeric G proteins are the molecular switches that turn on intracellular signaling 
cascades in response to the activation of GPCRs by extracellular stimuli. Therefore, G 
proteins have a crucial role in defining the specificity and temporal characteristics of the 
cellular response. Heterotrimeric G proteins are composed of three subunits, !, " and #, and 
their switching function depends on the ability of the G protein !-subunit to cycle between 
an inactive GDP-bound conformation that is primed for interaction with an activated 
receptor, and an active GTP-bound conformation that can modulate the activity of 
downstream effector proteins. 
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Upon agonist binding, the activated receptor induces the release of GDP from the ! subunit 
of G protein that is replaced with GTP. This leads to dissociation of the G-protein 
complexes into ! subunits and "# dimer, which both activate several effectors. When the 
receptor is no longer active, the intrinsic GTPase activity of the G! subunit hydrolyzes the 
GTP to GDP and the GDP-bound G! subunit associates with G"# subunits. In this manner, 
the signaling cycle of the heterotrimeric G protein is complete. 
There are four major families of heterotrimeric G proteins, based on their ! subunits, named 
G!s, G!I, G!q, G!12, that mediate the activity of a variety of different effectors. 
• Gs (stimulatory) - activates adenylate cyclase to increase cAMP synthesis. 
• Gi (inhibitory) - inhibits adenylate cyclase. 
• Gq - stimulates phospholipase C. 
• G12 - stimulates the Rho-GTPase pathways. 
 
In the cardiac system, GPCRs play important roles during the embryonic develop of the 
heart in response to physiological stimuli and during pathological alterations [7]. In 
particular three GPCRs coupled with Gq play different important functions in the 
myocardium: the ! adrenergic receptors (!-AR), the endothelin A/B receptor (ETAR; 
ETBR) and the angiotensin 1/2 receptors (AT1R; AT2R).  
The ability of these receptors to mediate hypertrophic cardiomyocyte growth was 
demonstrated in vitro using primary cultures of rat neonatal ventricular cardiomyocytes 
(RNVMs) as a model system, as well as in vivo using animal models over-expressing or 
lacking individual GPCRs [8]. 
 
Several lines of evidence have characterized the role of the AT1Rs in the development of 
cardiac hypertrophy in vitro and in vivo. It has been demonstrated that AT1 mRNA 
expression increases in response to aortic coartation or acute myocardial infarction [9]. In 
addition, long-term treatment of stroke-prone spontaneously hypertensive rats with 
AT1 blocker candesartan significantly reduced left ventricular mass [10]. Moreover, 
beneficial effects of AT1 receptor blocker on left ventricular hypertrophy extend to patients 
with mild-to-moderate hypertension [11]. 
 
Similarly, it has been shown that stimulation of Endothelin receptors (ETAR and ETBR) 
cause cardiomyocyte hypertrophy in vitro and in vivo [12] and their expression is increased 
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in the hypertrophied [13] and failing heart [14]. On the other hand, it has been demonstrated 
the ET receptor antagonists attenuate the development of cardiac hypertrophy and heart 
failure [15]. These findings suggest that ETRs are involved in the development of cardiac 
hypertrophy and heart failure. 
 
On the other hand, it is now appreciated that !1-ARs are also involved in the regulation of 
various pathological processes including vascular muscle cell hypertrophy, proliferation and 
migration in response to injury [16, 17] as well as cardiac hypertrophy [18, 19]. 
The activation of the !1-ARs in RNVMs is a classical model of cardiac hypertrophy that 
has provided much of the available information about cardiac growth signaling pathways. 
Experiments in cultured neonatal rat cardiac myocytes show clearly that catecholamines 
induce hypertrophy via !1-AR [20]. 
In transgenic mice different experiments partly support the culture results and the idea that 
!1-ARs can be sufficient to induce hypertrophy during development.  
In particular, the activated mutant of the !1B-AR over-expressed in the heart amplified the 
hypertrophic response to pressure overload and also resulted in heart failure and premature 
death [18]. Similar results have been observed in transgenic mice that have a cardiac 
restricted over-expression of the WT !1B-AR given an infusion of phenylephrine (PE is a 
!1-AR agonist) [21]. 
In marked contrast, over-expression of !1A-ARs did not promote the cardiac hypertrophy 
in response to the thoracic aorta constriction (TAC) [22], in fact, heightened !1A-ARs 
activity improved survival [23]. 
These interesting and surprising results indicate that the pathological hypertrophy 
associated with pressure overload is influenced by !1B-ARs, whereas the physiological 
hypertrophy associated with postnatal growth may involve both receptor subtypes. 
The hypertrophic pathways activated by !ARs, ATIRs and ETRs have been associated with 
the activation of the two heterotrimeric G-proteins, Gq and G12/13 coupled to the receptors. 
Here below are summarized the main findings illustrating the importance of these two 
heterotrimeric G-proteins in the transduction of signals involved in cardiac hypertrophy. 
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1.2.1 Sensing the hypertrophic signals by the heterotrimeric G-
proteins Gq 
 
It is well established that the ! subunit of the heterotrimeric G protein Gq plays a major role 
to mediate the effects of !1-ARs, ATIRs and ETRs on cardiac hypertrophy [24]. 
Furthermore, mice lacking G!q/G!11 in cardiomyocytes are protected from cardiac 
hypertrophy in response to pressure overload [25]. In addition, an important study from the 
group of Lefkowitz has shown that inhibition of Gq protein, by targeting the receptor-Gq 
interface, reduced the myocardial hypertrophy induced by pressure overload [26]. 
 
Different studies using genetically modified mouse models have confirmed that Gq/11 
coupling is a necessary event in the induction of pathological cardiac hypertrophy. Gq/11, 
by activating phospholipase C" (PLC"), induce the generation of diacylglycerol (DAG), 
which functions as an intracellular ligand for protein kinase C (PKC), leading to PKC 
activation, and production of inositol-1,4,5-trisphosphate (Ins(1,4,5)P3) [8]. Accumulation 
of Ins(1,4,5)P3 leads to the mobilization of internal Ca2+ by directly binding to the 
Ins(1,4,5)P3 receptor located in the sarcoplasmic reticulum or the nuclear envelope. 
Liberation of internal Ca2+ stores can mediate the hypertrophic signaling through 
calcineurin–NFAT (nuclear factor of activated T-cells) activation or calmodulin-dependent 
kinase (CaMK)–HDAC (histone deacetylase) inactivation [27].  
 
In line with these findings, a recent study has demonstrated that GPCRs coupled to Gq can 
induce cardiac hypertrophy by a novel ERK1/2 activation. Interestingly, this paper has 
clearly shown that G!q activates the classical pathway of ERK1/2, while the "# subunits 
released from Gq enhanced the autophosphorylation of ERK1/2 on its Threonine 188, 
which increases the efficiency of ERK1/2 activation [28]. 
 
While most of the studies have focused on the role of Gq in mediating the hypertrophic 
effects, recent evidences now suggest that G12 and G13 also contribute importantly to the 
growth responses initiated by !1-AR, ATIRs ETRs [29]. In fact, it is now appreciated that 
 23 
functional inhibition of G proteins of the G12/G13 family can strongly impair receptor-
induced cardiomyocyte hypertrophy [29]. 
1.2.2 Sensing of hypertrophic signals by the heterotrimeric G-
proteins G12/13 
 
As reported in the paragraph above, the !1-ARs, ATIRs and ETRs are coupled also to the 
heterotrimeric G proteins G12/13 [30]. Interestingly this family of G proteins includes two 
distinct ! subunits, G!12 and G!13, that are responsible to regulate the activation of the 
Rho-GTPase through different RhoGEF proteins and modulate various cellular responses 
such as cytoskeletal changes and cellular growth [31]. However, despite their close 
similarity in sequences and some effectors, G!12 and G!13 have distinct roles in the 
cellular homeostasis. 
 
In vitro, it has been shown that G!13 is more potent to induce apoptosis [32], while G!12 
seems to play an important role to induce cardiomyocyte hypertrophy in response to !1-
ARs, ATIRs and ETRs stimulation [33-35].  
In particular, an important work has shown that the expression of RGS domain of 
p115RhoGEF, which blocks the activation of G!12 and G!13, inhibits JNK activation and 
the hypertrophic responses in RNVMs [33, 34]. Interestingly this study has demonstrated 
that the activation of Gq-mediated signaling pathway is not sufficient to induce the 
hypertrophy and it needs the concomitant activation of G12/13 to activate the cardiac 
hypertrophy. 
This line of evidence has been shown also by our group in RNVMs where over-expressing 
the dominant negative mutant of G!12 blocked cardiomyocyte hypertrophy induced by PE 
[36]. Collectively, all these data indicate the critical role of G12 family in vitro to activate 
hypertrophic signaling independently of Gq.  
 
On the other hand an important study in vivo has demonstrated that activation of G12/13 in 
cardiomyocytes did not affect the cardiac hypertrophy but it induced the cardiac fibrosis in 
response to pressure over-load [37]. 
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Altogether these findings highlighted the role of G12/13 to activate the Rho-GTPases and to 
induce the hypertrophic response of the heart. Here below are summarized the main 
findings illustrating the importance of Rho-GTPases in the transduction of signals involved 
in cardiac hypertrophy. 
1.3 The small G-proteins and Rho family 
 
Small molecular weight GTPases of the Rho family belong to the super-family of Ras-
GTPase. In humans the Ras super-family comprises more than 150 members and it is well 
conserved during the evolution, where different Ras orthologs are present in animals, 
Drosophila, C. elegans, S. cerevisiae and plants.  
The members of the Ras family are divided into five major branches on the basis of 
sequence and functional similarities: Ras, Rho, Rab, Ran and Arf. Although similar to the 
heterotrimeric G! subunits in biochemistry and function, Ras family proteins function as 
monomeric G proteins. Small G-proteins cycle between an active GTP-bound state, which 
is able to bind effector proteins, and an inactive GDP-bound state.  In this context they 
exhibit high-affinity binding for GDP and GTP, and possess low intrinsic GTP hydrolysis 
and GDP/GTP exchange activities.  
Interestingly, there are three main classes of regulatory protein that control GDP/GTP 
cycling. The first one catalyzes the exchange of GDP with GTP by its guanine-nucleotide-
exchange factor (GEF) domain [38], whereas the second one regulates the intrinsic GTPase 
activity of the small G protein to promote formation of the inactive GDP-bound by GTPase-
activating protein (GAP) domain (Fig. 1.3) [39]. 
The third class of regulators includes Rho-GDIs (GDP dissociation inhibitors), that 
sequester the prenylated GDP-Rho-GTPases as cytosolic complexes and prevent the 
exchange of GTP with GDP on the Rho-GTPases. 
 
Rho-GTPases are divided into 7 subgroups that include Rho, Rac, Cdc42, Rnd, RhoD, 
RhoH/TTF, RhoBTB and Miro. Currently the three best characterized members are RhoA, 
Rac1 and Cdc42 (Fig. 1.4). 
It is now clear that Rho GTPases are involved in several actin-dependent processes such as 
migration adhesion, morphogenesis, axon guidance, and phagocytosis [40, 41]. In this 
context RhoA has been shown to promote actin stress fiber formation and focal adhesion 
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assembly; Rac1 lamellipodium formation and membrane ruffling; and Cdc42 formation of 
actin microspikes and filopodia [42].   
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition to their roles in controlling the actin cytoskeleton, Rho-GTPases regulate cell 
polarity [43], gene expression [44], cell cycle progression [45], and membrane transport 
pathways [46]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this introduction, I will focus on the different roles of Rho-GTPases to regulate the 
reorganization of cytoskeleton and to induce cardiomyocyte hypertrophy. 
Figure 1.4 Rho family GTPase and actin cytoskeleton remodeling: The Rho Family GTPase Rho 
induces stress fibers, GTPase Rac induces lamellipodia and GTPase Cdc42 induces filopodia 
Figure 1.3 Small G-proteins GDP–GTP 
cycle : GDP–GTP cycle is tightly regulated 
by three families of proteins, including the 
GEFs, GAPs and GDIs In the absence of 
intracellular or extracellular signals, the 
Rho GTPases are maintained in the cytosol 
by the GDIs which mask their lipid 
modifications. External or internal cues 
promote their release from the inhibitory 
complex (1) that enables them to associate 
with the plasma membrane (2) where they 
are activated by GEFs (3) and can signal to 
effector proteins. Then, GAPs inactivate 
the GTPases by accelerating the intrinsic 
GTPase activity, leading to the GDP-bound 
form (4). Once again, the GDI molecules 
stabilize the inactive GDP-bound form in 
the cytoplasm, waiting for further 
instructions (5). 
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1.4 The small G-proteins signaling in cardiac hypertrophy 
 
During the last decade two Rho-GTPase members, RhoA and Rac1, have been linked to 
agonist-induced cardiomyocyte hypertrophy in vitro. Moreover, the generation of different 
transgenic mice has demonstrated that RhoA and Rac1 signaling pathways have complex 
roles in inducing cardiac hypertrophy. 
1.4.1 Rac1 
 
It is well established that Rac1 has an important role in the induction of cardiomyocyte 
hypertrophy through different pathways.  
The early study performed by the group of Finkel had shown that expression of 
constitutively active Rac1 (V12Rac1) in RNVMs resulted in an increased sarcomeric 
reorganization and cell size compared to the controls. In contrast, the expression of the 
dominant negative Rac1 (N17Rac1) resulted in attenuated morphological hypertrophy in 
response to hypertrophic PE stimulation. These results suggest that Rac1 is an essential 
element of the signaling pathway leading to cardiac myocyte hypertrophy [47]. 
Rac1 is well characterized to mediate its hypertrophic effects through mitogen-activated 
protein kinases (MAPKs). In this context, it has been demonstrated that PE induced 
cardiomyocyte hypertrophy through the activation of a pathway involving Rac1 and the 
extracellular regulated kinase ERK1/2 pathway [48].  
Another study has clearly shown that mechanical stretch induces cardiac hypertrophy 
through the activation of a Rac1- reactive oxygen species (ROS)-p38 dependent pathway in 
cardiomyocytes [49]. 
In addition, it has been demonstrated that Rac1/ROS required the activation of the kinase 
ASK1, which in turn activates the transcription factor NF-kB, to induce cardiomyocyte 
hypertrophy [50]. 
On the other hand, the implication of Rac1 in cardiac hypertrophy in vivo cannot be studied 
by conventional gene targeting approaches, because the deletion of Rac1 gene results in 
embryonic lethality.  
Nevertheless, transgenic mice that express the constitutively active Rac1 (V12Rac1) 
specifically in the myocardium have been created (these mice expressed the mutant form of 
Rac1 at comparable levels to the endogenous Rac1). Interestingly, the constitutive 
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activation of the Rac1 signaling pathway resulted in two distinct cardiomyopathic 
phenotypes: a lethal dilated phenotype associated with neonatal activation of the transgene 
and a transient cardiac hypertrophy seen among juvenile mice that resolved with the age of 
mice [51].  
In line with these findings, a recent paper has demonstrated that conditional cardiomyocyte-
specific Rac1 deletion prevents Ang II-induced cardiac hypertrophy [52].  
 
In conclusion during the last decade different studied in vitro and in vivo have clearly 
shown a connection between Rac1 and cardiac hypertrophy.  
1.4.2 RhoA 
 
There are numerous data indicating that RhoA is required for cell transformation and 
proliferation in a variety of cell types. In particular, RhoA, the main Rho GTPase expressed 
in cardiomyocytes, has received particular attention in later years because of its crucial role 
in mediating hypertrophic responses. 
 
Initial experiments performed using RNVMs revealed that inhibition of RhoA using 
dominant negative mutants of RhoA or the C3 botulinum toxin could strongly impair 
hypertrophic gene expression, protein synthesis, and myofibrillar reorganization induced by 
hypertrophic stimuli [53-55].  
These early studies provided the evidence that, in vitro, RhoA is required for transducing 
growth signals downstream of hypertrophic stimuli. More in depth, these studies have 
demonstrated that receptors coupled to Gq and G12/13 including, !1-ARs, ATIRs and 
ETRs are able to induce the hypertrophic response through the activation of RhoA.  
On the other hand, in vivo, two lines of research have provided indirect evidence for the 
implication of RhoA in cardiac hypertrophy. 
The first study published more than ten years ago from the laboratory of Brown has 
characterized two lines of transgenic mice in which they expressed the constitutively 
activated RhoA (L63A) or wild type RhoA in a cardiac specific manner through the !-
MHC promoter [56]. Interestingly most of the founders and progeny of RhoA L63A mice 
did not survive to adulthood while there was just an increased mortality of the mice that 
over-expressed the wild-type RhoA. Surprisingly, these mice did not develop any obvious 
left ventricular hypertrophic response, even if the two hypertrophic genes Atrial natriuretic 
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factor (ANF) and the beta Myosin heavy chain (" MHC) were more expressed compared to 
the controls. 
In contrast, the transgenic mice had at typical phenotype of heart failure with a severe 
edema, ventricular chamber dilatation, increased cardiac fibrosis, atrial enlargement and 
decreased fractional shortening. Another important information given by this study was that 
some transgenic mice developed atrial fibrillation, atrioventricular block and a severe 
bradycardia. These effects can be explained by the roles of RhoA in modulating the activity 
of cardiac ion channels. 
Recently, an important study coordinated by the group of Condorelli has shown that 
inhibition of RhoA expression in healthy cardiac tissue by the micro RNA (miR) 133 
prevents activation of hypertrophic pathways and that down-regulation of miR 133 in 
response to pressure overload promotes an increase in RhoA expression and development of 
cardiac hypertrophy [57]. 
 
The concept that RhoA can promote the cardiac hypertrophy it was already suggested by 
studies showing that the inhibition of RhoA isoprenylation and membrane localization by 
statins could reduce the hypertrophy induced by mechanical stress or by GPCR agonists 
[58].  
 
Based on this findings I will present below the current state of knowledge on the activation 
of RhoA and its implication on signaling pathways in cardiac hypertrophy. 
1.5 Activation of Rho-GTPase by Rho-GEF proteins 
 
With their 69 distinct homologues, RhoGEFs proteins represent the largest family of direct 
activators of Rho-GTPases in humans, and they activate Rho-GTPases within particular 
spatio-temporal contexts, in response to different extracellular stimuli.  
All guanine nucleotide exchange factors that exhibit exchange activity towards Rho 
GTPases share a Dbl homology (DH) domain (named after Dbl, the first identified member 
of the family) and an adjacent pleckstrin homology (PH) domain [59, 60]. The DH/PH 
tandem domain is known as GEF domain. The DH domain interacts extensively with the 
switch regions of Rho GTPases and thanks to its nucleotide-exchange activity it catalyzes 
the exchanging reaction of GDP with GTP in Rho-GTPase. DH domains cause the 
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remodeling of the switch regions to alter the nucleotide-binding pocket. The induced 
alterations in the GTPase encourage GDP and Mg2+ dissociation. This event leaves the 
nucleotide-binding pocket completely exposed to allow rebinding of GTP-Mg2+ in cells 
[61]. 
The PH domain is located immediately distal to DH domains, and it cooperates for the 
activation of Rho GTPases, as several studies have demonstrated that DH–PH fragments 
show greater nucleotide-exchange activity as compared to DH domains alone [62]. 
This can be explained by the fact that PH domain can participate to the GTPase-binding 
interface as demonstrated for the Rho-GEF protein named LARG where the PH domain 
makes direct contacts with RhoA [63]. Another function of the PH domain is to target the 
RhoGEF at the plasma membrane where it can be positioned in proximity of Rho-GTPases 
allowing their efficient activation [64] [65]. 
 
The modulation of the GEF activity is the crucial event to activate the Rho-GTPases. In this 
context, different mechanisms have been characterized to regulate the GEF activity of 
different Rho-GEF proteins including the activation by GTP-binding protein, protein 
kinases and by the regulation of phosphoinositol kinases [60]. 
 
Several lines of evidence now suggest that Rho-GEFs can integrate signals from G protein-
coupled receptors [60]. In particular the RhoA specific GEFs, p115 Rho-GEF, LARG and 
PDZ-Rho-GEF, AKAP-Lbc can be activated by the !$subunits of G12/G13 [66-68]. 
On the other hand, LARG and the newly identified p63-Rho-GEF can also integrate signals 
from the ! subunit of Gq [69]. 
The best characterized mechanism to activate the GEF domain is through the GTP-binding 
protein G!12/13. Interestingly, biochemical studies identified p115RhoGEF, LARG and 
PDZ-RhoGEF, as a subset of GEFs containing a regulator of G-protein signaling (RGS)-
like domain, that is typically associated with enhancing the intrinsic GTPase activity of 
heterotrimeric G! subunits. This interaction is responsible for the activation of the GEF 
domain. However, the activation of Rho-GEF by G12/13 often needs protein tyrosin kinases 
as regulators. For example, LARG and PDZ-RhoGEF can be activated by G!12 after the 
phosphorylation by the two kinases FAK, (focal adhesion kinase) and Tec [67].  
Interestingly, also Gq can activate Rho in PLC" and PKC-independent manner. One of the 
best studies that validate this pathway had shown that in mouse embryonic fibroblasts the 
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Gq protein induced the stimulation of the Rho-GEF protein LARG, that in turn activated 
RhoA [70]. In addition a recent paper has determined the crystal structure of the G!q-
p63RhoGEF-RhoA complex, detailing the interactions of G!q with the Dbl and pleckstrin 
homology (DH and PH) domains of p63RhoGEF. These interactions involved the effector-
binding site and the C-terminal region of G!q and appear to relieve autoinhibition of the 
catalytic DH domain by the PH domain [71].  
  
The second important mechanism to activate the GEF domain is mediated by the 
phosphorylation of the Rho-GEF proteins by protein kinases. In this context the RhoGEF 
protein Vav1 has revealed that at the basal state its N-terminal region interacts with the DH 
domain to prevent access of the GTPases. Upon phosphorylation of Tyr174 by various 
receptor-associated tyrosine kinases, the N-terminal region becomes unstructured and 
releases the DH domain, that is able to activate the Rho-GTPases [72]. 
Finally, a third modulation mechanism involved in the activity of the GEF domain is 
mediated by the phosphoinositol kinase. In mammalian cells, early studies have shown that 
treatment with the PI3K inhibitor Wortmannin inhibited the activation of Rac downstream 
of growth factor receptor activation [73]. In addition, PtdIns(4,5)P2, the substrate of PI3K, 
was found to inhibit substrate binding and GEF activity of the DH domain of Vav and Sos1 
[74], while the PI3K product (PtdIns(4,5)P3) binding to the PH domain of Vav and Sos1 
displayed enhanced GEF activity.  
Altogether these results support the hypothesis that phosphatidylinositol and the PI3K are 
important to modulate the activity of different GEFs proteins. 
 
An important characteristic of Rho-GEFs is that they can organize pathways downstream of 
Rho-GTPases. This has been shown for the Rac-specific GEF Tiam1, which recruits, 
through the scaffold protein JIP 2, a signaling complex that transduces activating signals 
from Rac1 to the activation of p38 MAPK [75]. 
In addition, another Rho-GEF protein, named p115-Rho-GEF, is coupled with the scaffold 
protein hCNK1 (human connector enhancer of ksr), which organizes and regulates JNK 
pathway following RhoA activation (Fig. 1.5). Moreover, this study indicated that the 
macromolecular complex organized by hCMK1 is important to induce the stress-fiber 
formation and SRF activation [76].   
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Altogether these results have highlighted the role of Rho-GEFs as crucial proteins that 
transduce activating signals from the heterotrimeric G-proteins to the activation of the small 
Rho-GTPases. Moreover recent evidence has demonstrated that Rho-GEF proteins can act 
as scaffold proteins and organize macromolecular signaling complexes.  
 
 
 
 
 
 
 
 
 
 
1.6 Signaling pathways activated by RhoA during cardiac 
hypertrophy 
 
Rho-GTPases mediate their cellular effects by interacting and activating target proteins, 
termed effectors, which preferentially associate with the active (GTP-bound) form of the 
GTPase.  Several RhoA effectors are currently known, including three families of protein 
kinases, the Rho-activated kinases (ROCK1 and 2), Citron kinase and PKN-related kinases 
(PRK1 and PRK2), the myosin binding subunit of the myosin light chain phosphatase 
(MBS), as well as adaptor proteins such as Rhotekin, Rhophilin, Citron-N, Diaphanous 
homologues (Dia1, mDia2, and mDia3), and kinectin.  
Interestingly, among these effectors, only ROCKs and PRK1 have been shown to play a 
role in transducing hypertrophic pathways downstream of RhoA.  
1.6.1 ROCK   
 
The first characterized effector of RhoA is ROCK, a serine/threonine kinase that serves as 
an important mediator of numerous cellular functions, including focal adhesion formation, 
motility, smooth muscle contraction, and cytokinesis. ROCK is found in two forms, ROCK 
Figure 1.5: Scaffold proteins determine 
the signaling specificity of Rho-GTPase. 
Cell-surface receptors coupled to the 
heterotrimeric G proteins G!12 and G!13 
activate the small GTPase Rho via 
RhoGEFs, including p115-RhoGEF The 
ability of the scaffold protein hCNK1 to 
form a molecular bridge between p115-
RhoGEF, Rho, and the protein kinases 
MLK3 and MKK7, leads to the selective 
activation of JNK by Rho via this MAPK 
cascade. Marinissen and Gutkind. Trends 
Biochem. Sci. 2005. 
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1 (ROCK"; p160- ROCK) and ROCK 2 (ROCK!). Both ROCK 1 and ROCK 2 contain an 
amino-terminal catalytic kinase domain, a central coiled-coil domain of about 600 amino 
acids, and a carboxyl-terminal pleckstrin homology (PH) domain that is split by a cysteine-
rich region. The C-terminal of ROCK is thought to inhibit the kinase activity by masking 
the kinase domain. Rho-GTP interacts with the C-terminal portion of the central coiled-coil 
domain and activates the kinase activity of ROCK [45]. 
ROCK promotes actin–myosin-mediated contractile force generation through the 
phosphorylation of numerous downstream target proteins. For example, ROCK 
phosphorylates LIM kinase-1 and kinase-2 (LIMK1 and LIMK2) at conserved threonines in 
their activation loops, increasing LIMK activity, and the subsequent phosphorylation of 
cofilin proteins, which blocks their F-actin-severing activity [77].  
 
The implication of ROCK in cardiomyocyte hypertrophy has been shown in vitro and in 
vivo. Hypertrophic stimuli such as PE, AngII and ET-1 activate RhoA/ROCK pathway in 
RNVMs [53-55]. Interestingly blocking the ROCK activity in myocytes, using the specific 
inhibitor Y27632, reduced the activity of the transcription factors SRF and GATA4 that are 
known to mediate the hypertrophic response downstream of RhoA [78]. 
On the other hand, an important study indicates that ROCK1 haplo-insufficient mice did not 
show any decreased hypertrophy but rather decreased fibrosis in respect to the wild type 
mice [79]. 
Similarly, treating chronically hypertensive rats with two Rho kinase inhibitors, Y-27632 
and fasudil [80], abolished fibrosis but not hypertrophy induced by hypertension. 
Normally, inhibition of ROCK with Y-27632 can reduce infarct size and apoptosis resulting 
from 30 minutes ischemia followed by 24 hour of reperfusion. Interestingly, inhibition of 
Rho kinase prevented the ischemia/reperfusion-induced increase in proinflammatory 
cytokines, suggesting a possible role for RhoA/ROCK signaling in cardiac inflammation in 
vivo [81]. 
 
Altogether these findings indicate that activation of RhoA/ROCK signaling in the heart is 
deleterious. What is unclear from these studies is whether the observed salutary effect of 
blocking RhoA/Rho kinase signaling reflects changes in the cardiomyocyte or is a 
consequence of more directly inhibiting fibroblast proliferation/migration or of attenuating 
local inflammatory responses. 
 33 
1.6.2  PKN 
 
Protein Kinase N (PKN) is the first identified serine/threonine protein kinase activated by 
the RhoA. PKN is widely distributed in various organisms such as mammal, frog, fly, and 
starfish. There are at least three different PKN isoforms (PKN!/PAK-1/PRK-1, PKN", and 
PRK2/PAK-2/PKN#) in mammals. 
The general structure, common for all three isoforms (fig. 1.6), shows that in the C-terminal 
is placed a Ser/Thr type protein kinase domain which has high sequence homology to the 
one of PKC family members. The N-terminal region of PKN contains three tandem motifs 
of ~70 amino acids, each composed of a charged region followed by a leucine-zipper-like 
region. Structural analysis of the first repeat showed that it consists of two helices that form 
an anti-parallel coiled coil named ACC finger [82]. This domain is important because is 
responsible for the interaction with RhoA. 
In all isoforms of PKN there is a stretch of about 130 amino acids between the ACC domain 
and the catalytic domain of PKN that has a weak homology to the C2 domain of PKC % and 
&. The C-terminal part of the C2-like region functions as an auto-inhibitory region, which is 
sensitive to arachidonic acid (one of the activators of PKN) [83]. 
 
 
 
 
PKN has different effectors, which most of them include an SH3 domain such as 
phospholipase D1, !-actinin, and MLTK (Mixed lineage kinase-Like mitogen-activated 
protein Triple Kinase). Interestingly, it has been demonstrated that PKN! efficiently 
phosphorylates the kinase MLTK!, which has been recently identified as a MAPK kinase 
kinase (MAPKKK) for the p38 MAPK cascade. Phosphorylation of MLTK! by PKN! 
Figure 1.6: Primary structure of human PKN Mukay, J. Biochem. 2003 
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enhances its kinase activity in vitro. Furthermore, PKN! associates with each member of 
the p38# MAPK signaling pathway (p38#, MKK6, and MLTK!). These results suggest that 
PKN! functions not only as an upstream activator of MLTK! but also a putative scaffold 
protein for the p38 MAPK signaling pathway [84].  
In vitro, it has been demonstrated that PKN! stimulates actin stress fiber depolymerization 
and membrane ruffling in 3T3 L1 and Rat1-IR fibroblasts. The kinase-negative forms of 
PKN! (T774A or K644D) prevent insulin-induced actin stress fiber breakdown and 
membrane ruffling, suggesting that PKN! is involved in insulin-induced actin cytoskeletal 
reorganization [85]. 
 
In cardiomyocytes, PKN! acts downstream of RhoA to regulate the transcription of the 
hypertrophic transcription factor ANF through a serum response element (SRE), located in 
the responsive region of ANF, following the RhoA activation by PE stimulation [86].  
 
In vivo, a recent study has demonstrated that the activation of PKN in the heart mediates the 
survival of cardiac myocytes during ischemia/reperfusion [87]. Interestingly this paper has 
clearly shown that activation of PKN by oxidative stress causes cardiac hypertrophy 
without left ventricular dysfunction. Moreover, this study demonstrated that PKN mediates 
its protective effect in part through the induction of the small Heat Shock Protein !B-
crystallin (!BC), which in turn activates the ubiquitin-proteasome system. 
 
In summary, in vitro experiments indicate that PKN contributes to the formation of stress 
fibers, to the activation of the p38 MAPK and to the expression of hypertrophic genes, 
whereas in vivo PKN is able to protect the cardiomyocytes from oxidative stress activating 
the ubiquitin-proteasome system mediated the activation of !BC. 
The hypertrophic pathways linking PKN to the activation of p38 has been investigated 
during the last few years and will be discussed below. 
1.7 Mitogen-Activated Protein Kinases and cardiac 
hypertrophy 
 
The mitogen-activated protein kinase (MAPK) pathways are major signaling systems that 
transduce extracellular signals into intracellular responses such as growth, proliferation, 
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differentiation and apoptosis [88, 89]. MAPKs are proline directed serine/threonine kinases, 
which induce the vast majority of their physiological responses through the phosphorylation 
and activation of transcription factors [90]. Members of this protein kinase family regulate 
the expression of specific sets of gene and hence can mediate specific genetic responses to 
extracellular stimuli. Members of the MAPK family are activated by a protein kinase 
cascades in which the MAPK is phosphorylated and activated by a MAP kinase kinase 
(MAPKK) that is, in turn, phosphorylated and activated by a MAP kinase kinase kinase 
(MAPKKK) [88]. Frequently, a MAPKKKK kinase (MAP4K or MKKKK) activates the 
MAPKKK. The MAPKKKK or MAPKKK can be linked to the plasma membrane through 
a small GTPase or lipid. These MAPK cascades are organized into signaling complexes to 
create functional MAPK modules. Evidences collected over the past few years suggest that 
the organization of these modules are mediated by scaffolding proteins that interact with 
each of the protein kinases [91]. 
MAPKs are activated by dual phosphorylation of conserved threonine and tyrosine residues 
within the activation loop (denoted T-X-Y) and phosphorylate targets on serine and 
threonine residues within a consensus PXT/SP motif (X can depend on the MAPK).  
On the other hand, the catalytic activity of MAPKs is attenuated by dual specificity MAPK 
phosphatases (MKPs), which dephosphorylates tyrosine and serine/threonine residues.  
Active MAPKs frequently translocate from the cytoplasm to the nucleus to phosphorylate 
nuclear targets.  
Pathway specificity is regulated at several levels, including kinase-kinase and kinase-
substrate interactions, colocalization of kinases by scaffold proteins and localization to 
numerous subcellular structures such as: microtubules, endosomes, endoplasmic reticulum 
and actin cytoskeleton. 
 
At present five families of MAPKs have been defined in mammalian cells: extracellular 
signal-regulated kinases (ERK1 and ERK2), Jun N-terminal kinases (JNK1, JNK2 and 
JNK3); p38 kinase isozymes (p38!, p38", p38# and p38'); ERK3/ERK4; and ERK5 (Fig 
1.7) [92]. The first three, and their activators, are the most known and characterized ones. 
They are implicated in development and in different human diseases, so for this reason are 
targets for drug development. 
Among these kinases, ERK1/2 JNK, p38 and ERK5 have been described to play a role in 
the transduction of signals leading to cardiac hypertrophy. 
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Here below I will mainly focus on the role of ERK1/2, JNK and p38 kinases and highlight 
their importance in cardiac hypertrophy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.7.1  ERK1/2 
 
ERK1 and ERK2 are expressed in many tissues and form part of a MAPK module that 
includes the MAPKKK Raf (A-Raf, B-Raf, C-Raf/Raf-1) and the MAPKK MEK1/2. 
Ligands that bind the cell-surface-receptor tyrosine kinases or GPCRs, result in the 
activation of the small G-protein Ras by the Ras-GEF protein son of sevenless (SOS). Ras-
GTP then triggers the activation of the MAPK cascade composed by Raf, MEK1/2 and 
finally ERK1/2. 
In the heart, the ERK1/2 pathway is important during the heart development, and during the 
processes that lead to cardiac hypertrophy. Interestingly, during heart development ERK 
pathway plays several important roles in cardiomyocyte differentiation, cardiac 
morphogenesis, valve development and ventricular compaction [93]. 
The role of ERK1/2 in promoting cardiac hypertrophy has been extensively documented. 
Figure 1.7: Schematic representation of mammalian MAPK cascades and target 
substrates, including transcription factors that are involved. Nature Reviews 
Molecular Cell Biology 3, 30-40 (January 2002) 
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In particular, in vitro experiments performed on RNVMs have shown that ERK1/2 is a 
mediator of cardiomyocyte hypertrophy induced by the stimulation of !1-ARs [94], "-ARs 
[95] ATRs [96] and ETRs [97]. In line with these findings, overexpression of a 
constitutively active MEK1 mutant in RNVMs, leads to cardiomyocyte hypertrophy, while 
overexpression of dominant-negative MEK1 attenuates this response [98].  
These findings have been partially confirmed in vivo. In fact transgenic mice expressing 
constitutively activated Ras (V-12-H-Ras) in cardiomyocytes developed pathological 
cardiac hypertrophy leading to sudden death [99]. In line with these results, the group of 
Muslin has shown that inhibition of the ERK1/2 pathway by overexpression in vivo the 
dominant negative Raf attenuated hypertrophy and fetal gene induction in response to 
pressure overload [100].  
However, several studies also indicate that the ERK1/2 pathway can protect cardiomyocytes 
from apoptosis. In fact cardiac specific overexpression of dominant negative-Raf sensitized 
the heart to pressure overload and promoted cardiomyocyte apoptosis [100]. Similarly it has 
been reported that reduction of ERK1/2 activity leads to an increase in cardiomyocyte 
apoptosis without a significant impact on cardiac hypertrophy [101].  
 
Recently, an important study has demonstrated that, upon dissociation from G!q, the G"# 
subunit of Gq can interact with ERK1/2. This leaded to autophosphorylation of the kinase, 
its translocation to the nucleus, and the activation of pro-hypertrophic genes. This event is 
sufficient to induce cardiac hypertrophy and it has been reported in different failing human 
hearts [28]. 
In the same period another paper has demonstrated the role of ERK1/2 pathway in the 
regulation of cardiac fibrosis. In particular this study has shown that microRNA-21 (miR-
21, also known as Mirn21) regulates the ERK pathway in cardiac fibroblasts, through the 
inhibition of sprouty homologue 1 (Spry1), that in turn negatively regulates the Ras/ERK 
pathway. Interestingly this paper has reported that in different human failing heart the levels 
of miR-21 and phosphorylated-ERK were increased whereas the level of Spry1 was 
dramatically decreased compared to the non-failing hearts [102]. In contrast a very recent 
paper of Olson has indicated that miR-21-null mice are normal and, in response to a variety 
of cardiac stresses, display cardiac hypertrophy, fibrosis, up-regulation of stress-responsive 
cardiac genes, and loss of cardiac contractility similarly to wild-type mice [103]. 
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Altogether these results suggest that ERK1/2 has an important role to induce cardiomyocyte 
hypertrophy and to prevent cardiomyocyte apoptosis. On the other hand this pathway seems 
to be essential during the progression of cardiac fibrosis. 
 
1.7.2  JNK 
 
Members of the JNK family play crucial roles in regulating responses to various stresses, 
cellular development, inflammation, and apoptosis. There are ten isoforms derived from 
three genes: JNK1, JNK2 and JNK3. Interestingly JNK1 and JNK2 are expressed in many 
tissues while JNK3 is more restricted to the heart, brain and testis. At the molecular level 
JNK activation is induced by two MAPKKs named MEK4 and MEK7, which can integrate 
activating signals from at least 13 MAPKKKs including MEKK1-MEKK4, ASK and 
MLKs.  
JNK cascades are organized by different scaffold proteins (including JIP1, JIP2, 
JIP3/JSAP1, JIP4, "-arrestin 2, filamin and CrkII) that presumably target the JNK modules 
to different sites in the cell and play roles in kinase activation and/or substrate selection 
[104]. 
The role of JNK in the heart and particularly in cardiac hypertrophy is not clear because 
there are conflicting results among the experiments performed in vitro and in vivo. 
Initial in vitro studies have shown a potential role of the JNK pathway to induce 
hypertrophy. For example, the over-activation of JNK by constitutively active MKK7 led to 
a hypertrophic phenotype [105]. Likewise the dominant negative MKK4 was able to block 
the ET-1-induced hypertrophy of cultured myocytes [106]. Interestingly the same group has 
confirmed this last result in vivo, by over-expressing the dominant negative MKK4 in the 
adult rat heart by adenovirus-mediated gene transfer. This study indicated that 
overexpression of dnMKK4 reduced cardiac hypertrophy induced by pressure over-load 
[107]. In addition, another study has shown that cardiac specific inactivation of MEKK1 
(the MAPKKK upstream of MKK4 and MKK7) blocked Gq-induced hypertrophy [108].  
In contrast, several additional studies in vivo did not support this hypothesis. In particular, it 
has been shown recently that cardiac-specific deletion of MKK4 increased cardiac 
hypertrophy in response to pressure overload and in response to "-adrenergic stimulation 
[109]. Similarly the activation of JNK by overexpressing constitutively active MKK7 in the 
heart of transgenic mice did not induce cardiac hypertrophy [110]. 
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Finally, an important study performed by the group of Rockman has investigated the role of 
the three different JNK isoforms in pressure overload induced cardiac remodeling. In this 
study they have generated three different cardiac specific knockout mice for the JNK1, 
JNK2 and JNK3. In response to pressure overload all three JNK knockout mice developed 
cardiac hypertrophy similar to wild-type mice (WT). [111]. 
 
In summary the role of JNK pathway in cardiac hypertrophy is still controversial with clear 
contrast results obtained in vitro, using cultured cardiomyocytes showing a pro-
hypertrophic role of the JNK pathway, and in vivo using animal models showing an anti-
hypertrophic role of the JNK pathway. This discrepancy perhaps reflects the complexity of 
signaling network involved in this process. 
1.7.3  p38  
 
The p38 MAPK (p38) family constitutes a second family of MAPK that are activated by 
numerous physical and chemical stresses, such as: UV irradiation, ischemia, cytokines 
(interleukin-1 and tumor necrosis factor), osmotic shock and heat shock.  
Currently four isoforms of p38 including p38! (MAPK14), p38" (MAPK11), p38# 
(MAPK12/ERK6) and p38' (MAPK13/SAPK4) have been identified. 
The p38! and p38" isoforms are expressed ubiquitously in adult tissues while the 
expression of p38# is restricted mostly to skeletal muscle, and p38' is enriched in lung, 
kidney, pancreas, placenta, and testis. 
Structurally the p38-MAPK is composed of two domains: a 135-residue N-terminal domain 
that is composed largely of "-sheets and a 225-residue C-terminal domain that contains the 
catalytic site, magnesium binding sites, and phosphorylation sites [112]. The catalytic site 
lies at the junction between the two domains [113], and the common docking domain is 
located towards the C-terminus and is involved in the specific binding of upstream 
activators, substrates and phosphatases [114].  
All the p38 kinases have the Thr-Gly-Tyr (TGY) dual phosphorylation motif, which is 
phosphorylated by upstream p38 activating kinases and corresponds to threonine (Thr180) 
and tyrosine (Tyr182). 
 
Numerous MAPKKKs participate in the activation of p38 MAPK pathway, including ASK1 
(Apoptosis signal-regulating kinase 1), kinases belonging to MLK (Mixed-lineage kinases) 
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family and Tak1 (TGF-beta-activated kinase 1). The MLKs regulate both p38 and JNK 
signaling pathways. Based on the domain arrangements and sequence similarity, MLK 
members are divided into three subgroups including: the MLKs, the dual-leucine-zipper-
bearing kinases (DLKs), and zipper sterile-alpha-motif kinase (ZAK) (table 1). 
In contrast, only three MAPKKs have been characterized to directly activate p38, including 
MKK3, MKK6 and MKK4. The MKK6 is able to activate all 4 isoforms of p38, whereas 
MKK3 preferentially phosphorylates the isoforms ! and ". [115]. MKK4 was originally 
identified to be an upstream kinase of JNK, however subsequent studies have shown that it 
can also promote the activation of p38! and p38' [116]. 
It is currently believed that p38 MAPK modules, containing distinct combinations of 
MAPKK and MAPKKK, can be assembled by specialized scaffolding proteins including 
JIP1, JIP2 and PKN [75, 84, 117]. Interestingly, among these scaffolds, PKN is the only one 
that is expressed in cardiomyocytes. 
An interesting study suggested that PKN might represent a key-signaling enzyme that 
transduces signals from activated RhoA down to p38. In particular this study has shown that 
PKN! can assemble and organize a signaling module that includes MLTK!, MKK3/6 that 
promotes the activation of p38# [84]. 
 
Subfamily Synonyms Production in 
mammals 
MLK   
MLK1 / Epithelial cells 
MLK2 MST Brain, skeletal muscle, 
testes. 
MLK3 SPRK1 
PTK1 
Widely produced 
MLK4! / Unknown 
MLK4" / Unknown 
DLK   
DLK ZPK 
MUK 
Brain, Keratinocytes, 
regenerating liver 
LZK / Widely produced 
ZAK   
ZAK! MRK Widely produced 
 
ZAK" 
MLTK 
MLK7 
ZAK 
Widely produced 
 
Table 1: Nomenclature and synonyms of mixed lineage kinase (MLK) 
 41 
p38 can also be activated in a MKK-independent manner by two non-canonical pathways. 
The first one is mediated by the interaction of p38 with TAB-1 (Transforming growth factor 
" Activated kinase 1 binding Protein-1) that in turn leads the autophosphorylation and 
activation of p38 [118]. The second requires the phosphorylation of p38 on Tyr 323 by the 
T cells receptor-activated tyrosine kinase Zap70 (Zeta-chain-associated protein kinase 70). 
This event promotes subsequent autophosphorylation of p38 on residues Thr180 and 
Tyr182 [119].  
Once activated, p38 can mediate its effects in the cytoplasm by activating substrates such as 
the MAP kinase-activated protein kinase 2 (MK2), MAP kinase interacting kinase1 
(MNK1) lymphocyte-specific protein 1 (LSP1), Na+/H+ exchanger isoform, keratin 8, exc, 
or by activating nuclear substrates such as different transcription factors (ATF1/2/6, CHOP, 
p53, GATA4, MEF2A/C, ELK1, NFAT exc) [120]. 
The different effector proteins activated by p38 signaling pathways indicate that this protein 
kinase can regulates different cellular processes such as: 
• Inflammation: A strong link has been established between the p38 pathway and 
inflammation. For example the activation of p38 plays essential roles in the production 
of pro-inflammatory cytokines (IL-1", TNF-! and IL-6) [120] 
• Apoptosis: Abundant evidences exist for the involvement of p38 in apoptosis [121]. 
In particular it seems that p38! has a strong role to induce apoptosis. This finding 
was clearly shown by that overexpression of the constitutively activated MKK3, 
which increased the apoptosis of RNVMs. This apoptotic effect was suppressed by 
co-expression of the dominant negative p38! [122]. 
• Cancer development: It has been reported that p38 activation may be reduced in tumors 
and that loss of components of the p38 pathway such as MKK3 and MKK6 results in 
increased proliferation and likelihood of tumorigenic conversion regardless of the cell 
line or the tumor induction agent used [123] On the other hand there are several 
findings that indicate an important role of p38 on cell proliferation [124]. 
• Cell differentiation: p38! and p38" have been implicated in cell differentiation for 
certain cell types for example differentiation of 3T3-L1 cells into adipocytes [125]. 
Interestingly, different studies support the hypothesis that p38 regulates the 
differentiation of human embryonic stem cells into cardiomyocytes [126, 127]. 
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• Cell cycle: The participation of p38! in cell growth has been observed in both yeast 
and mammals. For example G1 arrest of NIH3T3 cells caused by microinjection of 
Cdc42 was found to be p38!-dependent [128] 
• Development: p38 has been linked to placental angiogenesis and erythropoietin 
expression suggesting a role in erythropoiesis [89] 
• Cardiac hypertrophy: During progression of hypertrophy, both p38! and p38" levels 
were increased even if the 2 isoforms appear to have different effects that will be 
discussed below. 
 
p38 signaling in cardiac hypertrophy  
 
The implication of p38 isoforms in cardiomyocyte hypertrophy was initially suggested by in 
vitro studies performed in primary cultures of RNVMs using pharmacological inhibitors of 
p38. In particular, it has been shown that inhibition of the p38 pathway using the 
pharmacological inhibitor SB203580 was able to reduce hypertrophic cardiomyocyte 
growth in response to phenylephrine stimulation [129]. Likewise, the same study has shown 
that over-expression of the constitutively active MKK6, which specifically activates p38, 
was able to induce hypertrophy in absence of any hypertrophic stimuli. 
These findings are in contrast with other results showing that the p38 inhibitor, SB203580, 
had no effect on ET-1-induced hypertrophy [106]. 
The in vivo evidence of p38 in cardiac hypertrophy is even more conflicting. In fact some 
studies clearly showed that cardiac-specific overexpression of dominant negative p38 either 
had no effect on hypertrophy or sensitized the heart to hypertrophy in response to pressure 
overload [130, 131]. 
Similarly, a recent study reported that transgenic-mice over-expressing in the heart either 
constitutively active MKK3 and MKK6 did not develop cardiac hypertrophy, but instead 
interstitial fibrosis. These mice die prematurely due to cardiac failure [132]. 
In contrast other studies suggest a prohypertrophic role of p38. This is the case in mice with 
the cardiac-specific inducible expression of constitutively active MKK3 that led to 
cardiomyocyte hypertrophy, cardiac remodeling and contractile dysfunction. Interestingly, 
the hypertrophic effects of MKK3 required MK2-dependent up-regulation of ciclo-
oxigenase-2 (COX2). While COX-2 has been involved in the pathology of heart failure, the 
role and mechanism whereby COX-2 controls remain to be characterized. Furthermore, in 
this study it has been demonstrated that removal of the MK2 gene, that is one of the most 
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characterize p38 effectors, rescued some aspects of this pathological response, including 
partially ameliorated hypertrophy and contractile dysfunction, and prevention of early 
lethality. These beneficial effects were partially the consequence of the increased-protein 
synthesis of the MK2 [133]. Unfortunately the exact role of COX-2 in cardiac physiology 
and disease remains controversial even if during the last years different studies reported that 
specific COX-2 inhibitors significantly increased the risk of heart disease in chronic users 
[134].  
These conflicting results can be explained by the fact that in heart the two main isoforms of 
p38 can promote different functions. In this context it seems that p38! (the predominant 
isoforms) plays role in cardiomyocyte apoptosis while the p38" seems to promote 
cardiomyocyte hypertrophy [122, 129, 135, 136]. 
Taken together these results indicate that the role of p38 in cardiac hypertrophy is a 
conflicting one. It seems that an acute activation of p38 is pro-hypertrophic while a chronic 
activation can lead to suppression of hypertrophic growth.   
 
On the other hand recent findings have reported an interesting role of p38 in physiological 
hypertrophy. In particular an important study has shown that mice with a cardiac-specific 
deletion of ASK1 and a conditional cardiac knockout of p38 had an increased cardiac 
hypertrophy without fibrosis in response to swimming [137]. Partially in contrast, another 
study has demonstrated that transgenic mice over-expressing the p38 dominant-negative in 
response to swimming did not show any increased cardiac hypertrophy as compared to the 
wild-type mice [138]. 
Moreover, in the same study a transgenic mice line that over-expressed the dominant-
negative protein 14-3-3 (that is a regulatory protein for p38) has shown a maladaptive 
hypertrophy with increased fibrosis and cardiomyocyte apoptosis in response to swimming 
[138]. As expected these mice had an increased p38 activity. 
 
However, it is clear from both in vitro and in vivo studies that p38 activation has a 
detrimental effect on cardiac function and normal gene expression. Therefore, p38 induction 
is more closely related to pathological form of hypertrophy than to physiological 
compensation. 
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1.8 The p38 effector proteins activated during 
cardiomyocyte hypertrophy 
1.8.1 Transcription factors activated by p38  
 
In cardiomyocytes, p38 has been shown to promote the activation of the hypertrophic 
transcription factors GATA4 and MEF2. 
 
GATA transcription factors are characterized by the conserved double zinc fingers that are 
required for binding to the specific consensus DNA sequence (A/T)GATA(A/G). Among 
the six GATA transcription factors in vertebrates, GATA4, GATA5, and GATA6 are 
expressed in the heart. Interestingly, GATA4-cardiac specific knockout in mice resulted in 
embryonic lethality with strong morphological defects of the heart indicating an important 
role of GATA4 during cardiac embryonic morphogenesis [139].  
Functional analysis of the cis-regulatory elements has revealed that GATA4 directly 
regulates expression of cardiac-specific genes, such as: !-myosin heavy chain (!-MHC), "-
myosin heavy chain ("-MHC), myosin light chain 1/3 (MLC1/3), cardiac troponin 
C, cardiac troponin I, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), 
cardiac sodium-calcium exchanger (NCX1) exc [140]. 
Consistent with the different genes regulated by GATA4, several studies have demonstrated 
that GATA4 plays an essential role in the activation of the fetal gene program in response to 
hypertrophic stimulation. 
The functional activity of GATA4 is regulated through direct serine phosphorylation by the 
p38 and ERK1/2 following the stimulation of GPCRs, including !1ARs and AT1Rs [141-
143]. 
In this context, it has been shown that activation of !1ARs in RNVMs by PE stimulation, 
activates a signaling pathway, which includes RhoA and p38 that increase the GATA4 
transcription activity. In addition this study has identified for the first time that GATA4 is a 
RhoA/p38 mediator in sarcomere reorganization and hypertrophic gene regulation [141]. 
During the same period, the group of Sasayama demonstrated that the RhoA/ROCK 
pathway is linked to PE-induced GATA4 activation through the ERK pathway [55]. 
These findings demonstrate that regulation of GATA4 activity by the Rho/ROCK-ERK 
pathway promotes myocardial cell hypertrophy. 
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In addition, to phosphorylation the activity of GATA4 can also be regulated by interaction 
with transcriptional co-activators such as p300 and through the interaction with different 
transcription factors including: SRF, NFAT, FOG2, Nkx2-5 and MEF2 [144]. 
 
Taken together these results suggest that, hypertrophic stimuli positively regulate through 
multiple signaling pathways the GATA4 transcriptional activity. They also indicate that 
GATA4 plays an essential role in modulating the transcriptional regulation of subset of 
genes during the hypertrophic response. 
 
On the other hand MEF2 family are the other important class of transcription factors 
activated by p38 during the cardiac hypertrophy.  
In vertebrates, 4 members of MEF2 family (MEF2-A, MEF2-B, MEF2-C, and MEF2-D) 
have been identified. All the isoforms are expressed in many cells types and promote 
transcriptional regulation in the immune system, neurons, and striated muscle [145]. 
The two isoforms MEF2A and MEF2C appear to be more expressed in the postnatal mouse 
heart. Interestingly, targeted disruption of MEF2C has been shown to affect the 
morphological development of the heart during embryogenesis. Several cardiac genes 
including atrial natriuretic factor (ANF), cardiac !-actin, !-myosin heavy chain and myosin 
light chain (MLC)–1A expression have been shown to be down-regulated in MEF2C-null 
embryos, indicating an essential role of MEF2 in myocardial cell differentiation [146]. 
Similarly transgenic mice overexpressing dominant-negative MEF2C in the heart displayed 
attenuated postnatal growth of the myocardium [147].  
MEF2 specifically binds the consensus DNA sequence CAT(A/T)4TAG/A and, 
consistently, to the A/T-rich DNA sequences that have been identified within the promoter 
regions of a number of cardiac genes, including !-MHC, MLC1/3, MLC2v, skeletal !-
actin, sarcoplasmic reticulum Ca2+-ATPase, cardiac troponin T, cardiac troponin C, cardiac 
troponin I, desmin, and dystrophin [148].  
MEF2C is upregulated during the cardiac hypertrophy [147]. Interestingly, it has been 
reported that in the hypertrophied heart p38 phosphorylates and activates MEF2C but 
unfortunately the patho-physiological relevance of this event is not fully understood [129, 
148]. 
Like GATA4, the MEF2 activity is regulated by several other proteins including the protein 
kinase ERK5[149], Ca2+/CaM-dependent protein kinases (CaMKs), histone deacetylases 
(HDACs) [150], MyoD [151], NFAT [152], and GATA4 [153].  
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Altogether these results suggest that MEF2 and GATA4 are able to activate the transcription 
of several cardiac genes, such as ANP, BNP, !-MHC and !-cardiac-actin, indicating a 
cooperative role of MEF2 and GATA4 in the transcriptional regulation of these cardiac 
genes. However, it remains to be determined whether the transcriptional synergy between 
MEF2 and GATA4 is implicated in the generation of cardiac hypertrophy. 
1.8.2 Non-genomic pathway activated by p38 
 
As already reported before, p38 is able to activate a downstream protein kinase named MK2 
[154] [155]. 
 
The mRNA of MK2 is expressed at detectable levels in most tissues, while at the protein 
level two different isoforms of MK2 have been described.  
MK2 phosphorylates a variety of substrate proteins including heat shock proteins (Hsp27, 
!B-crystallin), enzymes that interact with the cytoskeleton (CapZ-IP, LSP1), mRNA-
binding proteins (hnRNP), transcription factors (SRF), and regulators of the cell cycle and 
apoptosis (Cdc25C, BAG). Phosphorylation of these substrates by MK2 regulates the 
different cellular processes, such as the reorganization of the cytoskeleton, cell migration, 
cell-cycle regulation, chromatin remodeling and apoptosis [156]. 
In the heart, two different studies have shown a potential adverse effect of MK2 in response 
to stress stimuli. The first shows that MK2 cardiac-specific knockout mice were resistant to 
ischemia reperfusion injury [157]. Similarly, a second study indicates that cardiac-specific 
KO of MK2 in mice partially protects the heart from cardiac hypertrophy, interstitial 
fibrosis and contractile dysfunction induced by the acute activation of the p38 pathway 
[133]. Altogether these studies in vivo suggest that MK2 is a potential target of intervention 
for cardiomyopathy. 
At the molecular level, one of the well characterized substrates of MK2 is the small 
chaperone protein Hsp27. Heat shock proteins (Hsps) are a family of highly conserved 
proteins which are activated by many cellular stresses and most of them function as 
chaperone proteins. 
Hsp27 is member of the small heat shock protein family (HSPB) and displays a molecular 
weight of  27 kDa, but it can form large aggregates of around 800 kDa in the cytosol [158]. 
The Hsp27 mRNA is highly expressed in several tissues such as breast, uterus, cervix, 
placenta, skin, lung, heart and platelets. It has been involved in different biological 
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functions including cell migration, inhibition of apoptotic regulation, protection against 
oxidative stress, and modulation of inflammation [159]. The best characterized functions of 
Hsp27 are the ability to modulate actin polymerisation and to protect filaments degradation 
interacting with cytoskeleton components such as actin, intermediate filaments and 
microtubule [160].  
In vitro it has been shown that in response to stress stimuli Hsp27 can be phosphorylated by 
different kinases including MK2/3/5, PKA and ASK1, that increased its chaperone activity, 
whereas in vivo studies have demonstrated that the phosphorylated-Hsp27 is able to 
stabilize actin filaments [161, 162].  
In particular, a recent study reported that in human endothelial cells the phophorylation of 
Hsp27 regulates the actin microfilament dynamics and cell migration [163]. Similarly, 
others studies on endothelial cells pointed out that a heat shock induces an association of 
Hsp27 with stress fibres [164].  
Collectively these results suggest that, following a stress, phosphorylated Hsp27 associates 
with actin filaments and stabilizes them.  
Nevertheless, during the last years different studies indicate that Hsp27 has a direct anti-
apoptotic function in response to stress stimuli. 
In this context  a recent study in monocytes has demonstrated that Hsp27 during apoptosis 
is able to interact with caspase-3 and inhibit its apoptotic activity [165]. 
In agreement with this anti-apoptotic effect, an important finding has clearly shown that 
Hsp27 regulates the p53 activity and blocks the cellular toxicity, induced by the 
doxorubicin treatment, in cardiac H9c2 cells. Overall this study has demonstrated that the 
anti-apoptotic effect of Hsp27 was mediated by an up-regulation of p21, which prevents the 
cell death [166].  
In addition, a very recent paper has demostrated that Hsp27 protects adenocarcinoma cells 
from UV-induced apoptosis by the increased Akt stability and subsequently a prolonged 
p21-activation pathway that improved the survival of the cells [167]. 
Altogether these findings demonstrated that Hsp27 has a strong link with the anti-apoptotic 
function.  
 
During the last five years different studies have begun to characterize the role of Hsp27 in 
cardiac phisiology.  
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An early study reported that the p38/Hsp27 pathway is involved in the differentation of the 
cardiomyocytes [126]. Interestingly, in xenopus Hsp27 is critical in the development of 
cardiac and skeletal muscle tissues [168].  
On the other hand, some studies have demonstrated that over-expression of Hsp27 can 
protect cardiomyocytes against ischemic injury. In this context, Gaitanaki et al. have 
reported that the phosphorylated Hsp27 has a cardio protective role  in isolated perfused 
amphibian heart, in response to oxidative stress [169]. Interestingly, different studies in vivo 
have suggested that Hsp27 can relocalize to the sarcomere in response to different stress 
stimuli, such as ischemic preconditioning and heat shock [170, 171]. 
 
Currently there is not evidence indicating a potential role of the pathway p38-MK2-Hsp27 
in cardiac hypertrophy. It will be challenging to understand the functional role of this 
pathway in cardiac hypertrophy. 
1.9 The A-kinase anchoring protein family  
 
The cyclic AMP-dependent protein kinase (PKA) is a ubiquitous broad specificity 
serine/threonine kinase that controls a variety of cellular functions including metabolism, 
gene transcription, channel conductivity, cell growth, cell division [172]. It consists of a 
heterotetramer formed by two catalytic subunits held in an inactive state by association with 
a regulatory (R) subunit dimer. Binding of cAMP to the R subunits induces the dissociation 
and the activation of the catalytic subunits, and results in the phosphorylation of local 
substrates [172]. Stimulation of cardiac "-adrenergic receptors by norepinephrine (NE) 
released by sympathetic nerve terminals promotes PKA activation via a signaling pathway 
that includes the ! subunit of the heterotrimeric G protein Gs and adenylyl cyclase (AC). 
Activated PKA plays a key role in modulating several cardiac functions including cardiac 
contractility, action potential duration and cardiac hypertrophy. At the cellular level, 
specificity of PKA action is achieved by controlling the subcellular localization of the 
kinase through the interaction of the regulatory subunits with A-kinase anchoring proteins 
(AKAPs), a group of functionally related proteins, which can be classified on the basis of 
their ability to associate with the PKA holoenzyme inside cells [173]. By positioning PKA 
in proximity of substrate targets and of cAMP gradients, which are generated at discrete 
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cellular microdomains by the opposing action of ACs and phosphodiesterases (PDEs), 
AKAPs ensure accurate substrate phosphorylation [174]. 
 
All members of the AKAP family share a conserved PKA anchoring domain which consists 
of a conserved amphipatic helix of 14-18 residues that interacts with an hydrophobic groove 
in the docking/dimerization (D/D) domain located in the extreme N-terminus of the 
regulatory subunit dimer [175, 176]. Compartmentalization of individual AKAP-PKA 
complexes occurs through specialized protein-protein or protein-lipid targeting domains 
located on each anchoring protein [173]. Another fundamental role of several AKAPs is 
their ability to coordinate other signaling enzymes such as kinases, phosphatases, 
phosphodiesterases, GTPases and other regulatory proteins into multivalent transduction 
complexes [174]. Finally, recent evidence demonstrates that AKAPs can form even larger 
macromolecular complexes by interacting directly or through adaptor proteins with 
upstream activators and/or with downstream PKA substrates [174]. Therefore, AKAPs can 
be considered as transduction units that ensure integration and processing of multiple 
signals to coordinately regulate the phosphorylation and function of specific cellular 
substrates. 
 
 
 
 
 
 
 
 
1.9.1 AKAPs in cardiac physiology 
 
Different AKAPs are expressed in cardiomyocytes including Gravin, Troponin T, AKAP2, 
AKAP9 (Yotiao), mAKAP, AKAP18!/', AKAP95, AKAP79, AKAP121, AKAP220, 
AKAP250, AKAP350 and AKAP-Lbc, however a clear functional role has been established 
for a few of them [177].   
 
 
Figure 1.9 Functional motifs of 
AKAPs : (1) A conserved binding 
domain interacts with the AKAP binding 
surface on the regulatory subunit dimer 
of PKA. (2) Unique targeting domains 
direct AKAP signaling complexes to 
distinct intracellular locations. (3) 
Additional binding sites for other 
signaling components such as kinases, 
phosphatases, or potential substrates (4) 
Activation of substrates by PKA. 
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In this context, AKAP9 (Yotiao) can form a complex with the potassium channel KCNQ1, 
which controls the myocardial duration of the action potential by carrying outward the K+ 
[178].  
Interestingly, Yotiao anchors the PKA responsible for the phosphorylation serine 27 and 
activation of KCNQ1. It interacts also with the protein phosphatase 1 (PP1) which is 
responsible for the de-phosphorylation the KCNQ1 at serine 27 inactivating the channel 
[179]. 
 
At the level of the sarcolemma, AKAP79 and Gravin interact with " adrenergic receptor 
("1/2 for AKAP79, "2 for Gravin). These interactions increase the PKA phosphorylation of 
the receptors, that in turn regulates desensitization, internalization and recycling of the " 
AR [180]. 
AKAP18!, another AKAP present in the sarcolemma regulates the open probability of the 
L-type Ca2+channel, by PKA phosphorylation. This event is critically involved in 
cardiomyocyte contraction because increasing the open probability of the channel causes an 
influx of Ca2+ in the cytosol that activates the ryanodyne receptor (RyR2). Once the RyR2s 
are activated they release Ca2+ from the sarcoplasmic reticulum (SR) into the cytosol, thus 
promoting the cardiac contraction. 
Interestingly, the open probability of RyR2 is positively controlled by PKA phosphorylation 
of the inhibitory protein FKBP12.6 that is in turn regulated by mAKAP [181]. 
After cardiac contraction, the concentration of Ca2+ in the cytosol has to decrease to allow 
the next contraction.  The largest amount of Ca2+ in cardiomyocytes is stored in the SR, and 
at this level AKAP18' plays an important role in the re-uptake the Ca2+ back to the lumen 
of SR. 
AKAP18' interacts directly with phospholamban, which is a regulatory protein of SERCA  
(sarco/endoplasmic reticulum calcium ATPase). In response to " adrenergic stimulation, 
PKA anchored on AKAP18' phosphorylates phosholamban that is not able to block the 
activity of SERCA [182]. 
 
Altogether these findings have shed new light on the role of AKAPs in heart 
pathophysiology. We will selectively discuss the role of AKAP-based transduction units in 
coordinating signaling pathways that control cardiomyocyte hypertrophy.  
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1.9.2 AKAPs in cardiac hypertrophy 
 
mAKAP 
 
Recent studies have shown that mAKAP, a large anchoring protein of 255-kDa highly 
expressed in the heart, can be targeted to the nuclear envelope of cardiomyocytes. At this 
location, mAKAP integrates and transduces several hypertrophic signals, as shown by the 
fact that silencing of mAKAP expression strongly reduces hypertrophic gene transcription 
induced by isoproterenol, phenylephrine and the leukemia inhibitor factor (LIF) [183, 184]. 
At the molecular level, it is now demonstrated that anchoring of PKA at the nuclear envelop 
through mAKAP favors "-AR-induced phosphorylation and activation of RyR2 [185]. The 
consequent increase in perinuclear calcium is thought to activate calcineurin A" which is 
bound to mAKAP [183]. This would results in the dephosphorylation and translocation of 
the pro-hypertrophic transcription factor NFAT to the nucleus whether it can activate 
hypertrophic gene transcription [186].  
Additional biochemical studies have revealed that mAKAP directly interacts with the 
phosphodiesterase PDE4D3, which can recruit the pro-hypertrophic kinase ERK5 and its 
upstream activator MEK5 [184]. Since activated ERK5 can phosphorylate and activate the 
hypertrophic transcription factor MEF2c, one could raise the attractive hypothesis that, by 
positioning ERK5 in proximity of the nucleus, mAKAP could contribute to the activation of 
MEF2c-regulated hypertrophic genes.  
 
AKAP121 
 
AKAP121 assembles a multivalent signaling complex that includes PKA, the tyrosine 
phosphatase PTPD1, and src (proto-oncogene from avian sarcoma) on the outer membrane 
of mitochondria, and this plays an essential role in mitochondrial respiration. AKAP121 is 
widely expressed in different tissues and cell types, including cardiomyocytes [187]. 
Recent findings point to an important role in the regulation of the cardiomyocyte 
hypertrophy. 
In this context it has been shown that silencing of AKAP121 in RNVMs induced a 
pronounced hypertrophy whereas the over-expression of AKAP121 reduced the 
cardiomyocyte size and impaired hypertrophy induced by isoprotenerol [188]. Interestingly, 
this study has shown that a reduction of AKAP121 expression is associated with a strong 
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de-phosphorylation and nuclear localization of the NFATc3 transcription factor. Moreover, 
it has been demonstrated by co-immuno-precipitation experiments that AKAP121 interacts 
with the phosphatase calcineurin, which is the up-stream activator of NFATc3. 
Altogether these results identified AKAP121 as a negative regulator of cardiomyocyte 
hypertrophy. 
1.10 AKAP-Lbc 
 
We and others have identified a novel member of the AKAP family mainly expressed in 
cardiac tissues, termed AKAP-Lbc (AKAP13), that functions as a type II PKA anchoring 
protein as well as guanine nucleotide exchange factor (GEF) for the RhoA-GTPase [189, 
190]. RhoA-activation is mediated by consecutive Dbl (DH) and pleckstrin homology (PH) 
domains that are located in the C-terminal half of the anchoring protein [189]. 
  
A truncated form of AKAP-Lbc missing both N- and C-terminal regulatory sequences, 
called Onco-Lbc, was originally identified as an oncogene from myeloid leukemia patients 
[191]. This oncogenic protein displays constitutive Rho-GEF activity and is able to induce 
cell transformation in a Rho-dependent manner [192].  
Another splice variant of AKAP-Lbc, called Brx, has been identified in testis, estrogen-
sensitive tissues, and immune cells [193]. In lymphocytes Brx-activating p38 signaling 
pathway leads to the activation of the NFAT5 messenger RNA that promotes the production 
of cytokines and induces inflammation [194]. 
AKAP-Lbc is the longest isoform with 2817 ammino-acids and it is expressed 
predominantly in the heart while in other tissue such as lung, placenta, kidney, pancreas, 
skeletal muscle and liver its expression is very low. Interestingly AKAP-Lbc is also 
expressed in different cell lines including HEK293, NIH3T3 and HeLa cells. 
Our group has previously shown that Rho-GEF activity of AKAP-Lbc is strongly 
stimulated by the over-expression of the constitutive active G!12 as well as by the 
activation of GPCRs coupled to G!12 such as !1-ARs, ATIRs and LPA receptors (Fig. 
1.10) 
These findings place AKAP-Lbc in the growing family of Rho-specific exchange factors, 
including LARG, PDZ-RhoGEF and p115-RhoGEF, which relay signals from 
heterotrimeric G12/13 proteins to RhoA. 
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Evidence collected over the last ten years clearly indicates that PKA as a profound 
antagonistic effect on Rho signaling [195]. It is now appreciated that activation of the PKA 
holoenzyme anchored to AKAP-Lbc inhibits the Rho-GEF activity of the anchoring protein 
and blocks the activation of RhoA [195, 196]. 
 
 
 
 
 
 
 
 
 
Activated PKA phosphorylates the anchoring protein on serine 1565. This induces the 
recruitment of the regulatory protein 14-3-3, which inhibits the Rho-GEF activity of AKAP-
Lbc [195, 196] (Fig. 1.11). The inhibitory effect of 14-3-3 is also dependent upon the 
oligomerization state of AKAP-Lbc as well as the anchoring of PKA to the complex [197]. 
In this context, a second mechanism involving the ubiquitin-like protein LC3 regulates the 
GEF activity of AKAP-Lbc. Interestingly, binding of LC3 to AKAP-Lbc strongly reduced 
the ability of the anchoring protein to interact with RhoA, profoundly impairing the Rho-
GEF activity of the anchoring protein and, as a consequence, its ability to promote 
cytoskeletal rearrangements associated with the formation of actin stress fibers [198].  
 
During the last years several studies have demonstrated that AKAP-Lbc is able to act as a 
scaffold protein that organizes different multiprotein complexes that mediate the activation 
of numerous signaling pathways. 
 
Figure 1.11 Inactivation of AKAP-
Lbc: ([cAMP] activates the PKA 
localized on AKAP-Lbc. PKA promotes 
the phosphorylation of AKAP-Lbc on 
serine 1565. This phosphorylation event 
induces the recruitment of a 14-3-3 
dimer, which inhibits the Rho-GEF 
activity of AKAP-Lbc 
 
Figure 1.10 Activation of AKAP-Lbc: Activation of 
AKAP-Lbc occurs in response to agonists that 
stimulate G proteins coupled receptors linked to the 
heterotrimeric G protein G12. The G!12 activates the 
guanosine exchange factor located in the region 1922-
2337 of AKAP-Lbc which in turn switch on the small 
G protein RhoA. RhoA, through its effectors, 
regulates the organization of actin cytoskeleton and in 
the heart it is important during the process of cardiac 
hypertrophy 
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In this context, recently, the group of John Scott has reported that in HEK cells AKAP-Lbc 
and the scaffolding protein kinase suppressor of Ras (KSR-1) form a signaling complex that 
efficiently relay signals from Raf, through MEK, and on to ERK1/2 [199]. 
 
In addition the group of Podolsky has demonstrated that AKAP-Lbc mediates the NF-$B 
activation following the Toll Like-receptors induction (TLR2). Moreover this study has 
demonstrated that NF-$B activation depends on the GEF function of AKAP-Lbc and that 
AKAP-Lbc knockdown reduces TLR2-induced JNK phosphorylation but not ERK1/2 and 
p38 [200]. 
 
In cardiomyocytes, AKAP-Lbc activation occurs following stimulation of !1-ARs via the ! 
subunit of the heterotrimeric G protein G12 [189, 201]. Interestingly, silencing AKAP-Lbc 
expression in RNVMs strongly reduces both !1-AR-mediated RhoA activation and 
hypertrophic responses [201]. This suggested that this anchoring protein participates in a 
transduction pathway activated by the !1-ARs that includes G!12, AKAP-Lbc and RhoA 
that promotes cardiomyocyte hypertrophy. It is currently unknown which Rho effector 
molecules mediate the hypertrophic effect of AKAP-Lbc in cardiomyocytes.  Possible 
candidates could include ROCK [202] PKN [203] and stress-activated protein (SAP) 
kinases [29], which have been shown to control the transcription of genes involved in 
cardiomyocyte hypertrophy downstream of RhoA.   
Recently, Carnegie and colleagues have reported the very interesting finding that AKAP-
Lbc assembles a multiprotein complex that mediates the activation of protein kinase D 
(PKD) [204]. AKAP-Lbc contributes to PKD activation in two ways: first it recruits both 
PKD and its upstream activator kinase protein kinase Ch (PKCh), which phosphorylates and 
activates PKD in response to the activation of Gq-coupled GPCRs. Second, it facilitates the 
release of activated PKD into the cytosol, which occurs when serine 2737 within the PKD 
binding site of AKAP-Lbc is phosphorylated by anchored PKA [204]. Since PKD has 
recently been shown to play an important role in activating hypertrophic gene transcription 
via the regulation of chromatin-modifying enzymes [205, 206], one could raise the 
intriguing hypothesis that the released PKD could also contribute to the growth responses 
mediated by AKAP-Lbc. In fact they have demonstrated that PKD phosphorylates the 
histone deacetylase HDAC5 promoting its nuclear export. This event is crucial to increase 
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the activity of MEF2 transcription factor, which activates the hypertrophic response of 
RNVMs [207]. 
Based on these findings, one could speculate that interfering with the ability of AKAP-Lbc 
to activate Rho and/or to interact with PKD might represent a potential interesting strategy 
to reduce cardiac hypertrophy.  
 
Recent evidence indicates that in mice, expression of AKAP-Lbc is strongly induced in the 
heart at the onset of cardiac hypertrophy in response so several hemodynamic or 
neurohumoral stresses such as thoracic aortic constriction, chronic infusion of angiotensin II 
or phenylephrine [36]. High AKAP-Lbc expression is subsequently maintained during the 
transition from hypertrophy to heart failure. This raises the hypothesis that AKAP-Lbc 
might play a role in the pathological cardiac remodeling process in vivo. AKAP-Lbc Knock 
out mice die in utero between 8.5 and 10.5 days post because of defects in heart tube 
formation [208]. While this argued for a role of AKAP-Lbc in cardiac development, it does 
not preclude the possibility to analyze the implication of the anchoring protein in the 
process of cardiac hypertrophy and heart failure. 
 
So far, only few Rho-GEFs have been identified in cardiomyocytes. Interestingly, two 
sarcomere-associated Rho-GEFs, termed obscurin and p63Rho-GEF, have been proposed to 
control the organization of the sarcomeric cytoskeleton in RNVMs [209, 210]. 
These studies indicate that Rho-GEF proteins have a potential role in the organization of 
sarcomeric cytoskeleton, however it is not understood which pathways are activated by 
Rho-GEFs in response to hypertrophic stimuli. 
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II AIM OF THE THESIS 
 
 
In response to numerous pathologic stimuli, the myocardium undergoes a hypertrophic 
response characterized by increased myocardial cell size and activation of fetal cardiac 
genes. 
Our laboratory has previously shown that AKAP-Lbc is critical for transducing 
hypertrophic signals downstream of !1-ARs. While it is established that the effects of 
AKAP-Lbc on cardiomyocytes hypertrophy are mediated by the small molecular weight 
GTPase RhoA, it is currently unknown how hypertrophic signals are transmitted 
downstream of RhoA.  
 
In the first part of my thesis, I have characterized at the molecular level a newly identified 
signaling complex organized by AKAP-Lbc that is critical for activating the p38! MAPK 
downstream of !1-ARs. 
 
In the second part of my thesis, I have determined the implication of AKAP-Lbc/p38 
activation complex in cardiomyocyte hypertrophy. In particular I have characterized novel 
hypertrophic pathways activated by the AKAP-Lbc signaling complex in primary cultures 
of rat neonatal cardiomyocytes. 
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III MATERIALS & METHODS 
 
Expression Constructs  
 
AKAP-Lbc fragments encoding amino acids 1585-1922, 1625-1922, 1655-1922, 1715-
1922, 1765-1922, 1388–1585, 1388-1655, 1388-1715, 1388-1765 were PCR-amplified 
from the AKAP-Lbc pEGFPN1 vector [189] and subcloned at EcoRI/SalI into pFLAG-
CMV6 vector to generate protein fragments fused with the Flag epitope. A region encoding 
residues 1388-1922 of AKAP-Lbc was PCR-amplified from the AKAP-Lbc pEGFPN1 
vector and subcloned at SalI/NotI into pET30a vector to generate protein fragments fused 
with the histidine-tag. The AKAP-Lbc fragment encoding residues 1585-175 and 
corresponding to the PKN! binding domain of AKAP-Lbc was PCR-amplified from the 
AKAP-Lbc pEGFPN1 vector and subcloned at EcoRI/SalI into pFLAG-CMV6 and 
pEGFPN vectors to generate protein fragments fused with the Flag epitope and GFP, 
respectively. 
The Flag-tagged AKAP-Lbc mutant missing the PKN! binding domain was generated by 
deleting the region encoding amino acids 1585-1715 by standard PCR-directed mutagenesis 
using the Flag-AKAP-Lbc vector [42] as a template. 
Double-stranded hairpin (sh) oligonucleotides based upon the human AKAP-Lbc mRNA 
sequence (GI: 15986728, bases 6688-6706 and 228-246) were cloned into the HindIII and 
BglII sites in the pSUPER vector. The following oligonucleotides sequences were used: 
human AKAP-Lbc shRNA1 (sense strand) 5’ GTGCGTCTCAATGAGATTT 3’; human 
AKAP-Lbc shRNA2 (sense strand) 5’ GGTCAGTTCTGATACATTG  3’.  
To generate lentiviral transfer vectors encoding AKAP-Lbc shRNAs, cDNA fragments 
containing the H1 RNA polymerase III promoter as well as the sequences encoding 
shRNAs were excised using BamHI/SalI from the pSUPER vector and subcloned into the 
pAB286.1 transfer vector. Mission® lentiviral transfer vectors encoding PKN! shRNAs or a 
control non-target shRNA were purchased from Sigma.  These vectors contain a puromycin 
cassette that allows the selection of infected cells. The lentiviral packaging vectors 
pCMVDR8.91 and pMD2.VSVG  encode the viral capsid and the vesicular stomatitis virus-
G envelope protein, respectively [204]. 
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Double-stranded hairpin oligonucleotides based upon rat (GI: 109462150, bases 6533-6551) 
AKAP-Lbc mRNA sequence were cloned into the HindIII and BglII sites in the pSUPER 
vector. The following oligonucleotides sequences were used: rat AKAP-Lbc shRNA (sense 
strand) 5'-GCAAGTCGATCATGAGAAT-3'; mutated rat AKAP-Lbc shRNA (sense 
strand) 5'-GCATGTCGATCATGCGATT-3'. Underlined base pairs in the mutated shRNAs 
are different from the wild-type AKAP-Lbc shRNAs. To generate lentiviral transfer vectors 
encoding AKAP-Lbc shRNAs, cDNA fragments containing the H1 RNA polymerase III 
promoter as well as the sequences encoding shRNAs were excised using EcoRI/KpnI or 
BamHI/SalI from the pSUPER vector and subcloned into the pSD28-GFP or pAB286.1 
transfer vectors, respectively (1). The pSD28-GFP vector contains a GFP cassette under the 
control of a CMV promoter and was used to titer rat AKAP-Lbc shRNAs in HEK-293 
cells.. On the other hand, the vector. pAB286.1 vector contains a puromycin cassette that 
allows the selection of infected cells and was used to titer rat AKAP-Lbc shRNAs in HEK-
293 cells. Both vectors were used to express rat AKAP-Lbc shRNAs in primary cultures of 
rat cardiomyocytes. The lentiviral packaging vectors pCMVDR8.91 and pMD2.VSVG  
encode the viral capsid and the vesicular stomatitis virus-G envelope protein, respectively 
[204]. 
The full-length cDNA encoding human p38! was PCR amplified from a human heart 
cDNA library and subcloned at Not1-BamHI into pFLAG-CMV6, BamHI-XhoI into HA-
pRK5 or BamHI-Not1 into pGEX4T1 to generate proteins fused to the Flag and HA 
epitopes or GST, respectively. Similarly, the full-length cDNA encoding human MLTK" 
was PCR amplified from a human heart cDNA library and subcloned at NotI-BamHI into 
pFLAG-CMV6, BamHI-SalI into HA-pRK5 or BamHI-XhoI into pGEX4T1. Fragments 1-
305 and 305-942 of PKN! were amplified from Myc-PKN! (generous gift from Dr. S. 
Gutkind, NIH, Bethesda, USA) and subcloned at Not1-SalI and NotI/XhoI into pET30a, 
respectively, to generate fusion proteins with the histidine-tag. HA-tagged JNK1, MKK3, 
MKK6, MEK1, and MEKK1 as well as Flag-tagged JNK1 constructs were generous gifts 
from Dr. C. Widmann (Department of Morphology and Cell Biology, University of 
Lausanne). GFP-ERK1 was obtained from Addgene. Plasminds encoding HA-MLK3 and 
HA-TAK1 were generous gifts form Dr. L. B. Holzman (University of Michigan Medical 
School) and Dr. J. Ninomiya-Tsuji (North Carolina State University), respectively.  
The GATA4 Luciferase Reporter (Vector 0.7-kb ANF- luciferase plasmid) was provided by 
Mona Nemer (Montreal, Canada). 
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Vectors encoding Flag-AKAP-Lbc S1565A, AKAP-Lbc S1565A-GFP, Flag-tagged AKAP-
Lbc fragments encoding residues 1-503, 504-1000, 1001-1387, 1388-1922, 1923-2336, 
2337-2817, as well as 14-3-3" -GFP were described previously [42].  
 
Expression and purification of recombinant proteins in bacteria  
 
GST fusion proteins of AKAP-Lbc, p38!, MKK3 and MLTK were expressed using the 
bacterial expression vector pGEX-4T1 in the BL21DE3 strain of Escherichia coli and 
purified. Exponentially growing bacterial cultures were incubated 16 hours at 16°C with 
1mM IPTG, and subsequently subjected to centrifugation. Pelleted bacteria were lysed in 
buffer D (20mM Tris pH 7.4, 150mM NaCl, 5mM MgCl2, 1% (w/v) Triton-X-100, 1%g/ml 
aprotinin, 2%g/ml leupeptin, 2%g/ml pepstatin, 0,1mM PMSF), sonicated and centrifuged at 
38,000 x g for 30 min at 4 ˚C. After incubating the supernatants with glutathione Sepharose 
beads (Pharmacia) for 2 h at 4 ˚C, the resin was washed five times with 10 bed volumes of 
buffer D and stored at 4 ˚C.  
His6-tagged fusion proteins of PKN! and AKAP-Lbc were expressed using the bacterial 
expression vector pET30 in BL21DE3 bacteria and purified. Bacterial extracts containing 
His6-tagged fusion proteins were prepared in buffer E (20mM Hepes pH 7.8, 500mM NaCl, 
10mM imidazole, 1mM benzamidine, 2%g/ml leupeptin, 2%g/ml pepstatin). After a 1 min 
sonication, the lysates were centrifuged at 38,000 x g for 30 min at 4 ˚C. The His6-tagged 
fusion proteins were purified by incubating the supernatant with Nickel-NTA chelating 
resin (Amersham Pharmacia Biotech) for 1 h at 4 ˚C. The resin was then washed 5 times 
with 10 bed volumes of buffer E and stored at 4 ˚C. His6-tagged fusion proteins were eluted 
from the resin with 20mM Hepes pH 7.8, 500mM NaCl, 300 mM imidazole, 1mM 
benzamidine, 2%g/ml leupeptin, 2%g/ml pepstatin for 1h at room temperature, dialyzed and 
stored at –20 ˚C. The protein content of the eluates was assessed by Coumassie staining of 
SDS-PAGE gels. 
 
Cell culture and transfections  
 
HEK-293 were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal calf serum and gentamycin (100 µg/ml) and transfected at 50-60% 
confluency in 100 mm dishes using or the calcium-phosphate method. For the 
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overexpression of constructs containing the full-length AKAP-Lbc, HEK-293 cells were 
transfected at 80% confluency in 100 mm or 35 mm dishes using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions.  After transfection, cells were 
grown for 48 h in DMEM supplemented with 10% fetal calf serum before harvesting. The 
total amount of transfected DNA was of 10-24 µg /100 mm dish and 1-4µg /35mm dish. 
 
Rat neonatal cardiomyocyte preparation 
 
Rat neonatal ventricular myocytes were prepared from 1- to 2-days-old Sprague-Dawley 
rats. Excised hearts were digested by three cycles of enzymatic digestion at 37ºC for 15 
min, using a mixture of 0.45 mg/ml collagenase type II (Worthington) and 1mg/ml 
pancreatine (Sigma), followed by centrifugation (800 rpm, 10min). The cells contained in 
the final pellet were suspended in dark medium (DMEM:M199 (4:1) medium supplemented 
with 1% penicillin/streptomycin, 1% hepes, 5% fetal calf serum and 10% horse serum 
(Invitrogen, Gibco)), and seeded on T75 cell culture flasks to deplete fibroblast. After two 
sequential steps of 1h of differential plating, non adherent neonatal myocytes were seeded 
in cell culture dishes pre-coated with 1% gelatine. After 24h the medium was changed and 
cells were cultured in dark medium. Cardiomyocyte culture purity was >95% as assessed by 
immunocytochemistry using an anti-actinin monoclonal antibody. 
 
Production of lentiviruses 
 
VSV-G pseudotyped lentiviruses were produced by cotransfecting 293-T cells with 20 %g 
of pAB286.1 or pSD28 vectors [205], pAB286.1-AKAP-Lbc shRNA vectors or pSD28-
AKAP-Lbc shRNA, pAB286.1-AKAP-Lbc shRNA mutated or pSD28-AKAP-Lbc shRNA 
mutated [198], 15 %g of pCMVDR8.91 and 5 %g of pMD2.VSVG [204] using the calcium 
phosphate method.  Culture medium was replaced by serum free DMEM at 12 hours after 
transfection.  Cell supernatants were collected 48h later, filtered through a 0.45 mm filter 
unit, concentrated using Centricon-Plus-70 MW 100,000 columns (Millipore). Virus titers 
were determined by infecting 293-T cells using serial dilutions of the viral stocks and by 
scoring the number of puromycin-resistant clones at 6 days after infection (for pAB vectors) 
or scoring the number of GFP positive cells at 6 days after infection (for pSD28 vectors). 
Titers determined using these method were between 3x108 and 8x108 transducing units 
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(TU)/ml for viruses generated from pAB286.1 vectors and between 2x108 and 5x108 TU/ml 
for viruses generated from pSD28 vectors. 
 
Lentiviral infection of HEK-293 cells 
 
HEK-293 cells were infected at 60% confluency using pAB286.1-based lentiviruses 
encoding wild type or mutated AKAP-Lbc shRNAs at a multiplicity of infection (MOI) of 
20 in the presence of 8%g/ml of polybrene. Two days after infection puromycin was added 
to the culture medium at a final concentration of 2 %g/ml. After four days of selection 
puromycin resistant cells were collected and amplified in selective medium containing 
puromycin at a final concentration of 2 %g/ml.  
 
Lentiviral infection of rat neonatal cardiomyocytes 
 
Rat neonatal cardiomyocytes were infected at 90% confluency using pSD28 based 
lentiviruses encoding wild type or mutated AKAP-Lbc shRNAs at a multiplicity of 
infection (MOI) of 50 in the presence of 8%g/ml of polybrene. 24h late ththe medium has 
been changed with the same volume of Maintainig medium. 48 hour later the 
cardiomyocyte have been subjected to serum starvation for 24 h with Light medium.  
 
Real-Time PCR 
Determination of the mRNAs levels of ANF, and skeletal !-actin in rat neonatal 
cardiomyocytes was carried out by real-time RT-PCR analysis by using a LightCycler 
Instrument (Roche Applied Science). Total mRNA was extracted from rat cardiomyocytes, 
and single-strand cDNA was synthesized from 2.5 µg of total RNA by using random 
hexamers (Applied Biosystems) and SuperScript II reverse transcriptase (Invitrogen). RT-
PCR reactions were prepared by using a LightCycler kit (Eurogentec, Belgium) in a final 
volume of 20 µl containing 125 ng of reverse-transcribed total RNA and 0.5 µl of SYBR 
Green in the presence of the following forward and reverse primers described. Real-time 
PCR reactions were performed using the following forward (F) and reverse (R) primers: rat 
ANF (F) 5'-ATTTCAAGAACCTGCT-3' and (R) 5'-TCCTGTCAATCCTACC-3'; rat 
skeletal !-actin (F) 5'-TCTTGTGTGTGACAAC-3' and (R) 5'-
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ATTTGAGTCATCTTCTCC-3', Glyceraldehyde3-phosphate dehydrogenase (F) 5'-
GTCGGTGTGAACGGATTTGG-3' and (R) 5'-ACTCCACGACATACTCAGC-3'. 
Glyceraldehyde-3-phosphate dehydrogenase mRNA was used as invariant internal control. 
The relative amount of all mRNAs was calculated by using the LightCycler analysis 
software Version 3.5. 
 
Dual Luciferase assay  
 
RNVMs infected have been transfected with GATA4 Luciferase Reporter and with pcmv-
Renilla in a ratio of 7:1 with lipofectamine. 24 hours after trasfection cells were starved 
with Light medium for 24h. Following the starvation cardiomyocyte were stimulated for 
24h with or without phenylephrine (PE) 10-4 M. Cells were washed 2 times with PBS cold 
and subsequently lysed (active lysis) with lysis buffer provide by promega kit (Dual-
Glo® Luciferase Assay System). Lysates were store at -20°C overnight. The day after all 
samples were centrifuged at 10000 rpm for 1 minute at 4°C and then 20 µl of each samples 
were loaded in a reading plate. Dual luciferase values were read by the luminometer mithras 
LB 940 (Berthold).  
 
In vitro GST pulldown experiments  
 
For in vitro GST pulldowns, 100nM of bacterially purified His6-tagged fragments 
encompassing PKN! residues 1-305 and 305-942 as well as AKAP-Lbc residues 1388-1922 
were incubated with glutathione-sepharose beads (Amersham Biosciences) coupled to GST, 
or to GST-fusion proteins of p38!, MKK3, MLTK, or of the AKAP-Lbc fragment 
encompassing residues 1388-1922 in 0.5 ml of buffer A (20 mM Tris pH 7.4, 150 mM 
NaCl, 1% (w/v) Triton-X-100, 5 µg/ml aprotinin, 10 µg/ml leupeptin and 1 mM PMSF) for 
4h at 4˚C. The beads were then washed five times with buffer A containing 300mM NaCl, 
resuspended in SDS-PAGE sample buffer (65 mM Tris, 2% SDS, 5% glycerol, 5% "-
mercaptoethanol, pH 6.8) and boiled for 3 min at 95°C. Eluted proteins were analyzed by 
SDS-PAGE and Western blotting. 
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Immunoprecipitation Experiments (cardiomyocytes) 
 
For immunoprecipitation experiments, 7 *106 RNVMs grown in 100-mm dishes in 10 ml of 
DARK medium. 48 hours later RNVMs were lysed in 1 ml of buffer 1 (20 mM HEPES, pH 
7.4, 150 mM NaCl, 1% (wt/vol) Triton X-100, 0,1% Na deoxycholate, 5mg/ml 
aprotinin/10 mg/ml leupeptin/1 mM PMSF). Cell lysates were incubated 4 h at 4°C on a 
rotating wheel. The solubilized material was centrifuged at 100,000 ´g for 30 min at 4°C, 
and the supernatants were dialyzed in 5 liters of buffer 2 (20 mM HEPES, pH 7.4, 150 mM 
NaCl, 0,5 % (wt/vol)) 2 hours at 4°C. Next the supernatants were dialyzed again in 5 liters 
of fresh buffer 2 overnights at 4°C. The day after the supernatants were incubated 2h at 4°C 
with 4µg of polyclonal anti-AKAP-Lbc or with 4µg of rabbit IgG (negative control) on a 
rotating wheel. Next all the samples were incubated with 20 µl of protein-A sepharose 
beads for 2 hours at 4°C on a rotating wheel. Following a brief centrifugation on a bench-
top centrifuge, the pelleted beads were washed five times with buffer B and twice with PBS, 
and proteins were eluted in SDS/PAGE sample buffer (65 mM Tris/2% SDS/5% 
glycerol/5% 2-mercaptoethanol, pH 6.8) by boiling samples for 3 min at 95°C. Eluted 
proteins were analyzed by SDS/PAGE and Western blotting 
 
Immunoprecipitation experiments (HEK 293 cells) 
 
For immunoprecipitation experiments, HEK-293 cells grown in 100 mm dishes and  
expressing various constructs were lysed in 1 ml of buffer A. Cell lysates were incubated 1h 
at 4˚C on a rotating wheel. The solubilized material was centrifuged at 100,000 x g for 30 
min at 4˚C and the supernatants were incubated 4h at 4˚C with 20%l of anti-FlagM2 affinity 
resin (Sigma) to immunoprecipitate overexpressed Flag-tagged proteins. Following a brief 
centrifugation on a bench-top centrifuge, the pelleted beads were washed five times with 
buffer C, twice with PBS and proteins eluted in SDS-PAGE sample buffer by boiling 
samples for 3 min at 95°C. Eluted proteins were analysed by SDS-PAGE and Western 
blotting. For immunoprecipitation of endogenous AKAP-Lbc complexes, HEK-293 cells 
were lysed in 1 ml of buffer B (20mM Hepes pH 7.4, 150mM NaCl, 1% Triton-X-100 and 
1 mM PMSF). Soluble proteins were isolated by centrifugation as indicated above and 
incubated with or without 0.25mM dithiobis [succinimidyl propionate] for 1h at 4˚C. 
Crosslinking reactions were blocked by adding Tris pH7.4 to the lysate to a final 
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concentration of 50mM. Immunoprecipitations were performed as indicated previously [42] 
by incubating 3mg of lysate with 4%g of affinity-purified rabbit polyclonal anti-AKAP-Lbc 
antibodies (Covance).  
 
p38!, JNK and MLTK activity assays. 
 
Transfected HEK-293 cells grown in 100 mm dishes were lysed in 1 ml of buffer C (20 mM 
Tris pH 7.4, 150 mM NaCl, 1% (w/v) Triton-X-100, 10mM NaF, 10mM Na-pyrophosphate, 
1mM Na-orthovanadate, 1mM glycerophophate, 5 µg/ml aprotinin, 10 µg/ml leupeptin and 
1 mM PMSF). Cell lysates were incubated 10 min at 4˚C on a rotating wheel. The 
solubilized material was centrifuged at 100,000 x g for 30 min at 4˚C. 200%l of supernatant 
were incubated either with 2%l of mouse monoclonal anti-p38! antibodies (Cell Signaling 
technology) and 20%l of protein A-sepharose beads (Amersham) for 2h at 4˚C to 
immunoprecipitate endogenous p38! or with 20%l of anti-FlagM2 affinity resin (Sigma) for 
1h at 4˚C to immunoprecipitate overexpressed Flag-tagged JNK1 or MLTK. Following a 
centrifugation on a bench-top centrifuge, the pelleted beads were washed three times with 
buffer C and twice with a buffer containing 50mM Tris pH 7.4 and 5mM MgCl2. 
Immunoprecipitates containing p38! or JNK1 were incubated with 1%g of purified GST-
ATF2 (Cell Signaling Technology) whereas those containing Flag-tagged MLTK were 
incubated with 1%g of purified GST-MKK3. Reactions were carried out in 50mM Tris pH 
7.4, 5mM MgCl2 and 1mM ATP-Na2 for 30 min at 30˚C and ended by the addition of SDS-
PAGE sample buffer and loaded on SDS-PAGE gels.  
 
SDS-PAGE and Western blotting  
 
Samples denatured in SDS-PAGE sample buffer were separated on acrylamide gels and 
electroblotted onto nitrocellulose membranes. The blots were incubated with primary 
antibodies and horseradish-conjugated secondary antibodies (Amersham) as previously 
indicated [189]. The following affinity purified primary antibodies were used for 
immunoblotting: affinity purified rabbit polyclonal anti-AKAP-Lbc (Covance, 0.1 mg/ml, 
1:1000 dilution), mouse monoclonal anti-Flag (Sigma, 4.9 mg/ml, 1:2000 dilution), mouse 
monoclonal anti-GFP (Roche, 400%g/ml, 1:500 dilution), rabbit polyclonal anti-GFP 
(Roche 400%g/ml, 1:1000 dilution), rabbit polyclonal anti-HA (Sigma, 1:1000 dilution), 
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mouse monoclonal anti-HA (Sigma, 1:5000 dilution), rabbit polyclonal anti-phospho p38! 
(threonine 180 and tyrosine 182) (Cell Signaling Technologies, 1:1000 dilution), rabbit 
polyclonal and mouse monoclonal anti-p38! (Cell Signaling Technologies, 1:1000 
dilution), rabbit polyclonal anti-phospho ATF2 (Threonine 71) (Cell Signaling 
Technologies, 1:1000 dilution), rabbit polyclonal anti-ATF2 (Cell Signaling Technologies, 
1:1000 dilution), mouse monoclonal anti-phospho MKK3 (Serine 189 and Threonine 193) 
(Cell Signaling Technology, 1:500 dilution), mouse monoclonal anti-MKK3 (Assay 
designs, 1:1000 dilution), mouse monoclonal anti-MLTK (Abnova, 1:500 dilution), rabbit 
polyclonal anti-MLK3 (Cell Signaling Technology, 1:500 dilution), mouse monoclonal 
anti-PKN! (BD Biosciences Pharmingen, 1:1000 dilution), rabbit polyclonal anti-ERK1/2 
(Santa Cruz Biotechnology, 1:500 dilution), rabbit polyclonal anti-phospho ERK1/2 
(threonine 202 and tyrosine 204) (Santa Cruz Biotechnology, 1:500 dilution), rabbit 
polyclonal anti-JNK (Cell Signaling Technologies, 1:500 dilution), rabbit polyclonal anti-
phospho JNK (threonine 183 and tyrosine 185) (Cell Signaling Technologies, 1:500 
dilution), rabbit polyclonal anti-phospho Hsp27 (serine 82) (Cell Signaling Technologies, 
1:500 dilution), rabbit polyclonal anti-Hsp27  (Cell Signaling Technologies, 1:500 dilution), 
rabbit polyclonal anti-phospho GATA4 (serine 105) (Sigma, 1:1000 dilution), rabbit 
polyclonal anti-GATA4  (Santa Cruz Biotechnology, 1:250 dilution), mouse monoclonal 
anti-actin (Sigma, 1:1000 dilution), mouse monoclonal anti-Histidine tag (Qiagen 
100%g/ml, 1:1000 dilution). 
 
Fluorescence Microscopy 
 
RNVMs were grown for 24 h in the presence of maintaining medium. Cells were then 
incubated for 1 h with or without 10-4 M phenylephrine, washed twice with PBS, and then 
fixed for 10 min in PBS/3.7% formaldehyde, permeabilized for 5 min with 0.2% (wt/vol) 
Triton X-100 in PBS, and blocked for 1 h in PBS/1% BSA. The expression of the Hsp27 
was assessed by incubating cardiomyocytes for 12 h with a 1:250 dilution of the rabbit anti-
Hsp27 polyclonal antibody (Santa Cruz) followed by 1 h incubation with Rhodamine-
conjugated anti-rabbit secondary antibodies (Jackson ImmunoResearch). The expression 
of !-actinin was assessed by incubating cells for 1 h with a 1:500 dilution of mouse 
monoclonal antibodies against anti-!-actinin (Sigma) followed by 1 h incubation with 
rhodamine-conjugated anti-mouse secondary antibodies (Jackson ImmunoResearch). The 
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expression of actin was assessed by incubating cells for 1 h with a 1:1000 dilution of 
rhodamine-conjugated phalloidin (Jackson ImmunoResearch). The cells were mounted 
using Prolong (Molecular Probes).  
 
RNVMs were transfected with pEGFP plasmid or with AKAP-Lbc 1585-1715 in pEGFP 
with lipofectamine. After 48 hours cells were starved for 24h and then stimulated for 24 h 
with or without 10-4 M phenylephrine. Cells were washed twice with PBS, and then fixed 
for 10 min in PBS/3.7% formaldehyde, permeabilized for 5 min with 0.2% (wt/vol) Triton 
X-100 in PBS, and blocked for 1 h in PBS/1% BSA. The expression of !-actinin was 
assessed by incubating cells for 1 h with a 1:500 dilution of mouse monoclonal antibodies 
against anti-!-actinin (Sigma) followed by 1 h incubation with rhodamine-conjugated anti-
mouse secondary antibodies (Jackson ImmunoResearch). The cells were mounted using 
Prolong (Molecular Probes). Intrinsic GFP fluorescence, as well as immunofluorescent 
staining, was visualized using a Zeiss Axiophot fluorescence microscope. 
 
Statistical analysis 
 
Statistical significance was analyzed using a Kruskal-Wallis test followed by Mann-
Whitney U tests with the Bonferroni corrections. 
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IV. RESULTS I: Characterization of the signaling pathway 
activated by the AKAP-Lbc signaling complex 
 
These results have been published: Cariolato L, Cavin S, Diviani D. (2011.). A-kinase anchoring 
protein (AKAP)-Lbc anchors a PKN-based signaling complex involved in !1-adrenergic receptor-
induced p38 activation. J. Biol. Chem. 286(10):7925-37 (see annexe) 
 
4.1  AKAP-Lbc activates p38 MAPK in HEK-293 cells. 
 
While our previous findings indicate that AKAP-Lbc/RhoA complex is a key mediator of 
the growth responses induced by GPCRs including !1-ARs and AT1-Rs, the signaling 
pathways linking AKAP-Lbc to the activation of hypertrophic genes remain to be 
elucidated.  
In this context, evidence collected over the past few years suggests that activated RhoA can 
regulate the transcription of genes involved in cardiac hypertrophy through the activation of 
transduction cascades involving protein kinases of the MAPK family including ERK, JNK 
and p38 [34, 141, 211]. Based on these findings we have raised the hypothesis that, in 
cardiomyocytes, AKAP-Lbc might induce hypertrophic gene expression by promoting the 
activation of MAPKs. 
To initially address the hypothesis that AKAP-Lbc can activate members of the MAPK 
family, HEK-293 cells were transfected with an empty Flag vector or with the cDNA 
encoding a Flag-tagged mutant of AKAP-Lbc (AKAP-Lbc S1565A) displaying constitutive 
Rho-GEF activity and serum starved for 24 h. Cell lysates were prepared and the presence 
of active phosphorylated forms of ERK1/2, JNK and p38 determined by western blot using 
anti-phospho ERK1/2, anti-phospho JNK and anti-phospho p38 specific antibodies, 
respectively. Interestingly, we found that the active mutant of AKAP-Lbc could enhance 
p38 phosphorylation without affecting ERK phosphorylation and JNK phosphorylation 
(Figure 1A, 1B and 1C upper panel, lane 2). This suggests that the AKAP-Lbc signaling 
complex selectively activates p38.  
 
4.2. RhoA mediates !1b-AR-mediated p38 MAPK activation. 
 
Since AKAP-Lbc is a guanine nucleotide exchange factor that selectively activates RhoA, 
and since RhoA has been described as being an upstream activator of p38 MAPK in 
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cardiomyocytes, we determined whether the activity of this small molecular weight G 
protein might mediate the activation of p38 MAPK activity induced the !1b-AR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To initially determine the implication of RhoA in the pathways linking !1b-ARs to the 
activation of ERK1/2, JNK and p38, HEK-293 cells expressing the HA-tagged !1b-AR 
were treated for 2h in the absence or presence of 1%g/ml of a cell permeable form of the C3 
botulimun toxin and subsequently incubated with or without 10-4 M epinephrine for 10 min. 
Activation of ERK1/2, JNK in cell lysates was assessed by western blot using antibodies 
recognizing the phosphorylated forms of ERK1/2 and JNK. On the other hand, p38! 
activity was determined using a kinase assay that measured the ability of 
immunoprecipitated endogenous p38! to induce the phosphorylation of purified GST-
ATF2. Interestingly, inhibition of RhoA impaired by 58% and 69% the ability of !1b-ARs 
to induce p38! activation under basal conditions and following epinephrine stimulation, 
respectively (Fig. 2A, panel 1, lanes 7 and 8;), without affecting !1b-AR-mediated 
phosphorylation of ERK1/2 and JNK (Fig. 3A, panel 1, lanes 7 and 8; Fig. 3B, panel 1 lanes 
7 and8). This suggests that RhoA is involved in the pathway that links !1b-ARs to the 
activation of p38!.  
To directly determine whether AKAP-Lbc can enhance p38! activation through its ability 
to activate RhoA, we assessed whether RhoA inhibition could affect the p38! activating 
Figure 1: AKAP-Lbc activates p38 inside cells. A-C) HEK-293 cells expressing empty Flag vector (lane 
1) or the Flag-tagged form of the constitutively active S1565A mutant of AKAP-Lbc (lane 2) were serum 
starved for 24 h. Proteins in the cell lysates were separated by SDS-PAGE and the phosphorylated form of 
p38, ERK1/2 and JNK were detected with phospho specific antibody of p38, ERK1/2 and JNK (upper 
panel). The amounts of total p38, ERK1/2 and JNK in the cell lysates were assessed using specific 
antibodies against p38, ERK1/2 and JNK (middle panel). The amounts of total Flag-tagged AKAP-Lbc in 
the cell lysates was assessed using monoclonal antibodies against the Flag epitope (lower panel). 
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potential of the S1565A mutant of AKAP-Lbc, which displays constitutive Rho-GEF 
activity. HEK-293 cells transfected with the Flag-tagged AKAP-Lbc S1565A mutant were 
serum starved for 24h and incubated for 2h in the absence or presence of 1%g/ml of C3 
botulinum toxin. As shown in Fig. 2B, overexpression of the Flag-tagged AKAP-Lbc 
S1565A mutant induced a 2.9 fold enhancement of p38! kinase activity, which was 
reduced after RhoA inhibition (Fig.2B, panel 1, lanes 2 and 3). Altogether, these findings 
indicate that the AKAP-Lbc/RhoA complex specifically mediates !1-AR-induced p38! 
activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: AKAP-Lbc mediates !1b-AR-induced p38a activation. A) HEK-293 cells were transfected 
with the empty pRK5 plasmid or the cDNA encoding the HA-tagged !1b-AR. After a 24 h serum 
starvation, cells were incubated for 2 h with or without 1%g/ml of purified C3 toxin and incubated for 10 
min with or without (Ctrl) 10-4 M epinephrine (EPI). Cell lysates where subjected to immunoprecipitation 
using anti-p38! monoclonal antibodies. Kinase reactions were performed by incubating p38! 
immunoprecipitates with 1 %g of purified GST-ATF2 and in the presence of ATP. Phospho-GST-ATF2 
was detected by immunoblot using rabbit polyclonal antibodies recognizing phospho-threonine 71 of 
ATF2 (panel 1). The amounts of GST-ATF2, p38! and HA-!1b-ARs were assessed using polyclonal 
antibodies against ATF2 (panel 2), p38! (panel 3) and the HA epitope (panel 4), respectively. 
Quantitative analysis of phosphorylated ATF2 was obtained by densitometry. The amount of phospho-
ATF2 was normalized to the total amount of ATF2 and p38!. Results are expressed as mean ± S.E. of 3 
different experiments. § p< 0.05 as compared with phospho-ATF2 levels measured in untreated control 
cells expressing HA-!1b-ARs. * p < 0.05 as compared with phospho-ATF2 levels measured in 
epinephrine-treated control cells expressing HA-!1b-ARs. B) HEK-293 cells were transfected with cDNA 
encoding the Flag-tagged S1565A mutant of AKAP-Lbc. After a 24 h serum starvation, cells were 
incubated for 2 h with or without 1%g/ml of purified C3 toxin. Kinase activity of immunoprecipitated 
p38! and detection of phospho-ATF2 (panel 1) and ATF2 (panel 2) and p38! (panel 3) in cell lysates was 
determined as indicated in A). Expression of the Flag-tagged AKAP-Lbc S1565A mutant was assessed 
using monoclonal antibodies against the Flag-tag (panel 4). Quantitative analysis of phosphorylated ATF2 
was obtained by densitometry as indicated before. * p< 0.05 as compared with phospho-ATF2 levels 
measured in untreated cells expressing Flag-AKAP-Lbc S1565A. 
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4.3 AKAP-Lbc is involved in !1b-AR-mediated p38 MAPK activation 
 
Our previous results indicate that AKAP-Lbc can be activated downstream of !1b-ARs in 
primary cultures of rat neonatal cardiomyocytes. Based on these findings and on our current 
results suggesting that AKAP-Lbc can activate p38, we initially investigated the possibility 
that AKAP-Lbc could mediate the activation of p38 downstream of !1b-ARs. To address 
this hypothesis, we decided to determine the impact of AKAP-Lbc silencing in HEK-293 
cells on the ability of !1b-ARs to induce the activation of p38. 
AKAP-Lbc silencing was achieved by infecting cells using lentiviruses encoding two 
distinct short hairpin (sh) RNAs directed against a sequence within the DH domain 
(shRNA1) and N-terminal regulatory region (shRNA2) of AKAP-Lbc, respectively. Both 
Figure 3 RhoA does not mediate !1b-AR-induced activation of ERK1/2 and JNK. A, B) HEK-293 cells 
were transfected with the plasmid encoding the HA-tagged !1b-AR. After a 24 h serum starvation, cells were 
incubated for 2 h with or without 1%g/ml of purified C3 toxin and subsequently stimulated for 10 min with or 
without (Ctrl) 10-4 M epinephrine (EPI). Phosphorylated ERK1/2 and JNK were detected by immunoblot 
using rabbit polyclonal antibodies recognizing phosphorylated threonine 202 and phosphorylated tyrosine 
204 of ERK and phosphorylated threonine 183 and phosphorylated tyrosine 185 of JNK1, respectively (A, B, 
panel 1). The amounts of total ERK1/2, JNK and HA-!1b-ARs in the cell lysates were assessed using 
antibodies against ERK1/2 (A, panel 2), JNK (B, panel 2) and the HA epitope  (A, B, panel 3), respectively. 
Results are expressed as mean ± S.E. of 4 different experiments.  Quantitative analysis of phosphorylated 
ERK1/2 and JNK was obtained by densitometry. The amount of phosphorylated ERK1/2 and JNK was 
normalized to the total amount of ERK1/2 and JNK. Results are expressed as mean ± S.E. of 3 different 
experiments.  
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shRNAs could inhibit AKAP-Lbc expression by about 90% as compared to cells infected 
with control lentiviruses (Fig.4A, panel 5). 
Infected cells were transfected with the cDNA encoding the HA-tagged !1b-AR, serum 
starved for 24 h and incubated in the absence or presence of epinephrine for 10 min. p38! 
was then immunoprecipitated and its activity assessed as indicated above.  
Silencing of AKAP-Lbc expression significantly reduced the ability of !1b-ARs to induce 
p38! activation both under basal conditions and following epinephrine stimulation. Basal 
p38! activation was inhibited between 67% (shRNA1) and 74% (shRNA2) whereas 
inhibition of epinephrine-induced p38! activation was between 63% (shRNA1) and 72%  
(shRNA2) (Fig. 4A, panel 1, lanes 9-12). On the other hand, control experiments revealed 
that the ability of !1b-ARs to promote phosphorylation of endogenous ERK1/2 and JNK 
was not affected by AKAP-Lbc silencing (Fig. 4B, panel 1 and 3, lanes 7 and 8). 
Interestingly, re-expression of a silencing-resistant mutant of AKAP-Lbc (2) in silenced 
cells rescued the ability of !1b-AR to promote the activation of p38! (Fig. 5, panel 1, lanes 
5 and 6). 
These results strongly suggest that AKAP-Lbc specifically contributes to the activation of 
p38! MAPK induced by !1b-ARs and its inhibition was strictly dependent on reduced 
AKAP-Lbc expression and not due to an off-target effect. 
4.4 AKAP-Lbc interacts with p38 
 
Our current findings reveal that AKAP-Lbc and RhoA mediate the activation of p38 MAPK 
but not that of ERK1/2 and JNK downstream of !1b-ARs (Figure 2-3-4). This suggests the 
existence of molecular mechanisms that allow the AKAP-Lbc signaling complex to select 
and activate the p38 effector pathway. One attractive hypothesis would be that AKAP-Lbc 
and p38 might be maintained within the same macromolecular unit. In this configuration, 
activating signals could be integrated by AKAP-Lbc and rapidly transmitted to p38. 
To assess whether AKAP-Lbc could form a complex with p38, we determined whether 
endogenous p38 could be co-immunoprecipitated with Flag-tagged AKAP-Lbc from lysates 
of transfected HEK-293 cells. 
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Figure 4 AKAP-Lbc is involved in !1b-AR-mediated p38!  MAPK activation. A) HEK-293 cells 
infected with control lentiviruses or lentiviruses encoding AKAP-Lbc shRNAs were transfected with the 
empty pRK5 plasmid or the cDNA encoding the HA-tagged !1b-AR. After a 24 h serum starvation, cells 
were incubated for 15 min with or without (Ctrl) 10-4 M epinephrine (EPI), lysed and subjected to 
immunoprecipitation using monoclonal anti-p38a antibodies. Kinase reactions and detection of phospho-
ATF2 (panel 1), ATF2 (panel 2), p38! (panel 3), and HA-!1b-ARs (panel 4) were performed as indicated in 
A). Expression of endogenous AKAP-Lbc and actin was detected using affinity purified anti-AKAP-Lbc 
polyclonal antibodies (panel 5) and anti-actin monoclonal antibodies (panel 6). Quantitative analysis of 
phosphorylated ATF2 was obtained by densitometry. The amount of phospho-ATF2 was normalized to the 
total amount of ATF2 and p38!. Results are expressed as mean ± S.E. of 3 different experiments. § p< 0.05 
as compared with phospho-ATF2 levels measured in untreated control cells expressing HA-!1b-ARs. *  p< 
0.05 as compared with phospho-ATF2 levels measured in epinephrine-treated control cells expressing HA-
!1b-ARs. B) HEK-293 cells infected with control lentiviruses or lentiviruses encoding AKAP-Lbc shRNAs 
directed against bases 6688-6706 of the human AKAP-Lbc sequence were subsequently transfected with the 
empty pRK5 vector (no receptor) or the vector encoding the HA-tagged a1b-AR. After a 24 h serum 
starvation, cells were incubated for 15 min with or without 10-4 M epinephrine (EPI) and lysed. 
Phosphorylation of ERK1/2 (panel1) and JNK (panel 3) was assessed by western blot using anti-phospho 
specific.The amounts of ERK1/2, JNK, HA-a1b-ARs and AKAP-Lbc in the cell lysates were assessed using 
polyclonal antibodies against ERK1/2 (panel 2) and JNK (panel 4), monoclonal antibodies against the HA 
epitope (panel 5), and affinity purified polyclonal antibodies against AKAP-Lbc (panel 6), respectively. 
Results are representative of 4 different experiments. 
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As shown in Fig. 6A, anti-Flag antibodies could immunoprecipitate HA-p38! from cells 
expressing the Flag-tagged AKAP-Lbc, but not from cells transfected with the empty pFlag 
vector (Fig. 6A, upper panel, lanes 1 and 2). Using a similar approach we could show that 
HA-JNK1 and GFP-ERK1 do not form stable complexes with AKAP-Lbc (Fig. 6B and 6C, 
upper panel, lanes 1 and 2). These results suggest that AKAP-Lbc specifically binds and 
activates p38!.  The p38 family of MAPK is constituted by four members (p38!, p38", 
p38# and p38')[212]. Co-immunoprecipitation experiments performed using the different 
recombinant p38 kinases indicate that Flag-AKAP-Lbc interacts mainly with p38!, to a 
lesser extent with p38", but not with p38# and p38'  (results not shown). 
 
 
 
 
Figure 5: Rescue of shRNA-mediated inhibition 
of !1b-AR-induced p38!  activation. HEK-293 
cells infected with control lentiviruses or 
lentiviruses encoding shRNAs directed against 
bases 6688-6706 of the human AKAP-Lbc sequence 
(shRNA1) were subsequently transfected with the 
plasmid encoding the HA-tagged a1b-AR in the 
combination with the empty Flag vector (lanes 1-4) 
or with the cDNA encoding the Flag-tagged 
silencing resistant mutant of AKAP-Lbc (lanes 5 
and 6). After a 24 h serum starvation, cells were 
incubated for 15 min with or without 10-4 M 
epinephrine (EPI). Cell lysates where subjected to 
immunoprecipitation using anti-p38a polyclonal 
antibodies. Kinase reactions were performed by 
incubating p38! immunoprecipitates with 1 %g of 
purified GST-ATF2 and in the presence of ATP. 
Phospho-GST-ATF2 was detected by immunoblot 
using rabbit polyclonal antibodies recognizing 
phospho-threonine 71 of ATF2 (panel 1). The 
amounts of GST-ATF2, p38!, HA-a1b-ARs, 
AKAP-Lbc and actin were assessed using 
antibodies against ATF2 (panel 2), p38a (panel 3) 
and the HA epitope (panel 4) and AKAP-Lbc (panel 
5), respectively.  
Quantitative analysis of phosphorylated ATF2 was 
obtained by densitometry. The amount of phospho-
ATF2 was normalized to the total amount of ATF2 
and p38!. Results are expressed as mean ± S.E. of 3 
different experiments. § p< 0.05 as compared with 
phospho-p38 levels measured in untreated cells 
infected with lentiviruses encoding shRNA1. * p< 
0.05 as compared with phospho-p38 levels 
measured in epinephrine-treated  cells infected with 
lentiviruses encoding shRNA1. 
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4.5 AKAP-Lbc assembles a p38 activation module 
 
MAPKs are activated by a protein kinase cascades in which the MAPK is phosphorylated 
and activated by a MAP kinase kinase (MAPKK) that is, in turn, phosphorylated and 
activated by a MAP kinase kinase kinase (MAPKKK). As mentioned in the introduction it 
is well established that p38! can be activated by the MAPKKs MKK3, MKK4 and MKK6 
[213].  In turn, these three p38-activating kinases can be phosphorylated and activated by 
several MAPKKKs such as TAK1, members of the mixed lineage kinase (MLK) family 
including MLK3, MLTK and DLK, and several members of the MEKK family of protein 
kinases [213, 214]. These MAPK cascades are organized into signaling complexes to create 
functional MAPK modules. Interestingly recent studies have shown that RhoA can promote 
the activation of p38 through a signaling pathway that includes PKN, MAPKKKs of the 
MLK family and MAPKKs such MKK3 and MKK6. Based on these observations we have 
investigated the possibility of whether these kinases known to act upstream of p38 would 
also associate with AKAP-Lbc. 
 
Figure 6: AKAP-Lbc interacts with p38!. A-C) Extracts from HEK-293 cells transfected with the 
plasmids encoding HA-tagged p38! ( &'A) (, HA-tagged JNK1 (B) or GFP-tagged ERK1 (C) in combination 
with the empty Flag vector (lane 1) or the vector encoding Flag-tagged AKAP-Lbc (lane 2) were subjected to 
immunoprecipitation with anti-Flag antibodies. Western blots of the immunoprecipitates and the cell extracts 
were revealed using anti-HA monoclonal antibodies to detect HA-p38!& and HA-JNK1 (A-B, upper and 
middle panels), anti-GFP polyclonal antibodies to detect GFP-ERK1 (C, upper and middle panels) or anti-
Flag monoclonal antibodies to detect Flag-AKAP-Lbc (lower panels). 
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To address this point, we performed coimmunoprecipitation experiments from HEK-293 
cells that were transiently transfected with the cDNA encoding the HA-tagged forms of the 
MAPKKs MKK3, MKK4 and MKK6 (Fig. 7A) as well as of the MAPKKKs MLK3, 
MEK1, TAK1 (Fig. 7B) and MLTK (Fig. 7C) in combination with the empty Flag vector 
(pFlag) or the Flag-tagged AKAP-Lbc. After immunoprecipitating the anchoring protein 
using anti-Flag antibodies, anti-HA antibodies were used to immunoblot the 
immunoprecipitated samples. Western blots revealed that MKK3 (Fig.7A, upper panel, lane 
5) as well as kinases belonging to MLK family including MLK3 and MLTK (Fig.7B, upper 
panel, lane 4; Fig. 7C upper panel, lane 2) could specifically co-immunoprecipitate with 
AKAP-Lbc whereas the MAPKKs MKK4 and MKK6 as well as the MAPKKKs MEKK1 
and TAK1 did not (Fig. 7A upper panel, lanes 4 and 6, Fig. 7B, upper panel, lanes 5 and 6). 
These results suggest that AKAP-Lbc can interact with a signaling module composed of 
p38!, its upstream kinase MKK3, and MAPKKKs of the MLK family such as MLK3 or 
MLTK. 
However, MLKs have never been reported as direct effectors of RhoA. Accordingly, control 
experiments performed in our laboratory using purified kinases failed to detect MLK 
activation by RhoA (results not shown).  This raises the question of how the AKAP-
Lbc/RhoA complex can transmit signals to the MLK-MKK3-p38! module. In this context, 
previous evidence indicates that protein kinase N! (PKN!), a well-characterized effector of 
RhoA, can act as an upstream activating kinase of MLTK [215]. Based on these findings, 
we raised the hypothesis of whether PKN! could also bind to AKAP-Lbc. Interestingly, 
western blots performed on Flag-AKAP-Lbc immunoprecipitates indicate that endogenous 
PKN! can co-immunoprecipitate with the anchoring protein (Fig. 7D, upper panel, lane 2).  
In a similar set of experiments, we could show that p38!, MKK3, MLTK and PKN! 
endogenously expressed in HEK293 cells could form a complex with endogenous AKAP-
Lbc. This is shown by the fact that p38!, MKK3, MLTK and PKN! could be detected in 
AKAP-Lbc immunoprecipitates (Fig. 8A, upper and middle panels, lane 3; Fig. 8 B, upper 
and middle panels, lane 3). On the other hand, no interaction between endogenous AKAP-
Lbc and MLK3 could be detected (Fig. 8C, upper panel, lane 3). Therefore, while 
overexpressed AKAP-Lbc has the potential of binding MLK3 and MLTK (Fig. 7B and 7C), 
endogenous AKAP-Lbc seems to preferentially assemble a complex that specifically 
contains MLTK. Collectively these results suggest that AKAP-Lbc can assemble a large 
signaling complex containing PKN!, MLTK, MKK3 and p38! that can link RhoA 
activation to the stimulation of the p38 transduction pathway.  
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Figure 7: AKAP-Lbc assembles a p38! activation complex. A) HEK-293 cells were transfected 
with the plasmids encoding HA-tagged MKK4, MKK3, or MKK6 in combination with the vector encoding 
Flag-tagged AKAP-Lbc. Immunoprecipitations and western blots were performed as indicated in A). B-C) 
HEK-293 cells were transfected with the plasmids encoding HA-tagged MLK3, MEKK1, TAK1 (E) or 
MLTK (F), in combination with the empty Flag vector or the plasmid encoding Flag-tagged AKAP-Lbc. 
Immunoprecipitations and western blots were performed as indicated in A). D) Extracts from HEK-293 cells 
transfected with the empty Flag vector or the plasmid encoding Flag-tagged AKAP-Lbc were subjected to 
immunoprecipitation with anti-Flag antibodies. Western blots of the immunoprecipitates and the cell extracts 
were revealed using anti-PKN! monoclonal antibodies. Results are representative of at least three 
independent experiments. 
Figure 8. AKAP-Lbc interacts with endogenous p38!, MKK3, MLTK and PKN!. HEK-293 cell extracts 
were subjected to immunoprecipitation with either non-immune IgGs or affinity purified anti-AKAP-Lbc 
polyclonal antibodies. Western blots of the immunoprecipitates and the cell extracts were revealed using 
either anti-p38! (A, upper panel), anti-MKK3 (A, middle panel), anti-PKN! (B, upper panel) anti-MLTK (B, 
middle panel), anti-MLK3 (C, upper panel) or affinity purified anti-AKAP-Lbc polyclonal antibodies  (lower 
panels). Results are representative of at least three independent experiments.  
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4.6 Mapping of the kinase binding sites on AKAP-Lbc. 
 
To identify the binding site for p38! as well as its upstream activating kinases on AKAP-
Lbc, we initially generated a series of Flag-tagged AKAP-Lbc fragments encompassing 
residues 1-503, 504-1000, 1001-1387, 1388-1922, 1923-2336 and 2337-2817 (Fig. 9A). 
The fragments were initially expressed in HEK-293 cells in combination with HA-MKK3 
and interactions assessed by co-immunoprecipitation. The Flag-tagged fragments were 
immunoprecipitated from cell lysates using anti-Flag antibodies and the presence of 
associated kinases detected using anti-HA antibodies. Our results indicate that MKK3 
interact exclusively with the fragment of AKAP-Lbc included between residues 1388 and 
1922 (Fig. 9B, upper panel, lane5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We have subsequently further narrowed the binding site using shorter Flag-tagged AKAP-
Lbc fragments derived from the region 1388-1922 (Fig. 10A).  As shown in Fig. 10B, our 
results indicate that HA-MKK3 interact with AKAP-Lbc in a minimal region encompassing 
residues 1585-1715 (Fig. 10B, upper panel).   
To validate these findings and to assess whether the identified domain was also required for 
binding the other kinases, we determined the impact of deleting residues 1585-1715 from 
the AKAP-Lbc on its ability to associate with HA-p38!, HA-MKK3, HA-MLTK and 
endogenous PKN! in co-immunoprecipitation experiments (Fig. 10C-F). 
 
 
Figure 9: Initial mapping of the MKK3 
interaction site on AKAP-Lbc. A) 
Schematic representation of the Flag 
tagged AKAP-Lbc fragments used for the 
mapping of the MKK3 binding site on 
AKAP-Lbc. PKA and 14-3-3 binding 
sites as well as C1, DH and PH domains 
are shown. For each fragment, the 
position of the first and the last amino 
acid is indicated. B) Extracts from HEK-
293 cells expressing HA-MKK3 in 
combination with the empty Flag vector 
or the plasmids encoding the various 
Flag-tagged AKAP-Lbc fragments 
indicated in A) were subjected to 
immunoprecipitation with anti-Flag 
antibodies. Western blots of the 
immunoprecipitates and cell extracts were 
revealed using anti-HA monoclonal 
antibodies to detect HA-MKK3 (upper 
and middle panels) or monoclonal anti-
Flag antibodies to detect the Flag-tagged 
fragments (lower panel).  
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Figure 10: Mapping the kinase interaction sites on AKAP-Lbc. A) Schematic representation of the 
AKAP-Lbc fragments used for the mapping experiments. The minimal binding site (residues 1585-1715) is 
boxed. LC3 and 14-3-3 binding sites as well as the C1 region (C1) are shown. (B) HEK-293 cells were 
transfected with HA-tagged MKK3 in combination with either the empty Flag vector or Flag-tagged 
fragments of AKAP-Lbc indicated in A). Cell lysates were subjected to immunoprecipitation with anti-Flag 
antibodies. Western blots of the immunoprecipitates and of the cell extracts were revealed using anti-HA 
polyclonal antibodies to detect the HA-tagged MKK3 (upper and middle panels), or anti-Flag monoclonal 
antibodies to detect the Flag-tagged AKAP-Lbc fragments (lower panel). C-F) Extracts from HEK-293 cells 
transfected with the plasmids encoding the empty Flag vector, Flag-AKAP-Lbc or the Flag-AKAP-Lbc 
D1585-1715 mutant in combination with the vectors encoding HA-tagged p38!& (C) )&, MKK3 (D) or MLTK 
(E) or the empty pRK5 vector (F). Western blots of the immunoprecipitates and the cell extracts were 
revealed using anti-HA polyclonal antibodies to detect HA-tagged p38!, MKK3 and MLTK (C-E, upper and 
middle panels), anti-PKN! monoclonal antibodies to detect endogenous PKN! (F, upper and middle panels) 
or anti-Flag monoclonal antibodies to detect Flag-AKAP-Lbc (lower panels).  
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The deletion reduced significantly the ability of all the tested kinases to co-
immunoprecipitate with the flag flag-tagged AKAP-Lbc (Fig. 10C-F, upper panel, lanes 2 
and 3). These findings suggest that residues 1585-1715 form a binding site that recruits 
p38! as well as its upstream activating kinases MKK3, MLTK and PKN!. 
4.7 PKN! directly binds AKAP-Lbc, p38!, MKK3 and MLTK 
 
While our current results suggest that AKAP-Lbc interacts with PKN!, MLTK, MKK3 and 
p38!, they do not indicate how the complex is organized.  Based on previous findings 
showing that PKN! can act both as an upstream activating kinase of MLTK and as a 
scaffolding protein [215], we hypothesized that it could recruit p38!, MKK3 and MLTK to 
AKAP-Lbc. Therefore, we determined whether PKN! could directly associate with AKAP-
Lbc as well as with the other kinases. 
 To assess whether the interaction of p38!, MKK3 and MLTK with AKAP-Lbc occurs 
through a direct interaction or whether it is mediated through PKN!, we monitored the 
ability of purified GST-fusion proteins of p38!, MKK3, MLTK and of the AKAP-Lbc 
fragment 1388-1922 to associate with purified His6-tagged N-terminal or C-terminal 
fragments of PKN!& (His-PKN-1-305 and His-PKN-305-942, respectively), or with the His6-
tagged 1388-1922 fragment of AKAP-Lbc using an in vitro pulldown assay. Interestingly, 
our results indicate that p38!, MKK3, MLTK as well as AKAP-Lbc can directly bind the 
C-terminal but not the N-terminal fragment of PKN! (Fig. 11A, upper panel, lanes 3, 5, 7, 
9; Fig. 11B, upper panel, lanes 2-6).  A weak direct interaction could also be detected 
between AKAP-Lbc and MKK3 (Fig.11 A, upper panel, lane 6), whereas no binding was 
observed between AKAP-Lbc and p38! or MLTK (Fig.11 A, upper panel, lane 4 and 8). 
These results indicate that AKAP-Lbc can directly bind PKN!, which, in turn can recruit 
p38!, MKK3 and MLTK. The association between AKAP-Lbc and MKK3 could stabilize 
the formation of the complex.  
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4.8 PKN! is required for proper assembly of the AKAP-Lbc/p38! 
signaling complex 
 
To assess whether PKN! could contribute to the assembly of the AKAP-Lbc/p38! complex 
inside cells, we determined the impact of silencing PKN! expression in HEK-293 cells on 
the interaction of AKAP-Lbc with p38! and MKK3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PKN! silencing was achieved by infecting cells using lentiviruses encoding shRNAs 
directed against PKN!. Using this approach, PKN! expression could be inhibited by 80-
90% as compared to cells infected with control lentiviruses (Fig. 12B, panel 1). 
AKAP-Lbc was immunoprecipitated from infected cells using affinity purified anti-AKAP-
Lbc antibodies and the presence of associated p38! and MKK3 revealed by western blot. 
As shown in Fig. 12A, silencing of PKN! expression significantly reduced the amount of 
 
Figure 11. PKN! directly interacts with MLTK, MKK3, p38! and AKAP-Lbc.   A) Bacterially purified 
His6-tagged fragments (100nM) encompassing residues 305-942 of PKN! and 1388-1922 of AKAP-Lbc 
were incubated with glutathione-sepharose beads coupled to 2%g of GST alone, or GST-tagged p38!, MKK3, 
MLTK and AKAP-Lbc 1388-1922. Associated His6-tagged fragments were detected using anti-His6 
monoclonal antibodies (upper panel). A control protein staining indicating the expression level of the 
different GST-tagged constructs used in the pulldown assay is shown (lower panel). B) Bacterially purified 
His6-tagged fragments encompassing residues 1-305 of PKN! (100nM) were incubated with glutathione-
sepharose beads coupled to 2%g of GST alone, or GST-tagged p38!, MKK3, MLTK and AKAP-Lbc 1388-
1922. Associated His6-tagged fragments were detected as indicated in A). 
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p38! and MKK3 interacting with endogenous AKAP-Lbc (Fig. 12A, panels 1 and 3, lane 
4). This suggests that PKN! favors the association of p38! and MKK3 with AKAP-Lbc. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.9 PKN! mediates AKAP-Lbc-induced activation of MLTK 
 
Previous findings have shown that PKN! can directly phosphorylate and activate MLTK 
[215].  Based on this evidence, we determined whether PKN! was required to transmit 
activating signals from AKAP-Lbc to MLTK.  To address this point, we assessed whether 
silencing of PKN! using shRNAs targeting two distinct regions of the kinase (PKN 
shRNA1 and PKN shRNA2) could affect the ability of the S1565A mutant of AKAP-Lbc, 
which displays constitutively Rho-GEF activity, to activate MLTK. 
Infected cells were transfected with the cDNAs encoding Flag-MLTK and the GFP-tagged 
AKAP-Lbc S1565A mutant. After a 24 h serum starvation, Flag-MLTK was then 
 
Figure 12 PKN is required for proper assembly of the AKAP-Lbc/p38 signaling complex A) Extracts 
from HEK-293 cells infected with control lentiviruses (control) or lentiviruses encoding PKN! shRNAs 
(PKN! shRNA1) were subjected to immunoprecipitation with either non-immune IgGs or affinity purified 
anti-AKAP-Lbc polyclonal antibodies. Western blots of the immunoprecipitates and the cell extracts were 
revealed using antibodies against p38! (panel 1 and 2), MKK3 (panel 3 and 4), AKAP-Lbc (panel 5). B) 
Western blots of extracts from HEK-293 cells infected with control lentiviruses (control) or lentiviruses 
encoding PKN! shRNAs (PKN! shRNA1) were revealed using antibodies against the PKN! (panel 6) or 
actin (panel 7) 
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immunoprecipitated and its ability to phosphorylate purified GST-MKK3 determined using 
an in vitro kinase assay. Interestingly, silencing of PKN! expression significantly reduced 
the ability of AKAP-Lbc S1565A to promote MLTK activation (Fig. 13, panel 1, lanes 5 
and 6) suggesting that PKN! is required for AKAP-Lbc-mediated MLTK activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.10 Disruption of AKAP-Lbc complex impairs !1-AR-mediated p38! activation 
 
Based on the mapping studies presented above, we investigated the possibility of whether a 
fragment of AKAP-Lbc encompassing residues 1585-1715 could be used as a competitor to 
disrupt the endogenous complexes formed by AKAP-Lbc and the various kinases. Such a 
competitor fragment could represent a valuable tool to study the role of the AKAP-Lbc 
signaling complex in the activation of p38! inside cells.   
 
Figure 13 PKN! mediates AKAP-Lbc-induced activation of MLTK HEK-293 cells infected with control 
lentiviruses or lentiviruses encoding PKN! shRNAs (shRNA1 and shRNA2) were transfected with the 
plasmids encoding Flag-MLTK in the presence of the vector encoding GFP or the GFP-tagged AKAP-Lbc 
S1565A mutant.  After a 24 h serum starvation, cells were lysed and Flag-MLTK subjected to 
immunoprecipitation using anti-Flag monoclonal antibodies. Kinase reactions were performed by incubating 
Flag-MLTK immunoprecipitates with 1 %g of purified GST-MKK3 and in the presence of ATP. Phospho-
GST-MKK3 was detected by immunoblot using a rabbit polyclonal antibody recognizing phospho-serine 189 
and phospho-threonine 193 of MKK3 (panel 1). The amounts of immunoprecipitated Flag-MLTK as well as 
the expression of AKAP-Lbc S1565A-GFP and PKN! in cell lysates were assessed using antibodies against 
the Flag tag (panel 2), GFP  (panel 3) and PKN! (panel 4), respectively. Results are representative of three 
independent experiments. 
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A GFP fusion of the competitor fragment was expressed in HEK-293 cells and its ability to 
inhibit the binding of HA-MKK3, HA-MLTK as well as PKN! to the Flag-tagged fragment 
of AKAP-Lbc encompassing residues 1388-1922 was assessed by co-immunoprecipitation 
(Fig. 14). Interestingly, overexpression of the fragment reduced the interaction between 
AKAP-Lbc and the various kinases by more than 80% suggesting that it can act as an 
efficient competitive inhibitor (Fig. 14A-C, upper panel, lane 3).  
Based on these results we determined the impact of overexpressing the GFP-tagged 
competitor fragment on the ability of !1b-adrenergic receptors to induce p38! activation in 
HEK-293 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: The fragment of AKAP-Lbc encompassing residues 1585-1715 acts as a competitive inhibitor 
of the association of MKK3, MLTK and PKN! with AKAP-Lbc. A-C) Extracts from HEK-293 cells 
transfected with the plasmids encoding HA-MKK3 (A), HA-MLTK  (B) or the pRK5 vector (C) together with 
the empty Flag vector and the pEGFP plasmid (lane 1), the vector encoding the Flag-tagged AKAP-Lbc 
fragment encompassing residues 1388-1922 and the pEGFP plasmid (lane 2) or a combination of the vectors 
encoding the Flag-tagged 1388-1922 fragment and the GFP-tagged fragment of AKAP-Lbc encompassing 
residues 1585-1715 (lane 3), were subjected to immunoprecipitation with anti-Flag antibodies. Western blots 
of the immunoprecipitates and cell extracts were revealed using anti-HA to detect HA-MKK3 (A, upper panel) 
and HA-MLTK (B, upper panel), anti-PKN! antibodies to detect PKN! (C, upper panel), anti-GFP antibodies 
to detect the GFP-tagged 1585-1715 fragment (middle panels), or anti-Flag antibodies to detect the Flag-
tagged 1388-1922 fragments (lower panels). 
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Figure 15. Disruption of the AKAP-Lbc complex inhibits !1b-AR-induced p38! activation. A) HEK-293 
cells were transfected with the vectors encoding GFP or the GFP-tagged AKAP-Lbc fragment 1585-1715 in 
the absence or presence of the plasmid encoding the HA-tagged !1-AR. After a 24 h serum starvation, cells 
were incubated for 15 min with or without 10-4 M epinephrine (EPI), lysed and subjected to 
immunoprecipitation using anti-p38! monoclonal antibodies. Kinase reactions were performed by incubating 
p38! immunoprecipitates with 1 %g of purified GST-ATF2 and in the presence of ATP. Detection of phospho-
ATF2 (panel 1), ATF2 (panel 2), p38! (panel 3) and HA-tagged !1-AR (panel 5) were performed as indicated 
in Fig. 1A.  Expression of GFP as well as the GFP-tagged AKAP-Lbc fragment 1585-1715 (panel 4) was 
detected using polyclonal anti-GFP antibodies. B) HEK-293 cells were transfected with the vectors encoding 
GFP or the GFP-tagged AKAP-Lbc 1585-1715 in the presence of the plasmid encoding HA-tagged !1b-AR. 
After a 24 h serum starvation, cells were incubated for 15 min with or without 10-4 M epinephrine (EPI) and 
lysed. Phosphorylation of ERK1/2 was assessed by western blot using polyclonal antibodies recognizing 
phospho-ERK1/2 (panel 1). The amounts of ERK1/2, GFP, GFP-tagged AKAP-Lbc 1585-1715 and HA-!1b-
ARs in the cell lysates were assessed using polyclonal antibodies against ERK1/2 (panel 2), GFP (panel 3), the 
HA epitope (panel 4), respectively. Results are representative of 3 different experiments. C) HEK-293 cells 
were transfected with the vectors encoding GFP or the GFP-tagged AKAP-Lbc fragment 1585-1715 and in the 
presence of the plasmids encoding HA-tagged !1b-AR and Flag-JNK1. After a 24 h serum starvation, cells 
were incubated for 15 min with or without 10-4 M epinephrine (EPI), lysed and subjected to 
immunoprecipitation using monoclonal anti-Flag antibodies. The kinase activity of immunoprecipitated JNK1 
was assessed in vitro by monitoring its ability to induce the phosphorylation of ATF2. The amounts of 
phospho-ATF2, ATF2, Flag JNK1, GFP-tagged AKAP-Lbc 1585-1715, and HA-tagged !1b-AR were 
assessed using antibodies against phospho ATF (panel 1), ATF2 (panel 2), the Flag epitope (panel 3), GFP 
(panel 4), and the HA-tag (panel 5), respectively. 
Quantitative analysis of phosphorylated ATF2 was obtained by densitometry. The amount of phospho-ATF2 
was normalized to the total amount of ATF2. Results are expressed as mean ± S.E. of 3 different experiments. 
). § p< 0.05 as compared with phospho-ATF2 levels measured in untreated cells expressing HA-!1b-ARs and 
GFP. * p< 0.05 as compared with phospho-ATF2 levels measured in epinephrine-treated cells expressing HA-
!1b-ARs and GFP. 
 87 
Interestingly, expression of the competitor fragment reduced by 62% and 58% the ability of 
!1b-ARs to promote p38! activation under basal conditions and in response to epinephrine 
stimulation, respectively (Fig. 15A, panel 1, lanes 7 and 8;), without affecting receptor-
induced phosphorylation of ERK1/2 and JNK1 (Fig. 15B-C, panel 1, lanes 3 and 4). These 
findings suggest that the integrity of the complex formed by AKAP-Lbc and the various 
kinases is required for the activation of p38! induced by !1b-ARs.  
4.11 Binding of 14-3-3 to AKAP-Lbc inhibits the recruitment of PKN! and 
reduces p38!  activation  
 
Our laboratory previously demonstrated that recruitment of the regulatory protein 14-3-3 to 
a motif located at position 1565 within the N-terminal regulatory region of AKAP-Lbc 
strongly inhibits the Rho-GEF activity of the anchoring protein [195]. Our current results 
indicate that this site is located in close proximity of the binding domain for the p38! 
activation complex. This raises the possibility that 14-3-3 recruitment could also interfere 
with the interaction of AKAP-Lbc with the p38! signaling complex and therefore inhibit 
AKAP-Lbc-mediated p38 activation.  
To address this question, we initially determined whether the overexpression of 14-3-3" in 
HEK-293 cells could affect the ability of AKAP-Lbc to associate with PKN!. HEK-293 
cells were transfected with Flag AKAP-Lbc together with increasing amounts of GFP-
tagged 14-3-3". After immunoprecipitating the anchoring protein using anti-Flag 
antibodies, anti-PKN! antibodies were used to immunoblot the immunoprecipitated 
samples. Western blots revealed that overexpression of increasing amount of 14-3-3" 
progressively reduced the ability of PKN! to co-immunoprecipitate with AKAP-Lbc (Fig. 
16A, panel 1, lanes 2-4;). In line with these results, we could show that the S1565A mutant 
of AKAP-Lbc, which is unable to bind 14-3-3, display a 2 fold higher ability to associate 
with endogenous PKN!& when compared to wild type AKAP-Lbc (Fig. 16B, panel 1, lanes 2 
and 3). This indicates that recruitment of 14-3-3 inhibits PKN! binding to AKAP-Lbc. 
To determine whether this reduction of PKN! binding induced by 14-3-3 could affect the 
ability of AKAP-Lbc to induce p38! activation, we compared the p38 activating potential 
of the wild type and 14-3-3 binding deficient forms of AKAP-Lbc.  We could show that 
deletion of the 14-3-3 binding site increases by 2.7 folds the activation of p38! induced by 
the anchoring protein (Fig. 16C, upper panel, lanes 2 and 3). Collectively, these results 
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suggest that 14-3-3 exerts an inhibitory effect on the ability of AKAP-Lbc to recruit and 
activate the p38! signaling complex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16) 14-3-3 inhibits the interaction between AKAP-Lbc and PKN!. A) HEK-293 cells were 
transfected with the empty pFlag vector or the vector encoding Flag-AKAP-Lbc in combination with 
increasing amounts (indicated above each lane) of the plasmid encoding 14-3-3" -GFP. Cell extracts were 
subjected to immunoprecipitation with anti-Flag antibodies. Western blots of the immunoprecipitates and of 
the cell extracts were revealed using anti-PKN! polyclonal antibodies (panels 1 and 2), anti-14-3-3" 
polyclonal antibodies (panels 3 and 4) or anti-Flag monoclonal antibodies to detect the Flag-AKAP-Lbc 
(panel 5). Densitometry of the bands corresponding to PKN! coimmunoprecipitated with AKAP-Lbc. The 
amount of PKN! in the immunoprecipitates was normalized to the PKN! content of the cell extracts. Results 
are expressed as mean± S.E. of three independent experiments. * p< 0.05 as compared with the levels of co-
immunoprecipitated PKN! measured in cells expressing only Flag-AKAP-Lbc.  B) Extracts from HEK-293 
cells transfected with the plasmids encoding the empty Flag vector, Flag-AKAP-Lbc or the Flag-AKAP-Lbc 
S1565A. Cell extracts were subjected to immunoprecipitation with anti-Flag antibodies. Western blots of the 
immunoprecipitates and the cell extracts were revealed as indicated in A). Densitometry of the bands 
corresponding to PKN! coimmunoprecipitated with AKAP-Lbc was performed as indicated in B). Results 
are expressed as mean± S.E. of three independent experiments. * p< 0.05 as compared with the levels of co-
immunoprecipitated PKN! measured in cells expressing Flag-AKAP-Lbc.  C) Extracts from HEK-293 cells 
transfected with the vectors encoding Flag AKAP-Lbc-GFP or Flag-AKAP-Lbc S1565. After a 24 h serum 
starvation, cells were lysed and subjected to immunoprecipitation using monoclonal anti-p38! antibodies. 
Kinase reactions and detection of phospho-ATF2 (panel 1), ATF2 (panel 2) and p38! (panel 3) were 
performed as indicated in Fig. 1A. Expression of the AKAP-Lbc constructs was detected using anti-Flag 
monoclonal antibodies (panel 4). Quantitative analysis of phospho-ATF2 was obtained as indicated in Fig. 
1B. Results are expressed as mean ± S.E. of three different experiments. * p< 0.05 as compared with 
phospho-ATF2 levels measured in cells expressing Flag-AKAP-Lbc. 
 89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 90 
 
 91 
V DISCUSSION 
 
Here, we report that AKAP-Lbc organizes a molecular signaling complex that is required to 
mediate the p38 MAP kinase activation downstream of !1b-adrenergic receptors.  
MAP kinase pathways are crucial mediators of several pathophysiological responses 
induced by !1-adrenergic receptors [23, 211-213]. In particular p38 kinases were originally 
described to mediate cellular responses to various types of stresses [208, 214]. During the 
last years, however, it has become increasingly clear that members of this kinase family can 
participate in signaling pathways activated by a variety of other membrane receptors, 
including cytokine and G protein coupled receptors, to promote cellular functions such as 
proliferation, growth, inflammation, and contraction [208, 214]. Interestingly, it was shown 
that activation of p38! by !1-ARs could regulate arterial smooth muscle cell contractility 
[215] and promote cardiomyocyte sarcomere remodeling during cardiac hypertrophy [212].  
It is now clear, by different lines of evidence collected over the last years that these 
signaling cascades are organized in transduction modules [216], but it is currently unknown 
how such signaling complexes are assembled and get activated in response to !1-adrenergic 
receptor stimulation to generate specific cellular responses.  
In this study we have demonstrated that the RhoA-selective exchange factor, AKAP-Lbc, 
recruits a signaling module containing the RhoA effector PKN! and the kinases MLTK, 
MKK3 and p38, and it transduces activating signals from !1ARs down to p38 (Fig. 17) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17) Model for the AKAP-Lbc-
p38! activation complex. AKAP-Lbc 
assembles a signaling complex which 
includes the scaffolding protein PKN! as 
well as MLTK, MKK3 and p38!. The 
AKAP-Lbc signaling complex is 
activated in response to !1-AR 
stimulation through a G!12 mediated 
signaling pathway. Activated AKAP-Lbc 
promotes the formation of RhoA-GTP, 
which, in turn, induces the activation of a 
signaling cascade that includes PKN!, 
MLTK, MKK3 and p38!. The 
recruitment of 14-3-3, inhibits AKAP-
Lbc Rho-GEF activity, impairs the 
interaction between PKN! and AKAP-
Lbc, and reduces p38 activation. 
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In this context, it is well established that GTPases of the Rho family, including RhoA, Rac1, 
and Cdc42, are key mediators of p38 activation induced by membrane receptors [209, 212, 
217, 218]. However, how activation of Rho GTPases by upstream stimuli is translated into 
the activation of a specific p38 pathway is not clear.  
Similar to our findings, two previous studies have characterized that the GTPase Rac-1 and 
its upstream activator Tiam can recruit signaling complexes containing p38 and its upstream 
activating kinases. In the first study, Rac-1 was shown to directly bind to Osm, a scaffold 
protein that recruits MEKK3 and MKK3 [219]. This complex has been implicated in 
hyperosmotic shock-induced p38 activation. In a second study, the Rac-1 activator Tiam 
was shown to recruit a p38 signaling complex formed by the scaffold protein JIP2 and the 
kinases MLK3 and MKK3 [220]. This study, however, did not determine which 
extracellular stimuli activate this signaling module or whether Tiam and JIP2 can form a 
complex at the endogenous level.  
More recently, elegant studies showed that the pro-myogenic cell surface protein Cdo can 
recruit two proteins named Bnip-2 and JLP, which act as scaffolds for the Cdc42 and p38, 
respectively [221, 222]. The assembly of this signaling complex promotes Cdc42–
dependent p38 activation.  
 
In our project AKAP-Lbc can mediate !1-AR-induced p38 activation through the assembly 
of a signaling module composed of PKN!, MLTK, MKK3 and p38!. Interestingly our 
results indicate that deletion of the PKN! binding site (residues 1585-1715) from AKAP-
Lbc abolishes the ability of the anchoring protein to recruit the p38! and its upstream 
kinases MKK3 and MLTK. These results suggest that PKN in our model is not only an 
effector of RhoA but it acts as a scaffold protein that organizes a p38 signaling cascade to 
facilitates RhoA-dependent p38 activation.  
In line with our observations, the potential scaffold role of PKN was already described ten 
years ago by an interesting paper, which has demonstrated that PKN could promote the 
activation of p38# though the specific recruitment of MLTK and MKK6. These results raise 
the hypothesis that PKN, depending on the cell types, can recruit different combinations of 
signaling enzymes to modulate the activation of different p38 isoforms. In our project the 
co-immunoprecipitation experiments failed to detect an interaction between p38# and 
AKAP-Lbc (results not shown), suggesting that AKAP-Lbc might selectively stabilize the 
interaction between PKN! and p38!. 
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Currently, three other scaffold proteins including JIP2, JIP4 and Osm have been shown to 
promote p38 activation [216, 219, 223]. Interestingly, recent studies identified an 
interaction between recombinant JIP4 and a splice variant of AKAP-Lbc, called Brx, that 
contains only the last 1429 residues the anchoring protein [224]. However, while these 
studies mapped the interaction determinants for JIP4 to the last 400 amino acids of Brx, 
they did not determine whether the two proteins are able to interact at the endogenous level.  
In our control experiments, we could not detect the expression of JIP4 in HEK-293 cell 
lysates (results not shown), suggesting that JIP4 is unlikely to be involved in the recruitment 
of p38! and its upstream kinases to AKAP-Lbc in this cell line. 
Altogether these results provide new mechanistic insights on how specific signals can be 
driven from membrane receptors to p38!. 
This conclusion has been supported by the fact that AKAP-Lbc specifically mediates !1-
AR-induced p38! activation without affecting activation of ERK1/2 and JNK&. This was 
demonstrated by the co-immuoprecipitation experiments that did not show any interaction 
between ERK1/2 and JNK with AKAP-Lbc. 
In addition, our results suggest the presence of other signaling complexes that activate 
ERK1/2 and JNK in response to !1-AR-induced. In this context, a previous study has 
shown that the Rho-GEF p115 can recruit a scaffolding protein named CNK1, which binds 
the kinases MLK2 and MKK7, to coordinate the activation of JNK1 [225]. However, 
further investigations will be required to determine whether p115 or a different signaling 
complex is involved in the organization of the JNK pathway downstream of !1b-ARs. 
 
By mapping the interaction between AKAP-Lbc and PKN we could see that the PKN 
binding site (1585-1715) is located in proximity of the 14-3-3 binding site (serine 1565). 
The members of the 14-3-3 family are well characterized to negatively regulate a variety of 
transduction pathways including the p38 activation pathway [226, 227]. Interestingly, 
previous observations from our lab have demonstrated that 14-3-3 impairs the Rho-GEF 
activity of AKAP-Lbc. In this context, our current findings suggest that 14-3-3 can inhibit 
AKAP-Lbc-mediated p38! activation in two ways: by inhibiting the Rho-GEF activity of 
ALKAP-Lbc [42] and by inducing the dissociation of PKN!-MLTK-MKK3-p38! complex 
from AKAP-Lbc (Fig. 8). 
The second mechanism inhibiting p38 activation could be explained by the fact that 14-3-3 
recruitment might block the interaction between AKAP-Lbc and PKN! by directly masking 
the PKN! interaction site on the anchoring protein. This is reminiscent of the mechanism 
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through which 14-3-3 has been shown to inhibit the interaction between the pro-apoptotic 
protein Bad and pro-survival Bcl-2 family members [228].  
 
In conclusion, the implications of our findings are twofold. Firstly, they identify key 
molecular mechanisms controlling signaling specificity downstream of !1b-ARs. By 
assembling a macromolecular signaling complex containing RhoA, PKN!, MLTK, MKK3 
and p38!, AKAP-Lbc controls the specific transduction of signals from !1b-ARs to p38!. 
Secondly, they provide a novel hypothesis explaining the inhibitory action of 14-3-3 on the 
p38 pathway, suggesting that AKAP-Lbc might represent a molecular platform integrating 
14-3-3 and p38 signaling. 
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VI. RESULTS II: Characterization of novel hypertrophic 
pathway activated by the AKAP-Lbc signaling complex in 
cardiomyocytes 
 
5.1 AKAP-Lbc assembles a p38!  activation module in 
cardiomyocytes 
 
Our previous results have shown that AKAP-Lbc forms a stable complex with p38! and its 
upstream kinases MKK3, MLTK and PKN! in HEK 293 cells. Moreover our results 
indicate that the formation of this complex is required for the ability of AKAP-Lbc to 
activate p38!. 
To determine whether endogenous AKAP-Lbc can form a stable complex with these 
different kinases in cardiomyocytes, we immunoprecipitated AKAP-Lbc from RNVMs, 
using an affinity purified anti-AKAP-Lbc specific antibody, and assessed the presence of 
associated kinases by immunoblot using specific antibodies. Our results indicate that p38!, 
MKK3, MLTK and PKN! endogenously expressed in cardiomyocytes could specifically 
co-immuno-precipitate with AKAP-Lbc (Fig. 1).  
Interestingly, only the 39 kDa form of MKK3 (Isoform B [216]) (Fig. 1A, panel 2 lanes 1-
3) and the 75 kDa of MLTK (MLTK beta [217]) (Fig. 1B panel 1, lanes 1-3) could form a 
complex with the anchoring protein. On the other hand, no interaction could be detected 
between the endogenous AKAP-Lbc with MLK3 (Fig. 1B panel 2, lanes 1-3). 
Altogether, these results suggest that AKAP-Lbc specifically interact with p38! and its 
upstream kinases MKK3", MLTK" and PKN! to form a stable complex in 
cardiomyocytes.  
 
5.2 AKAP-Lbc is involved in !1-AR-mediated p38 activation in 
cardiomyocytes 
 
Our previous experiments performed in HEK-293 cells have demonstrated that AKAP-Lbc 
could activate the kinase p38 in response to !1-ARs stimulation. 
To provide a formal proof that AKAP-Lbc mediates the activation of p38! in 
cardiomyocytes, we silenced AKAP-Lbc expression in RNVMs using lentiviral vectors 
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encoding AKAP-Lbc specific shRNAs and determined whether this could affect the 
phosphorylation of p38! induced by the !1-ARs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Indeed, we could show that AKAP-Lbc silencing reduced the ability of !1-ARs to induce 
the phosphorylation of p38 (Fig.2, panel 1, lane 4), while in control experiments, infection 
of RNVMs with lentiviral vectors encoding mutated shRNAs did not affect p38! 
phosphorylation (Fig2, panel 1 lanes 2 and 6).  
These results indicate that, in cardiomyocytes, AKAP-Lbc transduces signals involved in 
the activation of the p38 in response to the stimulation of !1-ARs.  
5.3 The AKAP-Lbc/p38 complex is involved in !1-AR-mediated 
GATA4 activation in cardiomyocytes 
 
As reported in the introduction, p38 has a relevant role in activating transcription factors 
that control the transcription of genes involved in cardiac hypertrophy such as GATA-4 and  
MEF2C though direct phosphorylation of specific serine residues located within their 
transactivation domains (Ser 105 of GATA-4, Ser 59 of MEF-2C). In addition, an important 
study has demonstrated that RhoA potentiates the transcriptional activity of GATA-4 via a 
Figure 1. AKAP-Lbc interacts with endogenous p38!, MKK3" , MLTK"  and PKN!. NRVMs cell 
extracts were subjected to immunoprecipitation with either non-immune IgGs or affinity purified anti-AKAP-
Lbc polyclonal antibodies. Western blots of the immunoprecipitates and the cell extracts were revealed using 
anti-p38! (A, upper panel), anti-MKK3 (A, middle panel), anti-MLTK (B, upper panel), anti-MLK3 (B, 
middle panel) anti-PKN! (C, upper panel) or affinity purified anti-AKAP-Lbc polyclonal antibodies  (lower 
panels). Results are representative of at least three independent experiments.  
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p38-dependent pathway that phosphorylates GATA-4 activation domains and GATA 
binding sites [141]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to determine whether AKAP-Lbc silencing could inhibit the activity of GATA4 in 
response to the stimulation of !1-ARs, RNVMs have been infected with lentiviral 
expression vectors encoding shRNAs directed against AKAP-Lbc and subsequently 
transfected with the plasmid encoding the firefly luciferase under the control of GATA4 
responsive elements. The activity of GATA4 was measured by dual luciferase assay. 
Interestingly, GATA4 transcriptional activity induced by the stimulation of !1-ARs was 
inhibited by 65% following AKAP-Lbc silencing, as compared to the control cells (Fig. 
3B).  
Using the same assay we could show that p38 inhibition using the specific p38 inhibitor 
SB203580 could completely block !1-AR-induced GATA4 activation. 
These results suggest that AKAP-Lbc/p38! complex can activate the transcription factor 
GATA4 in response to the stimulation of !1-ARs in NRVMs. 
Notably it will important to determine whether the AKAP-Lbc/p38 complex contributes to 
the activation of GATA4 through the phosphorylation of serine 105 in response to !1-AR 
stimulation. 
 
Figure 2 Silencing of AKAP-Lbc 
expression inhibits !1-AR-mediated 
phosphorylation of p38:  RNVMs were 
infected with lentiviruses encoding GFP 
(control), GFP-wild-type and GFP-mutated 
AKAP-Lbc shRNAs at a moi of 50. Four 
days after infection, cardiomyocytes serum 
starved, were incubated for 15 min with or 
without (Ctrl) 10
-4
 M phenylephrine (PE). 
Proteins in the cell lysates were separated by 
SDS-PAGE and the phosphorylated form of 
p38, was detected using phospho specific 
antibody of p38, (upper panel). The amounts 
of total p38, in the cell lysates were assessed 
using specific antibodies against p38, (middle 
panel). The amounts of total AKAP-Lbc in 
the cell lysates was assessed using polyclonal 
antibodies against the AKAP-Lbc (lower 
panel). Quantitative analysis of 
phosphorylated p38 was obtained by 
densitometry. The amount of phospho-p38 
was normalized to the total amount of p38!. 
Results are expressed as mean ± S.E. of 6 
different experiments.  
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5.4 AKAP-Lbc signaling complex controls the expression of different 
hypertrophic genes that are under the control of GATA4 
 
It is well described that GATA4 regulates the transcription of some hypertrophic genes such 
as the Atrial natriuretic factor (ANF), "-myosin heavy chain ("-MHC), !-skeletal actin and 
! cardiac actin. To determine whether the AKAP-Lbc/p38! complex can control the 
expression of these genes, we have determined the impact of silencing AKAP-Lbc 
expression in RNVMs using lentiviral expression vectors encoding specific shRNAs on the 
expression of ANF, "-MHC, !-skeletal actin and !-cardiac actin induced by the stimulation 
of !1-ARs. To address this issue the expression of these genes has been measured by real 
time PCR.  
Interestingly, our results show that AKAP-Lbc silencing reduces by 50% the expression of 
ANF and by 35% the expression of "-MHC and !-skeletal actin in response to !1-AR 
stimulation compare as to the controls while the expression of ! cardiac actin was not 
influenced (Fig. 4). 
Figure 3 Silencing of AKAP-Lbc expression 
inhibits !1-AR-mediated activation of 
GATA4: A) RNVMs were infected with 
lentiviruses encoding GFP (control), GFP-wild-
type and GFP-mutated AKAP-Lbc shRNAs at a 
moi of 50. Four days after infection, 
cardiomyocytes serum starved, were incubated 
for 15 min with or without (Ctrl) 10
-4
 M 
phenylephrine (PE). Proteins in the cell lysates 
were separated by SDS-PAGE and the amount 
of total AKAP-Lbc in the cell lysates was 
assessed using polyclonal antibodies against the 
AKAP-Lbc (upper panel). B) RNVMs were 
infected with lentiviruses encoding GFP 
(control), GFP-wild-type and GFP-mutated 
AKAP-Lbc shRNAs at a moi of 50. Twenty-
four hours after infection cells were co-
transfected with GATA4-Luciferase (Firefly) 
reporter gene plasmid and pcmv-Renilla-
Luciferase. Forty-eight hours after transfection 
cells were incubated for 24 hours with or 
without (Ctrl) 10
-4
 M phenylephrine (PE). 
Firefly activity was measured and normalized 
to Renilla activity.  Luciferase activity 
measured in cells not stimulated was given an 
arbitrary value of 1. 
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These results suggest that the AKAP-Lbc signalling complex controls the expression of 
different hypertrophic genes that are under the control of GATA4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.5 The AKAP-Lbc/p38 complex is involved in !1-AR-mediated 
Hsp27 activation in cardiomyocytes 
 
It is well established that the MAPK p38 cascade leads to the activation of the kinase MK2, 
which directly phosphorylates the heat shock protein 27 (Hsp27). Interestingly 
phosphorylated Hsp27 interacts with actin and intermediate filaments and it protects them 
from fragmentation. In cardiomyocytes, Hsp27 is phosphorylated in response to the 
activation of the p38 pathway induced by several stresses. Specifically, phospho-Hsp27 has 
been shown to bind and stabilize both actin cytoskeleton and sarcomeres.  
Knowing the role of cytoskeleton remodelling and sarcomere reorganisation during 
cardiomyocyte hypertrophy, it is of special interest to characterize the role AKAP-Lbc/p38 
complex in the activation of Hsp27 in NRVMs. 
To address this issue we assessed whether silencing AKAP-Lbc expression using lentiviral–
delivered shRNAs, could significantly impair the phosphorylation of Hsp27 in response to 
the stimulation of !1ARs, as assessed using Hsp27 phospho-specific antibodies. 
 
Figure 4 Silencing of AKAP-
Lbc expression inhibits !1-
AR-mediated induction of 
hypertrophic genes 
transcribed by GATA4: 
RNVMs were infected with 
lentiviruses encoding GFP 
(control), GFP-wild-type and 
GFP-mutated AKAP-Lbc 
shRNAs at a moi of 50. 
Seventy-two hours after 
infection, cells were incubated 
for 24 h in the absence or 
presence of 10
"4
 M PE. Real-
time PCR analysis of atrial 
natriuretic factor (ANF) skeletal 
!-actin (Ska), " Myosin heavy 
chain and !-cardiac actin  
mRNA expression was 
performed on total RNA 
samples extracted from rat 
ventricular cardiomyocytes. 
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Interestingly, our results indicate that inhibition of AKAP-Lbc expression can reduce by 
65% the phosphorylation of Hsp27 in response to !1-ARs as compared to the controls (Fig. 
5, panel 1, lane 6). In addition, in the same experiments we have shown that p38 inhibition 
using specific p38 inhibitor SB203580, can completely block the !1-ARs-induced Hsp27 
phosphorylation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This suggests that AKAP-Lbc/p38 complex promotes the activation of the Hsp27 in 
response to !1-ARs stimulation, which may in turn stabilize cardiomyocyte cytoskeleton in 
response to hypertrophic stimuli. 
5.6 Hsp27 relocalizes to the cytoskeleton and to the sarcomere in 
response to !1-ARs stimulation in RNVMs 
 
To futher evaluate the potential role of Hsp27 in !1-Ars-induced cardiomyocyte 
remodelling, we have determined whether stimulation of RNVMs with PE could promote 
re-localization of Hsp27 from the cytosol to the cytoskeleton or to sacomeric components, 
as assessed by immunohystochemistry.  
Our results indicate that following 1 hour PE treatment, Hsp27 relocalizes to peripheral 
actin-positive filaments structures (Fig.6A-B). 
Figure 5 Silencing of AKAP-Lbc expression 
inhibits !1-AR-mediated phosphorylation of 
Hsp27:  RNVMs were infected with lentiviruses 
encoding GFP (control), GFP-wild-type and GFP-
mutated AKAP-Lbc shRNAs at a moi of 50. Four 
days after infection, cardiomyocytes serum 
starved, were incubated for 2h with or without 
(Ctrl) 10
-5
 M SB203580. Two hours later 
cardiomyocytes serum starved were incubated 
with or without (Ctrl) 10
-4
 M phenylephrine (PE). 
Proteins in the cell lysates were separated by 
SDS-PAGE and the phosphorylated form of 
Hsp27, was detected using phospho specific 
antibody of Hsp27, (upper panel). The amounts of 
total Hsp27, in the cell lysates were assessed 
using specific antibodies against Hsp27, (middle 
panel). The amounts of total AKAP-Lbc in the 
cell lysates was assessed using polyclonal 
antibodies against the AKAP-Lbc (lower panel). 
Quantitative analysis of phosphorylated Hsp27 
was obtained by densitometry. The amount of 
phospho-Hsp27 was normalized to the total 
amount of Hsp27. Results are expressed as mean 
± S.E. of 6 different experiments. 
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Figure 6 Hsp27 relocalize to the cytoskeleton after stimulation of the !1-AR in RNVMs A) RNVMs were 
serum starved for 24h. After the starvation RNVMs were incubated for 1 h in the absence or presence of PE. 
Cells were then fixed, permeabilized, and incubated with anti-Hsp27 polyclonal antibodies as well as FITC 
conjugated anti-rabbit secondary antibodies and with with anti-!-actinin (red) monoclonal antibodies as well 
as rhodamine-conjugated anti-mouse secondary antibodies. 
B) RNVMs were serum starved for 24h. After the starvation RNVMs were incubated for 1 h in the absence or 
presence of PE. Cells were then fixed, permeabilized, and incubated with anti-Hsp27 polyclonal antibodies as 
well as FITC conjugated anti-rabbit secondary antibodies and with rhodamine- conjugated phalloidine to 
detect the expression of the actin. 
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Moreover, in some cardiomyocytes PE stimulation induced Hsp27 to re-localize in the 
sarcomeric proteins. 
These results raise the hypothesis that Hsp27 might participate in the reorganization and/or 
stabilization of sarcomeres and cytoskeleton, following hypertrophic signals. Future 
experiments using Hsp27 specific shRNA will address this question. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.7 Over-expressing the competitor fragment of AKAP-Lbc 1585-
1715 impairs the hypertrophic response of NRVMs induce by !1-
ARs stimulation 
 
We have previously shown that AKAP-Lbc mediates !1-ARs induced cardiomyocyte 
hypertrophy. To determine whether this effect requires the ability of AKAP-Lbc to 
assemble a p38-activated complex, we determined the impact of disrupting the complex 
using the competitor fragment (AKAP-Lbc 1585-1715) on the ability of !1-ARs to induce 
cardiomyocyte hypertrophy. Induction of cardiomyocyte hypertrophy was assessed by 
measuring cell size as well as sarcomere assembly and reorganization. In RNVMs 
transfected with GFP alone, treatment with PE for 24 h induced a 70% increase in cell size 
(Fig.8A).  
Interestingly, this effect was impaired in cardiomyocytes expressing AKAP-Lbc-1585-
1715-GFP, in which PE treatment could only induce a 40% increase in cell size (Fig. 8B). 
 
Figure 7: Hsp27 forms sarcomeric-like structure in response to !1-AR stimulation: RNVMs serum 
starved were incubated for 1 h in the absence or presence of PE. Cells were then fixed, permeabilized, and 
incubated with anti-Hsp27 polyclonal antibodies as well as FITC conjugated anti-rabbit secondary antibodies 
and with rhodamine-conjugated-phalloidine to detect the expression of the actin. 
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Figure 8: AKAP-Lbc 
1585-1715 impairs the 
hypertrophic response of 
NRVMs induce by !1-
ARs stimulation: RNVMs 
were transfected with GFP 
(control) or with GFP-
AKAP-Lbc 1585-1715. 
Seventy-two hours after 
transfection 
cardiomyocytes serum 
starved were incubated for 
24 h in the absence or 
presence of PE. Cells were 
then fixed, permeabilized, 
and incubated with anti-!-
actinin (red) monoclonal 
antibodies  as well as 
rhodamine-conjugated anti-
mouse secondary 
antibodies. GFP expression 
was visualized directly by 
fluorescent excitation at 
490 nm. (B) Mean cell 
surface area (± SE) of 
cardiomyocytes trasfected 
and treated with or without 
PE. The cell surface area 
was determined on a total 
of 120 GFP-positive 
cardiomyocytes derived 
from four independent 
experiments by using the 
Image J software. Statistical 
significance was analyzed 
by paired Kruskal-
Wallis’test. !, P < 0.05 as 
compared with the cell 
surface area measured in 
PE stimulated 
cardiomyocytes with 
control no-stimulated. 
§, P < 0.05 as compared 
with the cell surface area 
measured in PE stimulated 
cardiomyocytes transfeted 
with GFP-AKAP1585-1715 
with control GFP cells. 
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In agreement with these findings, overexpressing the competitor fragment inhibited the PE 
induced sarcomere reorganization and assembly.  
Taken together these results suggest that the expression of the competitor fragment impairs 
the hypertrophic response induced by !1-ARs. These finding are in agreement with the 
hypothesis that AKAP-Lbc/p38 complex promotes cardiomyocyte hypertrophy. 
 
5.8 Over-expressing the longer competitor fragment of AKAP-Lbc 
1570-1764 impairs the phosphorylation of Hsp27 induced by !1-ARs 
stimulation in NRVMs 
 
To provide evidence that the integrity of the AKAP-Lbc/p38 complex is required for the 
phosphorylation induced by !1-ARs, we determined whether disruption of the AKAP-Lbc 
complex by overexpressing the competitor fragment encompassing residues 1585-1715 of 
AKAP-Lbc, could affect PE-induced Hsp27 phosphorylation.  
Our results indicate that infected RNVMs with lentiviral vectors encoding the competitor 
fragment, strongly inhibited the ability of !1-ARs to induce the phosphorylation of Hsp27 
(Fig.9 panel 1 lanes 4 and 6). Unfortunately, due to technical problems, it was not possible 
to detect the fragment in these cardiomyocytes by western blot (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 AKAP-Lbc 1570-1764 impairs 
the phosphorylation of Hsp27 induce by 
!1-ARs stimulation RNVMs were 
infected with lentiviruses encoding Flag 
(control), and Flag-AKAP-Lbc1570-1764 
at a moi of 50. Four days after infection, 
cardiomyocytes serum starved, were 
incubated 15 minutes with or without (Ctrl) 
10
-4
 M phenylephrine (PE). Proteins in the 
cell lysates were separated by SDS-PAGE 
and the phosphorylated form of Hsp27, 
was detected using phospho specific 
antibody of Hsp27, (upper panel). The 
amounts of total Hsp27, in the cell lysates 
were assessed using specific antibodies 
against Hsp27 (lower panel). Quantitative 
analysis of phosphorylated Hsp27 was 
obtained by densitometry. The amount of 
phospho-Hsp27 was normalized to the total 
amount of Hsp27. Results are expressed as 
mean ± S.E. of 8 different experiments. 
 
 105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 106 
 
 
 
 
 107 
VII DISCUSSION 
 
In response to various pathological stresses, the heart undergoes a pathological remodeling 
process that is associated with cardiomyocyte hypertrophy [1-3]. Since cardiac hypertrophy 
can progress to heart failure, a major cause of lethality worldwide, the intracellular 
signaling pathways that control cardiomyocyte growth have been subjected of intensive 
investigation. 
While previous studies performed in our laboratory have demonstrated the implication of 
AKAP-Lbc in the hypertrophic responses activated by !1-ARs and ATIRs, the downstream 
signaling pathways linking AKAP-Lbc to cardiomyocyte hypertrophy remained to be 
elucidated [28]. Our findings now indicate that AKAP-Lbc, in RNVMs, is able to organize 
a macromolecular signaling complex containing RhoA, PKN!, MLTK#, MKK3# and p38! 
that participates in the hypertrophic pathway upon !1-ARs activation in primary cultures of 
RNVMs. 
In particular our results indicate that suppression of AKAP-Lbc expression and disruption 
of the AKAP-Lbc/p38 complex not only reduces PE-induced p38 activation but also 
inhibits !1-ARs mediated cardiomyocyte hypertrophy as well as sarcomere reorganization. 
Interestingly, we could identify the transcriptional factor GATA-4 and the heat shock 
Hsp27 as effectors that could potentially mediate the hypertrophy and sarcomere 
reorganization effects of the AKAP-Lbc/p38 complex in cardiomyocytes. Overall these 
findings identify AKAP-Lbc/p38 complex as a signaling unit involved in the activation of 
hypertrophic response induced by !1-ARs. 
Previous studies have shown that p38 can controls hypertrophy and sarcomere assembly in 
cultured cardiomyocytes. This conclusion was based on the observation that inhibition of 
p38 using the specific inhibitor SB203580 or by overexpressing its dominant negative 
mutant could strongly reduce hypertrophic gene expression as well as sarcomere 
reorganization upon hypertrophic stimuli such as PE, Ang. II, ET-I [122, 129, 135, 136]. 
Our current results identify AKAP-Lbc/p38 complex as a mediator of hypertrophic 
response induced by PE. In fact the disruption of the complex using AKAP-Lbc 1585-1715 
competitor fragment can impair hypertrophic signaling responses, indicating that the 
assembly of PKN!, MLTK", MKK3" and p38! by AKAP-Lbc is required for the efficient 
transduction signals downstream of !1-ARs. 
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These findings are in agreement with previous results showing that RhoA, PKN! and p38 
as mediators of !1-ARs induced cardiomyocyte hypertrophy and sarcomeric reorganization 
[141]. They also indicate that hypertrophic signals generated by !1-ARs can be integrated 
at the molecular level by AKAP-Lbc and transmitted via RhoA to p38 activating module. 
It is apparent from our results that overexpression of AKAP-Lbc competitor fragment 
cannot completely inhibit PE induced hypertrophic responses. These results could be 
explained by an incomplete disruption of the AKAP-Lbc/p38 complex in all 
cardiomyocytes and/or they indicate that other additional pathways can induce 
cardiomyocyte hypertrophy.  
 
While our current findings identified a signaling complex involved in the activation of p38 
induced by !1-ARs, hypertrophic agonists can promote p38 activation through a variety of 
different pathways. In fact it has been shown that stimulation of ATIRs promotes p38 
activity through a signaling cascade, involving the activation of Rac1, the reactive oxygen 
species (ROS) and the subsequent activation of the MAPKKK ASK1 and its downstream 
kinases MKK3/6 [49, 50]. On the other hand, the hypertrophic transforming growth factor 
(TGF)-beta induces p38 activation via the MAPKKK TAK1 and MKK3/6 [218].   
Based on this evidence, it will be interesting to determine whether the transduction elements 
that composed these pathways are also organized into transduction modules that might 
specifically activate p38 in response to the stimulation of selected receptors. 
 
The role of p38 in cardiac hypertrophy is still debated. While our current findings are in 
agreement with previous evidence suggesting that p38! is phosphorylated in RNVMs, we 
are aware of the fact that it will be crucial to define whether AKAP-Lbc/p38 complex 
mediates hypertrophic response in vivo. 
In this respect, the impact of inhibiting p38 signaling in vivo is matter of controversy. 
Chronic inhibition of p38 signal by overexpressing dominant negative p38! induces pro-
hypertrophic effect suggesting that p38! in vivo is anti-hypertrophic [130, 131]. 
Moreover surprisingly, cardiac-specific KO mice of p38 did not affect the hypertrophic 
response induced by the stress. In contrast to these findings, acute activation of p38 
signaling in adult mice produces hypertrophy[133]. 
To understand the role of the AKAP-Lbc/p38 complex in cardiac hypertrophy our group 
has generated the transgenic mice that specifically overexpress the AKAP-Lbc 1585-1715 
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competitor fragment in the heart. Expression of the transgene is under control of the myosin 
heavy chain promoter. Using this strategy we expect to characterize the in vivo role of 
AKAP-Lbc/p38 complex in cardiac myocytes. Transgenic mice will be subjected to 
different hypertrophic stimuli (TAC, PE infusion exc.) and the cardiac hypertrophy will be 
assessed by echocardiography as well as by determining the heart weight index, the 
activation of hypertrophic genes and by measuring the cardiomyocyte cross-sectional area. 
 
Previous evidence indicates that the transcription factor GATA4 can mediate the 
transcription of hypertrophic genes downstream of !1-ARs. Activation of GATA4 occurs 
via a pathway that includes RhoA and p38 [141]. These findings are in line with our current 
results showing that the AKAP-Lbc/p38 complex mediates !1AR-induced activation of 
GATA4. !1ARs can promote the expression of GATA4-regulated hypertrophic genes such 
as ANF, !-skeletal actin, "-Myosin heavy chain exc.  
However, these genes are also regulated through the activation of other hypertrophic 
transcription factors such as MEF2 and SRF. Therefore, to formally demonstrate that 
AKAP-Lbc/p38 complex mediates cardiomyocyte hypertrophy via GATA4, future 
experiments will determine whether the silencing of GATA4 can inhibit the hypertrophic 
responses induced by the overexpression of AKAP-Lbc in RNVMs. In addition to GATA4, 
p38 is known to activate MEF2. Therefore it will be important to determine whether the 
AKAP-Lbc/p38 complex also activates MEF2 transcription factor. 
 
In cardiomyocytes Hsp27 plays an important role to stabilize the actin cytoskeleton and the 
sarcomere in response to stresses. 
While it is clear that Hsp27 phosphorylation, through the p38-MK2 pathway, induces its 
translocation to the actin cytoskeleton and to the sarcomere [162], it is currently unknown 
whether hypertrophic agonists can promote Hsp27 phosphorylation and translocation, and 
whether this contributes to their re-organization. Our current results indicate that !1AR 
stimulation promotes Hsp27 phosphorylation and that the AKAP-Lbc/p38 complex 
mediates this effect. Interestingly, we could observe the translocation of Hsp27 to the 
sarcomere and to actin filaments already 1h after PE stimulation. However, we currently do 
not know whether this effect is required to stabilize actin and sarcomeric structures. 
Therefore, future experiments will determine whether Hsp27 silencing in cardiomyocytes 
can affect actin and sarcomere reorganization induced by !1AR stimulation or by AKAP-
 110 
Lbc overexpression. By rescuing Hsp27 expression using either the wild type Hsp27 or its 
phosphorylation-deficient mutant, we will determine whether the effect of !1-AR and 
AKAP-Lbc require p38-dependent Hsp27 phosphorylation for sarcomere organization. 
 
In conclusion, the implications of our findings are twofold. Firstly, they have identified the 
novel hypertrophic signaling complex organized by AKAP-Lbc, (includes RhoA, PKN!, 
MLTK", MKK3" and p38!). This complex mediates activation of p38! downstream of 
!1AR. Once activated this pathway is able to promote the activation of the hypertrophic 
transcription factor GATA4. Secondly, they identify a non-genomic pathway activated by 
this macromolecular signaling complex that leads to the activation of the small chaperone 
protein Hsp27. 
Activation of Hsp27 could play a role in stabilizing actin cytoskeleton and sarcomeres, thus 
favoring their reorganization in response to hypertrophic agonists. 
Overall, this study contributes to our understandings of the role of AKAP-Lbc/p38 complex 
in cardiomyocyte hypertrophy and in general to the elucidation of the molecular 
mechanisms controlling cardiac remodeling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Model for the AKAP-
Lbc-p38! activation complex in 
cardiomyocyte: AKAP-Lbc 
assembles a signaling complex which 
includes the scaffolding protein PKN! 
as well as MLTK", MKK3" and p38!. 
The AKAP-Lbc signaling complex is 
activated in response to !1-AR 
stimulation. Activated AKAP-Lbc 
promotes the formation of RhoA-GTP, 
which, in turn, induces the activation 
of a signaling cascade that includes 
PKN!, MLTK", MKK3" and p38!. 
Once p38 is activated it can regulate 
the activation of the hypertrophic 
transcription factor GATA4 and the 
activation of Hsp27, which is known 
to protect the cytoskeleton actin and 
the sarcomere through direct 
interactions. 
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VIII. GENERAL CONCLUSIONS 
 
In response to numerous pathologic stimuli, the myocardium undergoes a hypertrophic 
response characterized by increased myocardial cell size and activation of fetal cardiac 
genes. 
In this context, our earlier work has identified AKAP-Lbc as an anchoring protein 
expressed in cardiomyocytes that is a key mediator of the hypertrophic responses induced 
by multiple stimuli that activate G protein-coupled receptors (GPCRs) including 
catecholamine, angiotensin II (Ang-II) and endothelin 1 (ET-1). However, the pathways 
whereby AKAP-Lbc promotes hypertrophy were largely unknown. 
During my thesis I have investigated the signaling pathways through which the AKAP-
Lbc/RhoA complex modulates cardiomyocyte hypertrophy. In particular, in the first part of 
my work I have identified and characterized a novel signaling complex organized by 
AKAP-Lbc that promotes p38! activation downstream of !1ARs, while in the second part 
of my project I have investigated the impact of this complex in cardiomyocyte hypertrophy. 
In this context I have identified GATA4 and Hsp27 as potential mediators of the 
hypertrophic effects of the AKAP-Lbc/p38 complex. 
In perspective it will be crucial to characterize the role of the AKAP-Lbc/p38 complex in 
cardiac remodeling in vivo, as mentioned before, by generating transgenic mice 
overexpressing the 1585-1715 fragment of AKAP-Lbc in the heart. This will allow us to 
determine whether disruption of the complex in cardiomyocytes affect the hypertrophic 
responses induced by various stresses. 
Alternatively, it will be important to define the role of AKAP-Lbc/p38 complex in cardiac 
fibroblasts. In this context, our group has recently shown that AKAP-Lbc is expressed also 
in cardiac fibroblasts, the most numerous cell type in the heart. In response to hypertrophic 
stresses cardiac fibroblasts differentiate in cardiac myofibroblasts, which display high 
proliferation capacity, secrete high amounts of extracellular matrix and promote cardiac 
fibrosis.  
 
Overall, this study contributes to our understandings of the role of AKAP-Lbc/p38 complex 
in cardiomyocyte hypertrophy and in general to the elucidation of the molecular 
mechanisms controlling cardiac remodeling. 
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RÉSUMÉ POUR TOUT PUBLIC 
  
L’hypertrophie cardiaque représente un mécanisme d’adaptation du myocarde en réponse à 
différents stress. Sur le long terme, l'hypertrophie cardiaque peut évoluer vers l'insuffisance 
cardiaque, l'une des principales causes de morbidité et de mortalité dans les pays 
industrialisés, pour cette raison, la communauté scientifique est très intéressée à élucider les 
voies de signalisation qui régulent ce phénomène pathologique dans le cœur.  
La protéine kinase A (PKA) est une protéine abondante dans les cellules qui est essentielle 
pour de nombreux phénomènes cellulaires. Les protéines d’ancrage de la protéine kinase A 
(AKAPs) constituent une grande famille de protéines qui dirigent la PKA à proximité de ses 
protéines cibles pour assurer leur régulation. Une nouvelle protéine de cette famille, appelée 
AKAP-Lbc, a été récemment découverte et fonctionne comme un activateur de RhoA, une 
protéine impliquée entre autres dans la croissance et la différenciation des cellules 
cardiaques (cardiomyocytes). Le but général de ce travail de thèse est de comprendre la voie 
de signalisation activée par le complexe AKAP-Lbc/RhoA au niveau moléculaire et 
déterminer la fonction dans les cardiomyocytes. 
Mes travaux montrent que AKAP-Lbc organise et active un complexe macromoléculaire, 
comprenant les protéines kinases PKN, MLTK, MKK3 et p38 en réponse à l'activation des 
récepteurs !1-adrénergiques. Dans les cardiomyocytes, cette voie de signalisation régule le 
processus de l'hypertrophie par l'activation du facteur de transcription hypertrophique 
GATA4, et par l'activation de la protéine Hsp27. 
Hsp27 joue un rôle crucial dans la protection du cytosquelette des cardiomyocytes. Ce 
mécanisme est particulièrement important pour la survie des cellules cardiaques au cours du 
stress hypertrophique. 
Pris ensembles, ces études contribuent à comprendre comment le complexe de signalisation 
formé par AKAP-Lbc régule l’hypertrophie dans les cardiomyocytes. Au-delà de leur 
intérêt au niveau biochimique, ces travaux pourraient aussi contribuer à la compréhension du 
phénomène de l’hypertrophie  dans le cœur. 
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A-Kinase Anchoring Protein (AKAP)-Lbc Anchors a PKN-based
Signaling Complex Involved in 1-Adrenergic Receptor-
induced p38 Activation*□S
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The mitogen-activated protein kinases (MAPKs) pathways
are highly organized signaling systems that transduce extracel-
lular signals into a variety of intracellular responses. In this
context, it is currently poorly understoodhowkinases constitut-
ing these signaling cascades are assembled and activated in
response to receptor stimulation to generate specific cellular
responses. Here, we show that AKAP-Lbc, an A-kinase anchor-
ing protein (AKAP) with an intrinsic Rho-specific guanine
nucleotide exchange factor activity, is critically involved in the
activation of the p38 MAPK downstream of 1b-adrenergic
receptors (1b-ARs). Our results indicate that AKAP-Lbc can
assemble a novel transduction complex containing the RhoA
effector PKN, MLTK, MKK3, and p38, which integrates sig-
nals from 1b-ARs to promote RhoA-dependent activation of
p38. In particular, silencing of AKAP-Lbc expression or dis-
rupting the formationof theAKAP-Lbcp38 signaling complex
specifically reduces 1-AR-mediated p38 activation without
affecting receptor-mediated activation of other MAPK path-
ways. These findings provide a novel mechanistic hypothesis
explaining how assembly of macromolecular complexes can
specify MAPK signaling downstream of 1-ARs.
1-Adrenergic receptors (1-AR)2 are seven-transmem-
brane domain receptors coupled to heterotrimeric G proteins
of the Gq and G12/G13 family (1, 2). Evidence accumulated over
the last years indicate that these receptors, besides their well
known implication in controlling vascular contractility, glucose
metabolism, genitourinary functions, and behavioral responses
(3), are also crucially involved in the regulation of various path-
ological cardiovascular remodeling processes including vascu-
lar smooth muscle cell hypertrophy, proliferation, and migra-
tion in response to injury (4, 5) as well as cardiac hypertrophy
(6–8). It is now evident that mitogen-activated protein kinases
(MAPKs) signaling pathways play a central role in mediating
many of these pathological responses (1, 9–11).
MAPKs are proline-directed serine/threonine kinases that
induce themajority of their physiological effects through phos-
phorylation and activation of transcription factors and the reg-
ulation of the expression of specific sets of genes (12).Mamma-
lian MAPKs can be subdivided into five families including
ERK1/2, JNK, p38, ERK3/4, and ERK5, which display different
biological functions (12). MAPK signaling cascades are orga-
nized into functional signaling modules of three kinases in
which a MAP kinase kinase kinase (MAPKKK) phosphorylates
and activates a MAP kinase kinase (MAPKK) that, in turn,
phosphorylates and activates a MAPK (13). The modular orga-
nization of the pathway is controlled by scaffolding proteins
that can bind each of the kinases (13). Although the implication
of MAPK pathways in the pathophysiological responses
induced by 1-ARs has been extensively studied it is currently
unknown how MAPK signaling modules are assembled and
activated in response to 1-AR stimulation to generate specific
cellular responses.
Several evidences indicates that small molecular weight
GTPase RhoA plays a central role in mediating the activation
of MAPK pathways downstream of 1-ARs (1, 10, 14). Rho-
GTPases are molecular switches that cycle between an active
GTP-bound state, which is able to bind effector proteins, and an
inactive GDP-bound state. In vivo, the cycling between the
GDP- and GTP-bound forms is regulated by guanine nucleo-
tide exchange factors (GEFs) that stimulate the exchange of
GDPwithGTP. All guanine nucleotide exchange factors exhib-
iting exchange activity towardRhoGTPases share aDbl homol-
ogy domain and an adjacent pleckstrin homology domain (15,
16). The Dbl homology domain is responsible for the guanine
nucleotide exchange activity, whereas the pleckstrin homology
domain determines the subcellular localization of the exchange
factor or contributes to the binding pocket for Rho-GTPases
(16).
We identified an exchange factor, termed AKAP-Lbc, which
functions as GEF for RhoA as well as an A-kinase anchoring
protein (AKAP) (17, 18). Interestingly, AKAP-Lbc is a key
mediator of 1-AR-induced activation of RhoA (2). 1-ARs
enhanceAKAP-LbcRho-GEF activity through a signaling path-
way that requires the  subunit of the heterotrimeric G protein
G12 (17). On the other hand, AKAP-Lbc inactivation occurs
through a mechanism that requires recruitment of the regula-
tory protein 14-3-3 (19).
Our present results indicate that AKAP-Lbc organizes a p38
MAPK complex composed of RhoA effectors PKN, MLTK,
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MKK3, and p38 that specifically promotes RhoA-dependent
activation of p38 in response to 1-AR stimulation. They also
provide evidence that the ability of AKAP-Lbc to assemble and
activate this p38 activation complex is inhibited following the
recruitment of the regulatory protein 14-3-3. Overall, these
findings provide a novel mechanistic hypothesis explaining
how MAPK signaling pathways can be selectively activated by
1-ARs.
EXPERIMENTAL PROCEDURES
Expression Constructs—AKAP-Lbc fragments encoding
amino acids 1585–1922, 1625–1922, 1655–1922, 1715–1922,
1765–1922, 1388–1585, 1388–1655, 1388–1715, and 1388–
1765 were PCR-amplified from the AKAP-Lbc pEGFPN1 vec-
tor (17) and subcloned at EcoRI/SalI into the pFLAG-CMV6
vector to generate protein fragments fused with the FLAG
epitope. A region encoding residues 1388–1922 of AKAP-Lbc
was PCR amplified from the AKAP-Lbc pEGFPN1 vector and
subcloned at SalI/NotI into pET30a vector to generate protein
fragments fused with the histidine tag. The AKAP-Lbc frag-
ment encoding residues 1585–1715 and corresponding to the
PKN binding domain of AKAP-Lbc was PCR amplified from
the AKAP-Lbc pEGFPN1 vector and subcloned at EcoRI/SalI
into pFLAG-CMV6 and pEGFPN vectors to generate protein
fragments fused with the FLAG epitope and GFP, respectively.
The FLAG-tagged AKAP-Lbc mutant missing the PKN bind-
ing domain was generated by deleting the region encoding
amino acids 1585–1715 by standard PCR-directedmutagenesis
using the FLAG-AKAP-Lbc vector (19) as a template.
Double-stranded hairpin (sh) oligonucleotides based upon
the human AKAP-Lbc mRNA sequence (GI: 15986728, bases
6688–6706 and 228–246) were cloned into the HindIII and
BglII sites in the pSUPER vector. The oligonucleotide
sequences used were: human AKAP-Lbc shRNA1 (sense
strand), 5-GTGCGTCTCAATGAGATTT-3, and human
AKAP-Lbc shRNA2 (sense strand), 5-GGTCAGTTCTGAT-
ACATTG-3.
To generate lentiviral transfer vectors encoding AKAP-Lbc
shRNAs, cDNA fragments containing the H1 RNA polymerase
III promoter as well as sequences encoding shRNAs were
excised using BamHI/SalI from the pSUPER vector and sub-
cloned into the pAB286.1 transfer vector. Mission lentiviral
transfer vectors encoding PKN shRNAs or a control non-tar-
get shRNA were purchased from Sigma. These vectors contain
a puromycin cassette that allows the selection of infected cells.
The lentiviral packaging vectors pCMVDR8.91 and pMD2.
VSVG encode the viral capsid and the vesicular stomatitis
virus-G envelope protein, respectively (20).
The full-length cDNA encoding human p38 was PCR
amplified from a human heart cDNA library and subcloned
at NotI-BamHI into pFLAG-CMV6, BamHI-XhoI into
HA-pRK5, or BamHI-Not1 into pGEX4T1 to generate proteins
fused to the FLAG and HA epitopes or GST, respectively. Sim-
ilarly, the full-length cDNA encoding humanMLTKwas PCR
amplified from a human heart cDNA library and subcloned at
NotI-BamHI into pFLAG-CMV6, BamHI-SalI into HA-pRK5,
or BamHI-XhoI into pGEX4T1. Fragments 1–305 and 305–942
of PKN were amplified from Myc-PKN (generous gift from
Dr. S. Gutkind,NIH, Bethesda,MD) and subcloned atNotI-SalI
and NotI/XhoI into pET30a, respectively, to generate fusion
proteins with the histidine tag. HA-tagged JNK1, MKK3,
MKK6, MEK1, andMEKK1 as well as FLAG-tagged JNK1 con-
structs were generous gifts fromDr. C.Widmann (Department
ofMorphology andCell Biology, University of Lausanne). GFP-
ERK1 was obtained from Addgene. Plasmids encoding
HA-MLK3 and HA-TAK1 were generous gifts from Dr. L. B.
Holzman (University of Michigan Medical School) and Dr. J.
Ninomiya-Tsuji (North Carolina State University), respec-
tively. Vectors encoding FLAG-AKAP-Lbc S1565A,AKAP-Lbc
S1565A-GFP, and FLAG-tagged AKAP-Lbc fragments encod-
ing residues 1–503, 504–1000, 1001–1387, 1388–1922, 1923–
2336, and 2337–2817, as well as 14-3-3-GFP, were described
previously (19).
Expression and Purification of Recombinant Proteins in
Bacteria—GST fusion proteins of AKAP-Lbc, p38, MKK3,
and MLTK were expressed using the bacterial expression vec-
tor pGEX-4T1 in the BL21(DE3) strain of Escherichia coli and
purified. Exponentially growing bacterial cultures were incu-
bated 16 h at 16 °C with 1 mM isopropyl 1-thio--D-galactopy-
ranoside, and subsequently subjected to centrifugation. Pel-
leted bacteria were lysed in buffer D (20 mM Tris, pH 7.4, 150
mM NaCl, 5 mM MgCl2, 1% (w/v) Triton X-100, 1 g/ml of
aprotinin, 2 g/ml of leupeptin, 2 g/ml of pepstatin, and 0.1
mM PMSF), sonicated, and centrifuged at 38,000 g for 30min
at 4 °C. After incubating the supernatants with glutathione-
Sepharose beads (GE Healthcare) for 2 h at 4 °C, the resin was
washed five times with 10 bed volumes of buffer D and stored at
4 °C.
His6-tagged fusion proteins of PKN and AKAP-Lbc were
expressed using the bacterial expression vector pET30 in
BL21(DE3) bacteria and purified. Bacterial extracts containing
His6-tagged fusion proteins were prepared in buffer E (20 mM
Hepes, pH 7.8, 500mMNaCl, 10mM imidazole, 1 mM benzami-
dine, 2g/ml of leupeptin, 2g/ml of pepstatin). After a 1-min
sonication, the lysateswere centrifuged at 38,000 g for 30min
at 4 °C. The His6-tagged fusion proteins were purified by incu-
bating the supernatant with nickel-nitrilotriacetic acid chelat-
ing resin (Amersham Biosciences) for 1 h at 4 °C. The resin was
thenwashed 5 times with 10 bed volumes of buffer E and stored
at 4 °C. His6-tagged fusion proteins were eluted from the resin
with 20 mM Hepes, pH 7.8, 500 mM NaCl, 300 mM imidazole, 1
mMbenzamidine, 2g/ml of leupeptin, 2g/ml of pepstatin for
1 h at room temperature, dialyzed, and stored at 20 °C. The
protein content of the eluates was assessed by Coomassie stain-
ing of SDS-PAGE gels.
Production of Lentiviruses—Vesicular stomatitis virus-G
(VSVG) pseudotyped lentiviruses were produced by cotrans-
fecting 293-T cells with 20 g of pAB286.1 vector (21),
pAB286.1-AKAP-Lbc shRNA vectors (2),MissionNon-target
shRNA control vector (Sigma) or Mission PKN shRNA vec-
tors (Sigma), 15 g of pCMVDR8.91, and 5 g of pMD2.VSVG
(20) using the calciumphosphatemethod. Culturemediumwas
replaced by serum-free DMEM at 12 h after transfection. Cell
supernatants were collected 48 h later, filtered through a
0.45-mm filter unit, and concentrated using Centricon-Plus-70
MW 100,000 columns (Millipore). Virus titers were deter-
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mined by infecting 293-T cells using serial dilutions of the viral
stocks and by scoring the number of puromycin-resistant
clones (at 6 days after infection). Titers determined using these
methods were between 5  108 and 1.0  109 transducing
units/ml for viruses generated from pAB286.1 vectors and
between 4  108 and 8  108 transducing units/ml for viruses
generated fromMission vectors.
Lentiviral Infection—HEK-293 cells were infected at 60%
confluence using pAB286.1-based lentiviruses encoding wild
type or mutated AKAP-Lbc shRNAs at a multiplicity of infec-
tion of 20 in the presence of 8 g/ml of Polybrene. Two days
after infection puromycinwas added to the culturemedium at a
final concentration of 2 g/ml. After 4 days of selection, puro-
mycin-resistant cells were collected and amplified in selective
medium containing puromycin at a final concentration of 2
g/ml.
Cell Culture and Transfections—HEK-293 were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum and gentamycin (100 g/ml) and
transfected at 50–60% confluence in 100-mm dishes using the
calcium-phosphate method. For the overexpression of con-
structs containing the full-length AKAP-Lbc, HEK-293 cells
were transfected at 80% confluence in 100- or 35-mm dishes
using Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions. After transfection, cells were grown for
48 h in DMEM supplemented with 10% fetal calf serum before
harvesting. The total amount of transfected DNA was 10–24
g/100-mm dish and 1–4 g/35-mm dish.
In Vitro GST Pulldown Experiments—For in vitro GST pull-
downs, 100 nM bacterially purified His6-tagged fragments
encompassing PKN residues 1–305 and 305–942 as well as
AKAP-Lbc residues 1388–1922 were incubated with glutathi-
one-Sepharose beads (Amersham Biosciences) coupled to
GST, or to GST fusion proteins of p38, MKK3, MLTK, or the
AKAP-Lbc fragment encompassing residues 1388–1922 in 0.5
ml of buffer A (20 mM Tris, pH 7.4, 150 mM NaCl, 1% (w/v)
Triton X-100, 5 g/ml of aprotinin, 10 g/ml of leupeptin, and
1 mM PMSF) for 4 h at 4 °C. The beads were then washed five
times with buffer A containing 300 mM NaCl, resuspended in
SDS-PAGE sample buffer (65mMTris, 2% SDS, 5% glycerol, 5%
-mercaptoethanol, pH 6.8) and boiled for 3 min at 95 °C.
Eluted proteins were analyzed by SDS-PAGE and Western
blotting.
Immunoprecipitation Experiments—For immunoprecipita-
tion experiments, HEK-293 cells grown in 100-mm dishes and
expressing various constructs were lysed in 1 ml of buffer A.
Cell lysates were incubated 1 h at 4 °C on a rotating wheel. The
solubilized material was centrifuged at 100,000 g for 30 min
at 4 °C and the supernatants were incubated 4 h at 4 °C with 20
l of anti-FLAG M2 affinity resin (Sigma) to immunoprecipi-
tate overexpressed FLAG-tagged proteins. Following a brief
centrifugation on a bench-top centrifuge, the pelleted beads
were washed five times with buffer C, twice with PBS, and pro-
teins were eluted in SDS-PAGE sample buffer by boiling sam-
ples for 3 min at 95 °C. Eluted proteins were analyzed by SDS-
PAGE and Western blotting. For immunoprecipitation of
endogenous AKAP-Lbc complexes, HEK-293 cells were lysed
in 1 ml of buffer B (20 mM Hepes, pH 7.4, 150 mM NaCl, 1%
Triton X-100, and 1 mM PMSF). Soluble proteins were isolated
by centrifugation as indicated above and incubated with or
without 0.25 mM dithiobis(succinimidyl propionate) for 1 h at
4 °C. Cross-linking reactions were blocked by adding Tris, pH
7.4, to the lysate to a final concentration of 50 mM. Immuno-
precipitations were performed as indicated previously (19) by
incubating 3 mg of lysate with 4 g of affinity-purified rabbit
polyclonal anti-AKAP-Lbc antibodies (Covance).
p38, JNK, and MLTK Activity Assays—Transfected HEK-
293 cells grown in 100-mmdishes were lysed in 1ml of buffer C
(20 mM Tris, pH 7.4, 150 mM NaCl, 1% (w/v) Triton X-100, 10
mM NaF, 10 mM sodium pyrophosphate, 1 mM sodium
orthovanadate, 1mMglycerophophate, 5g/ml of aprotinin, 10
g/ml of leupeptin, and 1 mM PMSF). Cell lysates were incu-
bated 10 min at 4 °C on a rotating wheel. The solubilized mate-
rial was centrifuged at 100,000 g for 30 min at 4 °C. 200 l of
supernatant was incubated either with 2 l of mouse monoclo-
nal anti-p38 antibodies (Cell Signaling Technology) and 20l
of protein A-Sepharose beads (Amersham Biosciences) for 2 h
at 4 °C to immunoprecipitate endogenous p38 or with 20l of
anti-FLAGM2 affinity resin (Sigma) for 1 h at 4 °C to immuno-
precipitate overexpressed FLAG-tagged JNK1 or MLTK. Fol-
lowing centrifugation on a bench-top centrifuge, the pelleted
beads were washed three times with buffer C and twice with a
buffer containing 50 mM Tris, pH 7.4, and 5mMMgCl2. Immu-
noprecipitates containing p38 or JNK1 were incubated with 1
g of purifiedGST-ATF2 (Cell SignalingTechnology), whereas
those containing FLAG-tagged MLTK were incubated with 1
g of purifiedGST-MKK3. Reactionswere carried out in 50mM
Tris, pH 7.4, 5 mM MgCl2, and 1 mM ATP-Na2 for 30 min at
30 °C and ended by the addition of SDS-PAGE sample buffer
and loaded on SDS-PAGE gels.
SDS-PAGE and Western Blotting—Samples denatured in
SDS-PAGE sample buffer were separated on acrylamide gels
and electroblotted onto nitrocellulose membranes. The blots
were incubated with primary antibodies and horseradish-con-
jugated secondary antibodies (Amersham Biosciences) as pre-
viously indicated (17). The following affinity purified primary
antibodies were used for immunoblotting: affinity purified rab-
bit polyclonal anti-AKAP-Lbc (Covance, 0.1 mg/ml, 1:1000
dilution), mouse monoclonal anti-FLAG (Sigma, 4.9 mg/ml,
1:2000 dilution), mouse monoclonal anti-GFP (Roche Applied
Science, 400 g/ml, 1:500 dilution), rabbit polyclonal anti-GFP
(Roche Applied Science, 400 g/ml, 1:1000 dilution), rabbit
polyclonal anti-HA (Sigma, 1:1000 dilution), mouse monoclo-
nal anti-HA (Sigma, 1:5000 dilution), rabbit polyclonal anti-
phospho-p38 (threonine 180 and tyrosine 182) (Cell Signaling
Technologies, 1:1000 dilution), rabbit polyclonal and mouse
monoclonal anti-p38 (Cell Signaling Technologies, 1:1000
dilution), rabbit polyclonal anti-phospho-ATF2 (threonine 71)
(Cell Signaling Technologies, 1:1000 dilution), rabbit poly-
clonal anti-ATF2 (Cell Signaling Technologies, 1:1000 dilu-
tion), mouse monoclonal anti-phospho-MKK3 (serine 189 and
threonine 193) (Cell Signaling Technology, 1:500 dilution),
mouse monoclonal anti-MKK3 (Assay designs, 1:1000 dilu-
tion), mouse monoclonal anti-MLTK (Abnova, 1:500 dilution),
rabbit polyclonal anti-MLK3 (Cell Signaling Technology, 1:500
dilution), mouse monoclonal anti-PKN (BD Biosciences
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Pharmingen, 1:1000 dilution), rabbit polyclonal anti-ERK1/2
(Santa Cruz Biotechnology, 1:500 dilution), rabbit polyclonal
anti-phospho-ERK1/2 (threonine 202 and tyrosine 204) (Santa
CruzBiotechnology, 1:500 dilution), rabbit polyclonal anti-JNK
(Cell Signaling Technologies, 1:500 dilution), rabbit polyclonal
anti-phospho-JNK (threonine 183 and tyrosine 185) (Cell Sig-
naling Technologies, 1:500 dilution), mouse monoclonal anti-
actin (Sigma, 1:1000 dilution), mouse monoclonal anti-histi-
dine tag (Qiagen 100 g/ml, 1:1000 dilution).
Statistical Analysis—Statistical significance was analyzed
using a Kruskal-Wallis test followed by Mann-Whitney U tests
with the Bonferroni corrections.
RESULTS
AKAP-LbcMediates 1-AR-induced p38MAPK Activation—
Evidence collected over the last decade indicates that protein
kinases of the MAPK family including ERK, JNK, and p38 play
an important role in mediating many of the pathophysiological
responses induced by 1-ARs (1, 9–11). Although several stud-
ies indicate that GTPase RhoA plays a central role in mediating
activation of MAPK pathways downstream of 1-ARs (1, 10,
14), it is currently not clear how signals are specifically trans-
ferred from activated RhoA to the activation of selected
MAPKs.
To initially determine the implication of RhoA in pathways
linking1-ARs to the activation of ERK1/2, JNK, and p38,HEK-
293 cells expressing the HA-tagged 1-AR were treated for 2 h
in the absence or presence of 1 g/ml of a cell permeable form
of the C3 botulism toxin and subsequently incubated with or
without 104 M epinephrine for 10 min. Activation of ERK1/2
and JNK in cell lysates was assessed byWestern blot using anti-
bodies recognizing the phosphorylated forms of ERK1/2 and
JNK. On the other hand, p38 activity was determined using a
kinase assay that measured the ability of immunoprecipitated
endogenous p38 to induce the phosphorylation of purified
GST-ATF2. Interestingly, inhibition of RhoA impaired by 58
and 69% the ability of 1b-ARs to induce p38 activation under
basal conditions and following epinephrine stimulation,
respectively (Fig. 1, A, panel 1, lanes 7 and 8, and B), without
affecting1-AR-mediated phosphorylation of ERK1/2 and JNK
(supplemental Fig. S1,A andC, panel 1, lanes 7 and 8, andB and
D). This suggests that RhoA is involved in the pathway that
links 1b-ARs to the activation of p38.
Based on these results and our previous evidence that the
RhoA-specific guanine nucleotide exchange factor AKAP-Lbc
mediates RhoA activation downstream of 1b-ARs (2), we
raised the question of whether AKAP-Lbc might organize the
signaling cascade linking 1b-ARs to the activation of p38. To
address this hypothesis, we initially determined the impact of
silencing AKAP-Lbc expression in HEK-293 cells on the ability
of 1-ARs to induce the activation of p38.
AKAP-Lbc silencing was achieved by infecting cells using
lentiviruses encoding two distinct shRNAs directed against a
sequence within the Dbl homology domain (shRNA1) and
N-terminal regulatory region (shRNA2) of AKAP-Lbc, respec-
tively. Both shRNAs could inhibit AKAP-Lbc expression by
about 90% as compared with cells infected with control lentivi-
ruses (Fig. 1C, panel 5).
Infected cells were transfected with the cDNA encoding the
HA-tagged 1b-AR, serum starved for 24 h, and incubated in
the absence or presence of epinephrine for 10 min. p38 was
then immunoprecipitated and its activity assessed as indicated
above.
Silencing of AKAP-Lbc expression significantly reduced the
ability of 1b-ARs to induce p38 activation both under basal
conditions and following epinephrine stimulation. Basal p38
activation was inhibited between 67 (shRNA1) and 74%
(shRNA2), whereas inhibition of epinephrine-induced p38
activation was between 63 (shRNA1) and 72% (shRNA2) (Fig.
1C, panel 1, lanes 9–12, and D). Interestingly, re-expression of
a silencing resistant mutant of AKAP-Lbc (2) in silenced cells
rescued the ability of 1b-AR to promote the activation of p38
(supplemental Fig. S2, A, panel 1, lanes 5 and 6, and B).
These results suggest that the inhibition of p38 activation
was strictly dependent on reduced AKAP-Lbc expression and
not due to an off-target effect. Control experiments revealed
that the ability of 1b-ARs to promote phosphorylation of
endogenous ERK1/2 and JNK was not affected by AKAP-Lbc
silencing (supplemental Fig. 3,A, panels 1 and 3, lanes 7 and 8).
These results strongly suggest that AKAP-Lbc specifically con-
tributes to the activation of p38MAPK induced by 1b-ARs.
To directly determinewhetherAKAP-Lbc can enhance p38
activation through its ability to activate RhoA, we assessed
whether RhoA inhibition could affect the p38 activating
potential of the S1565A mutant of AKAP-Lbc, which displays
constitutive Rho-GEF activity (19). HEK-293 cells transfected
with the FLAG-tagged AKAP-Lbc S1565A mutant were serum
starved for 24 h and incubated for 2 h in the absence or presence
of 1 g/ml of C3 botulinum toxin. As shown in Fig. 1E, overex-
pression of the FLAG-tagged AKAP-Lbc S1565A mutant
induced a 2.9-fold enhancement of p38 kinase activity, which
was reduced after RhoA inhibition (Fig. 1,E,panel 1, lanes 2 and
3, and F). Control experiments revealed that this constitutively
active AKAP-Lbc mutant was not able to promote phosphory-
lation of endogenous ERK1/2 and JNK (supplemental Fig. S3, B
and C, upper panel, lane 2). Altogether, these findings indicate
that the AKAP-LbcRhoA complex specifically mediates
1-AR-induced p38 activation.
AKAP-Lbc Interacts with p38—Our current findings reveal
that AKAP-Lbc and RhoA mediate the activation of p38 but
not that of ERK1/2 and JNK downstream of 1b-ARs. This sug-
gests the existence of molecular mechanisms that allow the
AKAP-Lbc signaling complex to select and activate the p38
effector pathway. One attractive hypothesis would be that
AKAP-Lbc and p38 might be maintained within the same
macromolecular unit. In this configuration, activating signals
could be integrated by AKAP-Lbc and rapidly transmitted to
p38.
To assess whether AKAP-Lbc could form a complex with
p38, we determined whether HA-tagged p38 could be co-im-
munoprecipitated with FLAG-tagged AKAP-Lbc from lysates
of transfected HEK-293 cells. As shown in Fig. 2A, anti-FLAG
antibodies could immunoprecipitate HA-p38 from cells
expressing the FLAG-tagged AKAP-Lbc, but not from cells
transfectedwith the empty pFLAGvector (Fig. 2A,upper panel,
lanes 1 and 2). Using a similar approach we could show that
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HA-JNK1 and GFP-ERK1 do not form stable complexes with
AKAP-Lbc vector (Fig. 2, B and C, upper panel, lanes 1 and 2).
These results suggest that AKAP-Lbc specifically binds and
activates p38. The p38 family of MAPK is constituted by four
members (p38, p38, p38, and p38) (22). Co-immunopre-
cipitation experiments performed using the different recombi-
nant p38 kinases indicate that FLAG-AKAP-Lbc interacts
mainly with p38, to a lesser extent with p38, but not with
p38 and p38 (results not shown).
AKAP-Lbc Assembles a p38 Activation Module—MAPKs
are activated by protein kinase cascades in which the MAPK is
phosphorylated and activated by a MAP kinase kinase
(MAPKK) that is, in turn, phosphorylated and activated by a
MAP kinase kinase kinase (MAPKKK). It is well established
that p38 can be activated by theMAPKKsMKK3,MKK4, and
MKK6 (23). In turn, these three p38-activating kinases can be
phosphorylated and activated by several MAPKKKs such as
TAK1, members of the mixed lineage kinase (MLK) family
includingMLK3,MLTK, and DLK, and several members of the
MEKK family of protein kinases (23, 24). Because these kinases
have been described to be organized into signaling complexes
to create functional MAPK modules, we have investigated the
possibility that kinases known to act upstream of p38 would
also associate with AKAP-Lbc.
To address this point, we performed coimmunoprecipitation
experiments from HEK-293 cells that were transiently trans-
fected with the cDNA encoding the HA-tagged forms of the
MAPKKsMKK3, MKK4, andMKK6 (Fig. 2D), as well as of the
MAPKKKsMLK3, MEK1, TAK1 (Fig. 2E), andMLTK (Fig. 2F)
in combination with the empty FLAG vector (pFLAG) or the
FLAG-tagged AKAP-Lbc. After immunoprecipitating the
anchoring protein using anti-FLAG antibodies, anti-HA anti-
bodies were used to immunoblot the immunoprecipitated sam-
ples. Western blots revealed that MKK3 (Fig. 2D, upper panel,
lane 5) as well as kinases belonging to MLK family including
MLK3 and MLTK (Fig. 2, E, upper panel, lane 4, and F, upper
panel, lane 2) could specifically co-immunoprecipitate with
AKAP-Lbc, whereas theMAPKKsMKK4 andMKK6 as well as
FIGURE 1. AKAP-Lbcmediates 1-AR-induced p38 activation. A, HEK-293 cells were transfected with the empty pRK5 plasmid or the cDNA encoding the
HA-tagged 1b-AR. After a 24-h serum starvation, cells were incubated for 2 h with or without 1 g/ml of purified C3 toxin and incubated for 15 min with or
without (Ctrl) 104 M epinephrine (EPI). Cell lysates where subjected to immunoprecipitation using anti-p38monoclonal antibodies. Kinase reactions were
performed by incubating p38 immunoprecipitates with 1 g of purified GST-ATF2 and in the presence of ATP. Phospho-GST-ATF2 was detected by immu-
noblot using rabbit polyclonal antibodies recognizing phosphothreonine 71 of ATF2 (panel 1). The amounts of GST-ATF2, p38, and HA-1b-ARs were
assessed using polyclonal antibodies against ATF2 (panel 2), p38 (panel 3), and the HA epitope (panel 4), respectively. B, quantitative analysis of phosphory-
lated ATF2 was obtained by densitometry. The amount of phospho-ATF2 was normalized to the total amount of ATF2 and p38. Results are expressed as
mean S.E. of 3 different experiments. §, p 0.05 as compared with phospho-ATF2 levels measured in untreated control cells expressing HA-1b-ARs. *, p
0.05 as compared with phospho-ATF2 levels measured in epinephrine-treated control cells expressing HA-1b-ARs. C, HEK-293 cells infected with control
lentiviruses or lentiviruses encoding AKAP-Lbc shRNAs were transfected with the empty pRK5 plasmid or the cDNA encoding the HA-tagged 1b-AR. After a
24-h serum starvation, cells were incubated for 15 min with or without (Ctrl) 104 M epinephrine, lysed, and subjected to immunoprecipitation using mono-
clonal anti-p38antibodies. Kinase reactionsanddetectionofphospho-ATF2 (panel 1), ATF2 (panel 2), p38 (panel 3), andHA-1b-ARs (panel 4)wereperformed
as indicated in A. Expression of endogenous AKAP-Lbc and actin was detected using affinity purified anti-AKAP-Lbc polyclonal antibodies (panel 5) and
anti-actinmonoclonal antibodies (panel 6).D, quantitative analysis of phospho-ATF2was obtained by densitometry as indicated in B. §, p 0.05 as compared
with phospho-ATF2 levels measured in untreated control cells expressing HA-1b-ARs. *, p  0.05 as compared with phospho-ATF2 levels measured in
epinephrine-treated control cells expressing HA-1b-ARs. E, HEK-293 cells were transfected with cDNA encoding the FLAG-tagged S1565A mutant of AKAP-
Lbc. After a 24-h serum starvation, cells were incubated for 2 h with or without 1 g/ml of purified C3 toxin. Kinase activity of immunoprecipitated p38 and
detection of phospho-ATF2 (panel 1), ATF2 (panel 2), and p38 (panel 3) in cell lysates was determined as indicated in A. Expression of the FLAG-tagged
AKAP-Lbc S1565A mutant was assessed using monoclonal antibodies against the FLAG tag (panel 4). F, quantitative analysis of phosphorylated ATF2 was
obtainedbydensitometry as indicated inB. *,p0.05 as comparedwithphospho-ATF2 levelsmeasured inuntreated cells expressingFLAG-AKAP-Lbc S1565A.
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the MAPKKKs MEKK1 and TAK1 did not (Fig. 2, D, upper
panel, lanes 4 and 6, and E, upper panel, lanes 5 and 6). These
results suggest that AKAP-Lbc can interact with a signaling
module composed of p38, its upstream kinase MKK3, and
MAPKKKs of the MLK family such as MLK3 or MLTK.
However, MLKs have never been reported as direct effectors
of RhoA. Accordingly, control experiments performed in our
laboratory using purified kinases failed to detect MLK activa-
tion by RhoA (results not shown). This raises the question of
how the AKAP-LbcRhoA complex can transmit signals to the
MLK-MKK3-p38 module. In this context, previous evidence
indicates that protein kinase N (PKN), a well characterized
effector of RhoA, can act as an upstream activating kinase of
MLTK (25). Based on these findings, we raised the hypothesis of
whether PKN could also bind to AKAP-Lbc. Interestingly,
Western blots performed on FLAG-AKAP-Lbc immunopre-
cipitates indicate that endogenous PKN can co-immunopre-
cipitate with the anchoring protein (Fig. 2G, upper panel,
lane 2).
In a similar set of experiments, we could show that p38,
MKK3, MLTK, and PKN endogenously expressed in HEK293
cells could forma complexwith endogenousAKAP-Lbc. This is
shown by the fact that p38, MKK3, MLTK, and PKN could
be detected in AKAP-Lbc immunoprecipitates (Fig. 3,A, upper
andmiddle panels, lane 3, and B, upper andmiddle panels, lane
3). On the other hand, no interaction between endogenous
FIGURE 2. AKAP-Lbc assembles a p38 activation complex. A–C, extracts from HEK-293 cells transfected with the plasmids encoding HA-tagged p38 (A),
HA-tagged JNK1 (B), or GFP-tagged ERK1 (C) in combination with the empty FLAG vector (lane 1) or the vector encoding FLAG-tagged AKAP-Lbc (lane 2) were
subjected to immunoprecipitation with anti-FLAG antibodies. Western blots of the immunoprecipitates and the cell extracts were revealed using anti-HA
monoclonal antibodies to detect HA-p38 and HA-JNK1 (A and B, upper andmiddle panels), anti-GFP polyclonal antibodies to detect GFP-ERK1 (C, upper and
middle panels), or anti-FLAG monoclonal antibodies to detect FLAG-AKAP-Lbc (lower panels). D, HEK-293 cells were transfected with the plasmids encoding
HA-taggedMKK4,MKK3, orMKK6 in combinationwith the vector encoding FLAG-taggedAKAP-Lbc. Immunoprecipitations andWesternblotswereperformed
as indicated in A. E and F, HEK-293 cells were transfected with the plasmids encoding HA-taggedMLK3, MEKK1, TAK1 (E) or MLTK (F), in combination with the
empty FLAG vector or the plasmid encoding FLAG-tagged AKAP-Lbc. Immunoprecipitations and Western blots were performed as indicated in A. G, extracts
from HEK-293 cells transfected with the empty FLAG vector or the plasmid encoding FLAG-tagged AKAP-Lbc were subjected to immunoprecipitation with
anti-FLAG antibodies. Western blots of the immunoprecipitates and the cell extracts were revealed using anti-PKN monoclonal antibodies. Results are
representative of at least three independent experiments.
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AKAP-Lbc and MLK3 could be detected (Fig. 3C, upper panel,
lane 3). Therefore, whereas overexpressed AKAP-Lbc has the
potential of binding both MLK3 and MLTK (Fig. 2, E and F),
endogenous AKAP-Lbc seems to preferentially assemble a
complex that specifically contains MLTK. Collectively these
results suggest that AKAP-Lbc can assemble a large signaling
complex containing PKN, MLTK, MKK3, and p38 that can
link RhoA activation to the stimulation of the p38 transduction
pathway.
Mapping of the Kinase Binding Sites on AKAP-Lbc—To iden-
tify the binding site for p38 as well as its upstream activating
kinases on AKAP-Lbc, we initially generated a series of FLAG-
tagged AKAP-Lbc fragments encompassing residues 1–503,
504–1000, 1001–1387, 1388–1922, 1923–2336, and 2337–
2817 (supplemental Fig. S4A). The fragments were initially
expressed in HEK-293 cells in combination with HA-MKK3
and interactions assessed by co-immunoprecipitation. The
FLAG-tagged fragments were immunoprecipitated from cell
lysates using anti-FLAG antibodies and the presence of associ-
ated kinases detected using anti-HA antibodies. Our results
indicate that MKK3 interact exclusively with the fragment of
AKAP-Lbc included between residues 1388 and 1922 (supple-
mental Fig. S4, upper panel, lane 5).
We have subsequently further narrowed the binding site
using shorter FLAG-taggedAKAP-Lbc fragments derived from
the 1388–1922 region (Fig. 4A). As shown in Fig. 4B, our results
indicate thatHA-MKK3 interacts withAKAP-Lbc in aminimal
region encompassing residues 1585–1715 (Fig. 4B, upper
panel).
To validate these findings and assess whether the identified
domain was also required for binding the other kinases, we
determined the impact of deleting residues 1585–1715 from
the AKAP-Lbc on its ability to associate with HA-p38, HA-
MKK3, HA-MLTK, and endogenous PKN in co-immunopre-
cipitation experiments (Fig. 4, C–F). The deletion reduced
significantly the ability of all the tested kinases to co-
immunoprecipitate with the FLAG-tagged AKAP-Lbc (Fig. 4,
C–F, upper panel, second and third lanes). These findings sug-
gest that residues 1585–1715 form a binding site that recruits
p38 as well as its upstream activating kinases MKK3, MLTK,
and PKN.
PKN Directly Binds AKAP-Lbc, p38, MKK3, and MLTK—
Although our current results suggest that AKAP-Lbc interacts
with PKN, MLTK,MKK3, and p38, they do not indicate how
the complex is organized. Based on previous findings showing
that PKN can act both as an upstream activating kinase of
MLTK and as a scaffolding protein (25) we hypothesized that it
could recruit p38, MKK3, and MLTK to AKAP-Lbc. There-
fore, we determined whether PKN could directly associate
with AKAP-Lbc as well as with the other kinases.
To assess whether the interaction of p38, MKK3, and
MLTK with AKAP-Lbc occurs through a direct interaction or
whether it ismediated through PKN, wemonitored the ability
of purified GST fusion proteins of p38, MKK3, and MLTK,
and AKAP-Lbc fragment 1388–1922 to associate with purified
His6-tagged N-terminal or C-terminal fragments of PKN
(His-PKN-(1–305) and His-PKN-(305–942), respectively), or
with the His6-tagged 1388–1922 fragment of AKAP-Lbc using
an in vitro pulldown assay. Interestingly, our results indicate
that p38,MKK3, andMLTK, aswell asAKAP-Lbc can directly
bind the C-terminal but not the N-terminal fragment of PKN
(Fig. 5, A, upper panel, lanes 3, 5, 7, and 9, B, upper panel, lanes
2–6). A weak direct interaction could also be detected between
AKAP-Lbc and MKK3 (Fig. 5A, upper panel, lane 6), whereas
no binding was observed between AKAP-Lbc and p38 or
MLTK (Fig. 5A, upper panel, lanes 4 and 8). These results indi-
cate that AKAP-Lbc can directly bind PKN, which, in turn can
recruit p38, MKK3, and MLTK. The association between
AKAP-Lbc and MKK3 could stabilize the formation of the
complex.
PKN Is Required for Proper Assembly of the AKAP-Lbcp38
Signaling Complex—To assess whether PKN could contribute
to assembly of the AKAP-Lbcp38 complex inside cells, we
determined the impact of silencing PKN expression in HEK-
293 cells on the interaction ofAKAP-Lbcwith p38 andMKK3.
PKN silencing was achieved by infecting cells using lentivi-
ruses encoding shRNAs directed against PKN. Using this
approach, PKN expression could be inhibited by 80–90% as
FIGURE 3.AKAP-Lbc interacts with endogenous p38, MKK3, MLTK, and PKN.HEK-293 cell extracts were subjected to immunoprecipitation with either
non-immune IgGs or affinity purified anti-AKAP-Lbc polyclonal antibodies. Western blots of the immunoprecipitates and the cell extracts were revealed using
anti-p38 (A, upper panel), anti-MKK3 (A, middle panel), anti-PKN (B, upper panel), anti-MLTK (B, middle panel), anti-MLK3 (C, upper panel), or affinity purified
anti-AKAP-Lbc polyclonal antibodies (lower panels). Results are representative of at least three independent experiments.
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compared with cells infected with control lentiviruses (Fig. 6A,
panel 6).
AKAP-Lbc was immunoprecipitated from infected cells
using affinity purified anti-AKAP-Lbc antibodies and the pres-
ence of associated p38 and MKK3 revealed by Western blot.
As shown in Fig. 6A, silencing of PKN expression significantly
reduced the amount of p38 and MKK3 interacting with
endogenous AKAP-Lbc (Fig. 6A, panels 1 and 3, lane 4). This
suggests that PKN favors the association of p38 and MKK3
with AKAP-Lbc.
PKN Mediates AKAP-Lbc-induced Activation of MLTK—
Previous findings have shown that PKN can directly phos-
phorylate and activate MLTK (25). Based on this evidence, we
determined whether PKNwas required to transmit activating
signals from AKAP-Lbc to MLTK. To address this point, we
assessed whether silencing of PKN using shRNAs targeting
two distinct regions of the kinase (PKN shRNA1 and PKN
shRNA2) could affect the ability of the S1565A mutant of
AKAP-Lbc, which displays constitutively Rho-GEF activity, to
activate MLTK.
FIGURE 4.Mapping the kinase interaction sites on AKAP-Lbc. A, schematic representation of the AKAP-Lbc fragments used for the mapping exper-
iments. The minimal binding site (residues 1585–1715) is boxed. LC3 and 14-3-3 binding sites as well as the C1 region (C1) are shown. B, HEK-293 cells
were transfected with HA-tagged MKK3 in combination with either the empty FLAG vector or FLAG-tagged fragments of AKAP-Lbc indicated in A. Cell
lysates were subjected to immunoprecipitation with anti-FLAG antibodies. Western blots of the immunoprecipitates and cell extracts were revealed
using anti-HA polyclonal antibodies to detect the HA-tagged MKK3 (upper and middle panels), or anti-FLAG monoclonal antibodies to detect the
FLAG-tagged AKAP-Lbc fragments (lower panel). C–F, extracts from HEK-293 cells transfected with plasmids encoding the empty FLAG vector, FLAG-
AKAP-Lbc, or the FLAG-AKAP-Lbc 1585–1715mutant in combination with the vectors encoding HA-tagged p38 (C), MKK3 (D), MLTK (E), or the empty
pRK5 vector (F). Western blots of the immunoprecipitates (IP) and the cell extracts were revealed using anti-HA polyclonal antibodies to detect
HA-tagged p38, MKK3, and MLTK (C–E, upper and middle panels), anti-PKNmonoclonal antibodies to detect endogenous PKN (F, upper and middle
panels), or anti-FLAG monoclonal antibodies to detect FLAG-AKAP-Lbc (lower panels).
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Infected cells were transfected with the cDNAs encoding
FLAG-MLTK and the GFP-tagged AKAP-Lbc S1565Amutant.
After a 24-h serum starvation, FLAG-MLTK was then immu-
noprecipitated and its ability to phosphorylate purified GST-
MKK3 determined using an in vitro kinase assay. Interestingly,
silencing of PKN expression significantly reduced the ability
of AKAP-Lbc S1565A to promote MLTK activation (Fig. 6B,
panel 1, lanes 5 and 6) suggesting that PKN is required for
AKAP-Lbc-mediated MLTK activity.
Disruption of AKAP-Lbc Complex Impairs 1-AR-mediated
p38 Activation—Based on the mapping studies presented
above, we investigated the possibility of whether a fragment
of AKAP-Lbc encompassing residues 1585–1715 could be used
as a competitor to disrupt the endogenous complexes formed
by AKAP-Lbc and the various kinases. Such a competitor frag-
ment could represent a valuable tool to study the role of the
AKAP-Lbc signaling complex in the activation of p38 inside
cells.
A GFP fusion of the competitor fragment was expressed in
HEK-293 cells and its ability to inhibit the binding of
HA-MKK3, HA-MLTK, as well as PKN to the FLAG-tagged
fragment of AKAP-Lbc encompassing residues 1388–1922was
assessed by co-immunoprecipitation (supplemental Fig. S5).
Interestingly, overexpression of the fragment reduced the
interaction between AKAP-Lbc and the various kinases by
more than 80% suggesting that it can act as an efficient compet-
itive inhibitor (supplemental Fig. S5,A–C, upper panel, lane 3).
Based on these results we determined the impact of overex-
pressing the GFP-tagged competitor fragment on the ability of
1b-adrenergic receptors to induce p38 activation inHEK-293
cells.
Interestingly, expression of the competitor fragment reduced
by 62 and 58% the ability of 1b-ARs to promote p38 activa-
tion under basal conditions and in response to epinephrine
stimulation, respectively (Fig. 7, A, panel 1, lanes 7 and 8, and
B), without affecting receptor-induced phosphorylation of
ERK1/2 and JNK1 (supplemental Fig. S6,A andB, panel 1, lanes
3 and 4). These findings suggest that the integrity of the com-
plex formed by AKAP-Lbc and the various kinases is required
for the activation of p38 induced by 1b-ARs.
Binding of 14-3-33 to AKAP-Lbc Inhibits the Recruitment of
PKN and Reduces p38 Activation—We previously demon-
strated that recruitment of the regulatory protein 14-3-3 to a
motif located at position 1565within theN-terminal regulatory
region of AKAP-Lbc strongly inhibits the Rho-GEF activity of
the anchoring protein (19). Our current results indicate that
this site is located in close proximity of the binding domain for
the p38 activation complex. This raises the possibility that
14-3-3 recruitment could also interfere with the interaction of
AKAP-Lbc with the p38 signaling complex and therefore
inhibit AKAP-Lbc-mediated p38 activation.
To address this question, we initially determined whether
overexpression of 14-3-3 in HEK-293 cells could affect the
ability of AKAP-Lbc to associate with PKN. HEK-293 cells
were transfected with FLAG AKAP-Lbc together with
increasing amounts of GFP-tagged 14-3-3. After immunopre-
cipitating the anchoring protein using anti-FLAG antibodies,
anti-PKN antibodies were used to immunoblot the immuno-
precipitated samples. Western blots revealed that overexpres-
sion of increasing amounts of 14-3-3 progressively reduced
the ability of PKN to co-immunoprecipitate with AKAP-Lbc
(Fig. 8, A, panel 1, lanes 2–4, and B). In line with these results,
FIGURE 5. PKN directly interacts with MLTK, MKK3, p38, and AKAP-Lbc. A, bacterially purified His6-tagged fragments (100 nM) encompassing residues
305–942 of PKN and 1388–1922 of AKAP-Lbc were incubated with glutathione-Sepharose beads coupled to 2 g of GST alone, or GST-tagged p38, MKK3,
MLTK, and AKAP-Lbc-(1388–1922). Associated His6-tagged fragments were detected using anti-His6 monoclonal antibodies (upper panel). A control protein
staining indicating the expression level of the different GST-tagged constructs used in the pulldown assay is shown (lower panel). B, bacterially purified
His6-tagged fragments encompassing residues 1–305 of PKN (100 nM) were incubated with glutathione-Sepharose beads coupled to 2 g of GST alone, or
GST-tagged p38, MKK3, MLTK, and AKAP-Lbc 1388–1922. Associated His6-tagged fragments were detected as indicated in A.
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we could show that the S1565Amutant of AKAP-Lbc, which is
unable to bind 14-3-3, display a 2-fold higher ability to associate
with endogenous PKNwhen comparedwith wild type AKAP-
Lbc (Fig. 8,C, panel 1, lanes 2 and 3, andD). This indicates that
recruitment of 14-3-3 inhibits PKN binding to AKAP-Lbc.
To determine whether this reduction of PKN binding
induced by 14-3-3 could affect the ability of AKAP-Lbc to
induce p38 activation, we compared the p38 activating poten-
tial of the wild type and 14-3-3 binding deficient forms of
AKAP-Lbc. We could show that deletion of the 14-3-3 binding
site increases by 2.7-fold the activation of p38 induced by the
anchoring protein (Fig. 8, E, upper panel, lanes 2 and 3, and F).
Collectively, these results suggest that 14-3-3 exerts an inhibi-
tory effect on the ability ofAKAP-Lbc to recruit and activate the
p38 signaling complex.
DISCUSSION
MAPkinase pathways are crucialmediators of several patho-
physiological responses induced by 1-adrenergic receptors (1,
9–11). Although evidence collected over the last years indicates
FIGURE 6. Silencing of PKN inhibits AKAP-Lbc-mediated activation of
MLTK. A, extracts from HEK-293 cells infected with control lentiviruses (con-
trol) or lentiviruses encoding PKN shRNAs (PKN shRNA1) were subjected to
immunoprecipitation (IP) with either non-immune IgGs or affinity purified
anti-AKAP-Lbc polyclonal antibodies. Western blots of the immunoprecipi-
tates and the cell extracts were revealed using antibodies against p38 (pan-
els 1 and 2), MKK3 (panels 3 and 4), AKAP-Lbc (panel 5), PKN (panel 6), or actin
(panel 7). B, HEK-293 cells infected with control lentiviruses or lentiviruses
encoding PKN shRNAs (shRNA1 and shRNA2) were transfectedwith the plas-
mids encoding FLAG-MLTK in the presence of the vector encodingGFP or the
GFP-tagged AKAP-Lbc S1565A mutant. After a 24-h serum starvation, cells
were lysed and FLAG-MLTK was subjected to immunoprecipitation using
anti-FLAGmonoclonal antibodies. Kinase reactions were performed by incu-
bating FLAG-MLTK immunoprecipitates with 1 g of purified GST-MKK3 and
in thepresence of ATP. Phospho-GST-MKK3wasdetectedby immunoblot (IB)
using a rabbit polyclonal antibody recognizing phosphoserine 189 andphos-
phothreonine 193 of MKK3 (panel 1). The amounts of immunoprecipitated
FLAG-MLTK as well as the expression of AKAP-Lbc S1565A-GFP and PKN in
cell lysateswereassessedusingantibodies against theFLAG tag (panel 2), GFP
(panel 3), and PKN (panel 4), respectively. Results are representative of three
independent experiments.
FIGURE 7. Disruption of the AKAP-Lbc complex inhibits 1b-AR-induced
p38 activation. A, HEK-293 cells were transfected with vectors encoding
GFP or GFP-tagged AKAP-Lbc fragment 1585–1715 in the absence or pres-
ence of the plasmid encoding the HA-tagged 1-AR. After a 24-h serum star-
vation, cells were incubated for 15 min with or without 104 M epinephrine
(EPI), lysed, and subjected to immunoprecipitationusing anti-p38monoclo-
nal antibodies. Kinase reactions were performed by incubating p38 immu-
noprecipitates with 1 g of purified GST-ATF2 and in the presence of ATP.
Detection of phospho-ATF2 (panel 1), ATF2 (panel 2), p38 (panel 3), and HA-
tagged 1-AR (panel 5) were performed as indicated in Fig. 1A. Expression of
GFP as well as the GFP-tagged AKAP-Lbc fragment 1585–1715 (panel 4) was
detected using polyclonal anti-GFP antibodies. B, quantitative analysis of
phosphorylated ATF2 was obtained by densitometry. The amount of phos-
pho-ATF2was normalized to the total amount of ATF2. Results are expressed
as mean  S.E. of 3 different experiments.). §, p  0.05 as compared with
phospho-ATF2 levelsmeasured inuntreated cells expressingHA-1b-ARs and
GFP. *,p0.05as comparedwithphospho-ATF2 levelsmeasured inepineph-
rine-treated cells expressing HA-1b-ARs and GFP.
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that MAPK cascades are organized in transduction modules
(13), it is currently unknown how such signaling complexes are
assembled and activated in response to 1-adrenergic receptor
stimulation to generate specific cellular responses.Our findings
now indicate that the RhoA-selective exchange factor AKAP-
Lbc recruits a signaling module containing the RhoA effector
PKN and the MLTK, MKK3, and p38 kinases, which trans-
duce activating signals from 1b-ARs down to p38. In partic-
ular, whereas we have previously shown that 1b-ARs mediate
AKAP-Lbc activation through the  subunit of the heterotrim-
eric G protein G12 (2), our current model proposes that acti-
vated AKAP-Lbc promotes, through RhoA, the sequential acti-
vation PKN,MLTK,MKK3, and p38within the complex.On
the other hand, inactivation of AKAP-Lbc-mediated p38 sig-
naling occurs following the recruitment of 14-3-3 to AKAP-
Lbc. This promotes the dissociation of the p38 activation
module from AKAP-Lbc (Fig. 9) and deactivates AKAP-Lbc
Rho-GEF activity (19). Therefore, AKAP-Lbc represents a
molecular platform where signals that activate or deactivate
p38 signaling converge.
p38 kinases were originally described to mediate cellular
responses to various types of stresses (23, 26). During the last
decade, however, it has become increasingly clear that mem-
bers of this kinase family can participate in signaling pathways
activated by of a variety of other membrane receptors, includ-
ing cytokine and G protein-coupled receptors, to promote cel-
lular functions such as proliferation, growth, inflammation, and
contraction (23, 26). In particular, it was shown that activation
of p38 by 1-ARs can regulate arterial smooth muscle cell
contractility (27) and promote cardiomyocyte sarcomere
remodeling during cardiac hypertrophy (10).
Because of the implication of p38 kinases in such a variety of
crucial responses, the molecular mechanisms involved in their
activation has been the subject of intensive investigation. In this
context, it is well established that GTPases of the Rho family,
including RhoA, Rac1, and cdc42, are key mediators of p38
FIGURE 8. 14-3-3 inhibits the interaction between AKAP-Lbc and PKN. A, HEK-293 cells were transfected with the empty pFLAG vector or the vector
encoding FLAG-AKAP-Lbc in combination with increasing amounts (indicated above each lane) of the plasmid encoding 14-3-3-GFP. Cell extracts were
subjected to immunoprecipitation with anti-FLAG antibodies. Western blots of the immunoprecipitates and cell extracts were revealed using anti-PKN
polyclonal antibodies (panels 1 and 2), anti-14-3-3 polyclonal antibodies (panels 3 and 4), or anti-FLAGmonoclonal antibodies to detect the FLAG-AKAP-Lbc
(panel 5). B, densitometry of the bands corresponding to PKN coimmunoprecipitated with AKAP-Lbc. The amount of PKN in the immunoprecipitates was
normalized to the PKN content of the cell extracts. Results are expressed asmean S.E. of three independent experiments. *, p 0.05 as comparedwith the
levels of co-immunoprecipitated PKNmeasured in cells expressing only FLAG-AKAP-Lbc. C, extracts from HEK-293 cells transfected with plasmids encoding
the empty FLAG vector, FLAG-AKAP-Lbc, or FLAG-AKAP-Lbc S1565A. Cell extracts were subjected to immunoprecipitation (IP) with anti-FLAG antibodies.
Western blots of the immunoprecipitates and the cell extracts were revealed as indicated in A.D, densitometry of the bands corresponding to PKN coimmu-
noprecipitated with AKAP-Lbc was performed as indicated in B. Results are expressed as mean  S.E. of three independent experiments. *, p  0.05 as
compared with the levels of co-immunoprecipitated PKNmeasured in cells expressing FLAG-AKAP-Lbc. E, extracts from HEK-293 cells transfected with the
vectors encoding FLAG-AKAP-Lbc-GFPor FLAG-AKAP-Lbc S1565A. After a 24-h serum starvation, cellswere lysed and subjected to immunoprecipitation using
monoclonal anti-p38 antibodies. Kinase reactions and detection of phospho-ATF2 (panel 1), ATF2 (panel 2), and p38 (panel 3) were performed as indicated
in Fig. 1A. Expression of the AKAP-Lbc constructswas detected using anti-FLAGmonoclonal antibodies (panel 4). F, quantitative analysis of phospho-ATF2was
obtained as indicated in Fig. 1B. Results are expressed as mean  S.E. of three different experiments. *, p  0.05 as compared with phospho-ATF2 levels
measured in cells expressing FLAG-AKAP-Lbc.
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activation induced by membrane receptors (10, 14, 24, 28).
However, how activation of Rho GTPases by upstream stimuli
is translated into the activation of a specific p38 pathway is far
from being entirely elucidated.
Two studies provided initial evidence that the GTPase Rac-1
and its upstream activator Tiam can recruit signaling com-
plexes containing p38 and its upstream activating kinases. In a
first study, Rac-1 was shown to directly bind to Osm, a scaffold
protein that recruitsMEKK3 andMKK3 (29). This complex has
been implicated in hyperosmotic shock-induced p38 activa-
tion. In a second study, the Rac-1 activator Tiam was shown to
recruit a p38 signaling complex formed by the scaffold protein
JIP2 and the kinases MLK3 and MKK3 (30). This study, how-
ever, did not determine which extracellular stimuli activate this
signalingmodule orwhetherTiamand JIP2 can forma complex
at the endogenous level.
More recently, elegant studies showed that the pro-myo-
genic cell surface protein Cdo can recruit two proteins named
Bnip-2 and JLP, which act as scaffolds for the Cdc42 and p38,
respectively (31, 32). The assembly of this signaling complex
promotes Cdc42-dependent p38 activation.
In this context, our current findings that AKAP-Lbc can
mediate1-AR-induced p38 activation through the assembly of
a signaling module composed of PKN, MLTK, MKK3, and
p38, provide newmechanistic insights on how specific signals
can be vehiculated from membrane receptors to p38. They
also highlight the key function of PKN as a scaffold protein
that facilitates RhoA-dependent p38 activation. This view is
supported by our results showing that PKN can directly inter-
act with AKAP-Lbc, MLTK,MKK3, and p38 (Fig. 5), and that
silencing of endogenous PKN inHEK-293 cells can reduce the
interaction of endogenous p38 andMKK3 with AKAP-Lbc as
well as AKAP-Lbc-mediated MLTK activation (Fig. 6).
Interestingly, previous studies have shown that PKN can
also promote the activation of p38 (28) potentially through its
ability to bind and activate MLTK and MKK6 (25). This sug-
gests that PKN can recruit a different combination of signal-
ing enzymes to modulate the activation of different p38 iso-
forms. The molecular mechanisms regulating the interaction
between PKN and p38 activating kinases are currently
unknown and will deserve further investigation. Based on our
co-immunoprecipitation experiments, which failed to detect an
interaction between p38 and AKAP-Lbc (results not shown)
one could raise the hypothesis thatAKAP-Lbcmight selectively
stabilize the interaction between PKN and p38.
In addition to PKN, three other scaffold proteins including
JIP2, JIP4, andOsmhave been shown to promote p38 activation
(13, 29, 33). Interestingly, recent studies identified an interac-
tion between recombinant JIP4 and a splice variant of AKAP-
Lbc, called Brx, that contains only the last 1429 residues the
anchoring protein (34). However, whereas these studies
mapped the interaction determinants for JIP4 to the last 400
amino acids of Brx, they did not determine whether the two
proteins can interact at the endogenous level.
In control experiments, we could not detect the expression of
JIP4 inHEK-293 cell lysates (results not shown), suggesting that
JIP4 is unlikely to be involved in the recruitment of p38 and its
upstream kinases to AKAP-Lbc in this cell line. In line with this
conclusion, our results indicate that deletion of the PKN bind-
ing site (residues 1585–1715) from AKAP-Lbc abolishes the
ability of the anchoring protein to recruit the p38 and its
upstream kinases MKK3 andMLTK (Fig. 4). This suggests that
the interaction between AKAP-Lbc and p38 is mediated by
the PKN binding domain and does not involve additional
interaction sites. It is possible, however, that the ability of
AKAP-Lbc and Brx to recruit PKN or JIP4 might be influ-
enced by the relative abundance of these scaffolding proteins in
different cell types.
Our current findings support the view that AKAP-Lbc spe-
cifically mediates 1-AR-induced p38 activation without
affecting activation of ERK1/2 and JNK (Figs. 1 and 7, and sup-
plemental Figs. S1 and S6). At the molecular level, this can be
explained by the fact that AKAP-Lbc forms a complex with
p38 and not with ERK and JNK (Figs. 2 and 3). Therefore, the
ability of AKAP-Lbc to transmit activating signals to specific
MAPK pathways is dictated by its ability to recruit specific
combinations of kinases. These results suggest therefore that
different signaling complexes might mediate 1-AR-induced
activation of ERK1/2 and JNK. In this respect, recent previous
findings indicate that the Rho-GEF p115 can recruit a scaffold-
ing protein named CNK1, which binds the kinases MLK2 and
MKK7 to coordinate the activation of JNK1 (35). Further inves-
tigations will be required to determine whether p115 or a dif-
ferent signaling complex is involved in the organization of the
JNK pathway downstream of 1b-ARs.
Members of the 14-3-3 family regulate a variety of transduc-
tion pathways either by affecting the catalytic activity, the sub-
cellular localization, or by regulating protein-protein interac-
FIGURE 9. Model for the AKAP-Lbcp38 activation complex. AKAP-Lbc
assembles a signaling complex that includes the scaffolding protein PKN as
well as MLTK, MKK3, and p38. The AKAP-Lbc signaling complex is activated
in response to 1-AR stimulation through a G12-mediated signaling path-
way (17). ActivatedAKAP-Lbcpromotes the formationof RhoA-GTP,which, in
turn, induces the activation of a signaling cascade that includes PKN, MLTK,
MKK3, and p38. The recruitment of 14-3-3 inhibits AKAP-Lbc Rho-GEF activ-
ity (19), impairs the interaction between PKN and AKAP-Lbc, and reduces
p38 activation.
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tion properties of signalingmolecules (36). It is well established
that 14-3-3 has an antagonistic effect on the p38 signaling path-
way (37, 38). This could be in part mediated by the inhibitory
action of 14-3-3 onAsk1, aMAPKKK that acts upstream of p38
(39). However, our current findings now suggest that 14-3-3
can inhibit AKAP-Lbc-mediated p38 activation by inducing
the dissociation of the PKNMLTKMKK3p38 complex
from AKAP-Lbc (Fig. 8) as well as by inhibiting the Rho-GEF
activity of the anchoring protein (19). Therefore, our results
provide a new molecular explanation on how 14-3-3 proteins
can impair p38 signaling inside cells.
Given the proximity of the binding sites for 14-3-3 andPKN
it is tempting to speculate that 14-3-3 recruitmentmight inhibit
the interaction between AKAP-Lbc and PKN by directly
masking the PKN interaction site on the anchoring protein.
This is reminiscent of the mechanism through which 14-3-3
has been shown to inhibit the interaction between the pro-
apoptotic protein Bad and pro-survival Bcl-2 family members
(40).
In conclusion, the implications of our findings are 2-fold.
First, they identify key molecular mechanisms controlling sig-
naling specificity downstream of 1b-ARs. By assembling a
macromolecular signaling complex containing RhoA, PKN,
MLTK, MKK3, and p38, AKAP-Lbc controls the specific
transduction of signals from 1b-ARs to p38. Second, they
provide a novel hypothesis explaining the inhibitory action of
14-3-3 on the p38 pathway, suggesting that AKAP-Lbc might
represent a molecular platform integrating 14-3-3 and p38
signaling.
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